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Summary of the project 
Background: Primary polydipsia is characterized by increased fluid intake and consistent excretion of 
profound quantities of diluted urine. It has mainly been described in psychiatric patients but with the 
current lifestyle-trend and believe that fluid intake is healthy, it is speculated to be increasing in the 
general population. One of the main and most severe complications of primary polydipsia is 
hyponatremia, which occurs when free water intake exceeds free water excretion. Despite the 
increasing prevalence, consistent clinical data on patients with primary polydipsia is lacking. Most of 
the existing data stems from case reports and retrospective studies within the psychiatric setting, 
particularly from patients with a schizophrenia spectrum disorder. Pathophysiological understanding 
and the risk for hyponatremia in non-psychiatric patients remains unclear. Treatment options for 
patients with primary polydipsia are scarce and have mainly been studied in the psychiatric setting.  
Objective: This MD-PhD thesis aims at contributing to improving the pathophysiological understanding 
of, to characterize complications in, and to find treatment options for patients with primary polydipsia.  
Methods: To reach the aspired aim, I first performed a secondary analysis of a prospective 
observational study to characterize patients with primary polydipsia hospitalized with profound 
hyponatremia. Second, I investigated the association of hyponatremia and outdoor temperature in 
patients with and without primary polydipsia in three distinct cohorts. Third, I was involved in a 
randomized, placebo-controlled cross-over trial evaluating glucagon-like peptide-1 receptor agonists, 
medications used to treat type 2 diabetes mellitus and obesity, as a treatment option for patients with 
primary polydipsia. 
Results: First, primary polydipsia’s main complication, i.e. hyponatremia, also occurs in medical 
patients also without psychiatric comorbidities. Second, the risk of profound hyponatremia increases 
in all polydisic patients in the presence of contributing factors impairing the renal excretory capacity: 
low solute intake or increased arginine vasopressin. Primary polydipsia in association with profound 
hyponatremia is furthermore associated with a poor outcome, e.g. hyponatremia recurrence, 
rehospitalization, and death. Third, hyponatremia shows a season dependent effect with increased 
hyponatremia prevalence during summer months in correlation with increased outdoor temperature. 
Fourth, glucagon-like peptide-1 receptor agonists reduce fluid intake in patients with primary 
polydipsia. 
Conclusion: Primary polydipsia has mainly been described in the psychiatric setting, but it seems to be 
also common in the general population. Special attention should be paid in patients with primary 
polydipsia to reduce hyponatremia inducing factors and prevent hyponatremia. Glucagon-like peptide-
1 receptor agonists are a promising new treatment option for patients with primary polydipsia.  
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Introduction 
Primary polydipsia is characterized by increased fluid consumption (>3000 ml/day) and consistent 
excretion of profound quantities of diluted urine (>40-50 ml/kg body weight per day) over an extended 
period of time, excluding reasons for secondary polydipsia, e.g. hyperglycemia, hypercalcemia [1–3]. 
It has most commonly been described in neurodevelopmental disorders, such as autism and 
intellectual disability, or psychotic disorders, such as schizophrenia spectrum, schizoaffective, bipolar 
disorder, and psychotic depression [1,3,4]. A particularly high prevalence in primary polydipsia has 
been described in chronic schizophrenia with a prevalence of 11–20% of patients [4,5]. With the 
increasing popularity of lifestyle-trends proclaiming that consuming plenty of fluid per day is healthy, 
is detoxifying, and improves cognition, the prevalence of this phenomenon seems to be constantly 
increasing, particularly outside of the psychiatric setting. Nevertheless, the prevalence of primary 
polydipsia in the general population and the current prevalence in the psychiatric setting is unknown. 
Presumably, a lack of knowledge regarding the burden of, consequences of, and treatment options for 
this disorder has limited studies in this field until now.  
 
Pathophysiology of primary polydipsia 
Maintaining a stable fluid level is a primary human need [6,7]. Water balance is an incessant 
equilibrium of water intake and its excretion through the kidneys, lungs, bowels, and skin. This balance, 
in order to keep plasma osmolality within a close range, is primarily regulated by the interplay of thirst 
and the hormone arginine vasopressin [8]. Arginine vasopressin, promoting water retention in the 
kidney, is released upon two main stimuli: high serum osmolality and low arterial blood volume [6,8–
10]. At the same time, a stimulus induces thirst perception leads to water intake. In primary polydipsia, 
arginine vasopressin levels are physiologically suppressed to compensate for the low serum osmolality 
following the increased fluid intake.  
 
Prefrontal regions
The anterior portions of the 
brain.
Autoradiographic metabolic 
trapping
A method of visualizing glucose 
utilization in the brain. It is 
used as a surrogate to indicate 
that neurons have been 
electrically activated.
Immediate early gene c-Fos
A gene that is transcribed 
and translated transiently and 
rapidly in response to 
increased cellular calcium. 
Expression of an immediate 
early gene often indicates that 
neurons have been electrically 
activated.
Studies in rodents have also provided support for the 
involvement of the prefrontal regions in thirst. For exam-
ple, autoradiographic metabolic trapping studies have 
shown that [14C]glucose accumulates in the ACC of 
water-deprived rats62, suggesting metabolic activation 
of that region. Moreover, hypovolaemic thirst induced by 
injection of the diuretic furosemide induces expression 
of the immediate early gene c-Fos in the rat IC, indicating 
neuronal activation63. Whether the activation of ACC 
and IC neurons is necessary and sufficient to mediate the 
Nature Reviews | Nephrology
Regulation of ECF volume
a
Hypervolaemia, high MAP
Set
point
Hypovolaemia, low MAP
↑ Natriuresis
(sodium excretion)
↓ Sodium appetite
(no sodium gain)
↓ Natriuresis
(sodium gain)
↑ Sodium appetite
(sodium gain)
↓ Thirst
(no water gain)
↓ Vasopressin
(diuresis)
↑ Thirst
(water gain)
↑ Vasopressin
(antidiuresis)
Regulation of ECF natraemia or osmolality
b
Hypernatraemia 
or hyperosmolality
Hyponatraemia
or hypoosmolality
Set
point
↑ Natriuresis
(sodium excretion)
↓ Sodium appetite
(no sodium gain)
↓ Natriuresis
(sodium gain)
↑ Sodium appetite
(sodium gain)
↑ Thirst
(water gain)
↑ Vasopressin
(antidiuresis)
↓ Thirst
(no water gain)
↓ Vasopressin
(diuresis)
Figure 1 | Feedback mechanisms to maintain body fluid balance. Perturbations in body fluid balance can involve 
changes in the osmolality and volume of the extracellular fluid (ECF), and their correction often requires the coordinated 
regulation of both parameters. Maintenance of volume and osmotic set points requires the intake and excretion of sodium 
and water to be controlled through feedback mechanisms involving volume receptors, osmoreceptors and sodium (Na+) 
detectors. a | When hypovolaemia occurs in the absence of a change in osmolality, for example, as a result of blood loss, 
maintenance of fluid homeostasis requires a net accumulation of both salt and water to achieve a net gain of isotonic fluid. 
This effect is achieved through the stimulation of both sodium appetite and thirst, together with an increase in the 
reabsorption of sodium and water by the kidney. Sodium reabsorption is promoted by the renin–angiotensin–aldosterone 
system (RAAS), whereas water reabsorption is stimulated by an increase in circulating levels of the antidiuretic hormone 
vasopressin, which is released from the neurohypophysis. The stimulation of salt appetite and thirst during hypovolaemia 
is mediated in part by ascending neural inputs from blood volume sensors in the periphery and by the central effects of 
angiotensin II and aldosterone. By contrast, correction of isotonic hypervolaemia requires a net loss of isotonic fluid, which 
is achieved in part by suppression of thirst and salt appetite and by stimulation of renal diuresis and natriuresis. Diuresis is 
provoked mainly by suppressing basal vasopressin release, which reduces water reabsorption248. Natriuresis, on the other 
hand, is enhanced by suppression of basal RAAS activity; by the release of natriuretic peptides, namely, atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP), from cardiac myocytes; and through regulation of the kidney via renal 
nerves. b | Increases in ECF osmolality (or natraemia) can be readily induced in the absence of an altered ECF volume by 
the ingestion of salt or food. Appropriate homeostatic responses to hypernatraemia include the suppression of sodium 
appetite and an increase in natriuresis, combined with an increase and water intake and antidiuresis to promote dilution 
of the ECF. Conversely, a hypoosmotic status is corrected by suppressing thirst and antidiuresis while promoting sodium 
intake and its reabsorption by the kidney. MAP, mean arterial pressure. 
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In healthy people, drinking leads to a pleasant feeling in response to thirst with an activation of the 
prefrontal cortex, the pleasure and reward center of the brain, as shown in neuroimaging experiments. 
In contrast, increased drinking after thirst has been satisfied, results in an unpleasant or even aversive 
sensation, which then stops the healthy person from further fluid intake [11,12]. Some patients with 
primary polydipsia report a drop of thirst after consuming water followed by a sudden rebound [4]. A 
dysfunction in the thirst center has been discussed as a pathophysiological process in patients with 
primary polydipsia, as described in patients with sarcoidosis [13]. It is speculated that some patients 
with primary polydipsia experience increased thirst in response to a lower osmotic set point for 
arginine vasopressin release [14]. Nevertheless, the pathogenesis of altered thirst and excessive fluid 
intake as seen in patients with primary polydipsia remains largely unknown.  
 
Differential diagnosis of the polyuria-polydipsia syndrome 
Primary polydipsia belongs to the polyuria-polydipsia syndrome. The differential diagnoses of primary 
polydipsia are central and nephrogenic diabetes insipidus. While primary polydipsia is primarily 
characterized by increased fluid intake, diabetes insipidus is determined by polyuria due to impaired 
arginine vasopressin secretion (central diabetes insipidus) or arginine vasopressin resistance in the 
kidneys (nephrogenic diabetes insipidus) with consecutive polydipsia to replace the lost fluid [9]. Until 
recently, the widely accepted gold standard for the differential diagnosis of the polyuria-polydipsia 
syndrome was the indirect water deprivation test, introduced in 1970 [15,16]. However, this procedure 
is limited by a poor diagnostic accuracy: 70% overall and only 41% for primary polydipsia [17]. Other 
methods have been studied, including direct measurement of vasopressin and of the vasopressin 
surrogate marker copeptin [3,18,19]. A baseline measurement of copeptin can differentiate between 
nephrogenic diabetes insipidus and central diabetes insipidus or primary polydipsia [19]. Currently, the 
most reliable method to differentiate between primary polydipsia and central diabetes insipidus is a 
stimulated copeptin level following hypertonic saline infusion [17]. This test, importantly, requires 
constant supervision by a trained physician due to side effects and the risk of sodium overstimulation. 
Arginine is known to stimulate prolactin and growth hormone from the anterior pituitary [20,21]. As 
arginine is well tolerated, it is widely used as provocation test to diagnose growth hormone deficiency, 
especially in children [22]. In accordance with the effects of other growth hormone secretagogues 
(e.g., hexarelin) [23,24], arginine could also stimulate the posterior pituitary (i.e., to release 
vasopressin) and might therefore provide a simple, alternative diagnostic test in the differential 
diagnosis of diabetes insipidus. 
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Complications of primary polydipsia 
One of the most common and severe acute complication of primary polydipsia is the development of 
hyponatremia [5,25,26]. Hyponatremia in patients with primary polydipsia occurs when free fluid 
intake exceeds free fluid excretion [25,27,28]. It is often associated with psychotic exacerbation of 
chronic schizophrenia [29]. The normal excretory capacity of the kidneys can compensate for fluid 
intake up to 15-18 l/day (considering a maximum urine diluting capacity of 50 mmol/l and an excretion 
of 900 mmol/24h), but this system may be disturbed by factors influencing the water excretion such 
as medications, stress, or low sodium intake [27].  
Most of the research on complications, especially hyponatremia, has been done in patients with 
chronic schizophrenia, where a hyponatremia prevalence of up to 20% in patients with psychogenic 
polydipsia has been found [5,30,31]. Information on the prevalence of hyponatremia in medical 
patients with primary polydipsia is scarce. Additionally, precipitating factors for hyponatremia and 
outcome have been poorly studied for patients with primary polydipsia.  
 
Treatment options for patients with primary polydipsia 
Voluntary reduction of water intake would be the ideal treatment for patients with primary polydipsia 
but often fails due to non-compliance of the polydiptic patient who suffers from thirst and compulsive 
drinking behavior [29,32,33]. Studies investigating behavioral therapy, such as disease education, 
relaxation training using biofeedback, conditioning of desired behavior, and group therapy, have 
shown to be the most success [34–37]. However, the feasibility of behavioral therapy, requiring 
substantial time and manpower, are limited in an outpatient setting [34]. Different medications have 
been suggested to improve polydiptic behavior and prevent hyponatremia. Most drugs showing 
symptom improvement are antipsychotic drugs and mood stabilizers, such as olanzapine, lithium, 
risperidone, aripiprazole, and clozapine [38–43]. The question however remains whether these drugs 
are treating the urge to drink, or whether they simply reduce acute psychosis and thereby treat 
Baseline copeptin
(without prior fluid deprivation)
≥21.4pmol/l
≥4.9pmol/l
Nephrogenic Diabetes Insipidus
(100% sens, 100% spec)
<21.4pmol/l
Stimulated copeptin
(plasma sodium >147mmol/l)
Primary Polydipsia
(100% sens, 93% spec)
<4.9pmol/l
Central Diabetes Insipidus
(93% sens
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primary polydipsia that might be a symptom of acute psychosis. Other medications have been studied 
in and outside the psychiatric setting with limited success to reduce polydiptic behavior: phenytoin, 
bupropion, and propranolol [44,45]. In conclusion, treatment options for patients with primary 
polydipsia, especially outside the psychiatric setting, are scarce. 
 
Importance and impact 
Primary polydipsia has mainly been described in the psychiatric setting. Outside the psychiatric setting, 
it has been described in young to middle aged life-style conscious people who feel the need to 
detoxicate their body and consider plenty of fluid intake healthy. Nevertheless, primary polydipsia 
bears the risk of complications, mainly hyponatremia, which is associated with morbidity, mortality, 
and health service utilization [31,46].  
Consistent clinical data on patients with primary polydipsia is lacking. Most of the existing data arises 
from case reports and retrospective studies within the psychiatric setting, and especially from patients 
with a schizophrenia spectrum disorder. Pathophysiological understanding and the risk for 
hyponatremia in non-psychiatric patients remains unclear. Furthermore, current treatment options 
are scarce and have mainly been studied in the psychiatric setting.  
This indicates the need for further research in the field of primary polydipsia with the focus on 
improving the pathophysiological understanding of primary polydipsia, characterizing complications 
in non-psychiatric patients, and finding treatment options that are safe and efficient for medical and 
psychiatric patients with primary polydipsia. 
 
  
Inaugural dissertation – Dr med. Clara Odilia Sailer 12 
Main objectives of this MD-PhD 
This MD-PhD thesis aims at improving the pathophysiological understanding of, to characterize 
complications in, and to find treatment options for patients with primary polydipsia.  
In the following, the different objectives and methodologies to accomplish these aims are described.   
 
Objective 1: Prevalence and pathophysiology of primary polydipsia 
Part 1 (prevalence): To clarify the current prevalence of, characterize, and investigate the outcome of 
patients with primary polydipsia in the acute psychotic patient, I planned, organized, and conducted a 
prospective observational study with a one-year follow-up.  
Part 2: (pathophysiology): To improve the pathophysiological understanding of patients with primary 
polydipsia, I designed, planned, and performed a neuroimaging study in patients with primary 
polydipsia and healthy volunteers.  
 
Objective 2: Differential diagnosis of the polyuria-polydipsia syndrome 
To improve differential diagnosis in patients with polyuria-polydipsia, I participated in a diagnostic 
study investigating copeptin levels following arginine infusion test as an alternative to the hypertonic 
saline infusion test. 
 
Objective 3: Complications of primary polydipsia 
Part 1: To investigate, characterize, and describe complications of patients with primary polydipsia, I 
performed a secondary analysis of a prospective observational study including a one-year follow up of 
patients hospitalized with profound hyponatremia due to primary polydipsia. 
Part 2: To clarify a season dependent effect of hyponatremia in patients with primary polydipsia, I 
investigated three different medical cohorts with hyponatremia in correlation to outdoor temperature 
with and without primary polydipsia.  
 
Objective 4: Treatment options for patients with primary polydipsia 
To investigate a new treatment option for patients with primary polydipsia, I participated in a 
randomized, placebo-controlled cross-over trial in patients with primary polydipsia receiving glucagon-
like peptide-1 receptor agonists.  
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Contribution by the MD-PhD student 
I had the great honor to be part of Professor Mirjam Christ-Crain’s research group for the whole time 
of my MD-PhD in clinical research. I was involved in several projects within the field of primary 
polydipsia and hyponatremia. I learned all relevant steps of clinical research from the planning of the 
project, the writing of the ethical and funding proposal, to the conduction of the project, the analysis 
and interpretation of the data, and the writing of the manuscript. 
At the beginning of my MD-PhD, I performed a thorough literature research and wrote a narrative 
review on characteristics, differential diagnosis, complications, and treatment options of patients with 
primary polydipsia [47]. During the literature research and the writing of the review, I identified several 
gaps in the field of primary polydipsia: first, uncertainty about the pathophysiology of primary 
polydipsia; second, a lack in prevalence of complications, mainly hyponatremia, in the medical patient 
with primary polydipsia; third, lack of an easy and accurate test for the differential diagnosis of the 
polyuria-polydipsia syndrome; fourth insufficient treatment options for patients with primary 
polydipsia.  
To shed light on these uncertainties, I analyzed data of a prospective observational study and wrote 
my first original paper on characteristics and outcome of patients with primary polydipsia and 
hyponatremia [48]. I was able to perform this analysis thanks to my knowledge from several statistical 
courses and was furthermore supported by the Clinical Trial Unit in Basel. I discussed and interpreted 
the data and wrote the manuscript with the support from Dr Bettina Winzeler and Professor Mirjam 
Christ-Crain.  
To clarify a season dependent effect of hyponatremia in patients with and without hyponatremia, I 
combined three data sets: first, the results from a prospective observational study, second, chart data 
from the emergency department, and third, meteorological data (temperature and humidity). Again, I 
analyzed the data, discussed the results and wrote the manuscript with the support dem the Clinical 
Trial Unit Basel, Dr Bettina Winzeler, and Professor Mirjam Christ-Crain [49]. To confirm the findings, I 
performed a similar analysis in a nation-wide cohort study together with Dr Alexander Kutz and Dr 
Fahim Ebrahimi [50]. 
To further investigate the prevalence of primary polydipsia in the psychiatric setting, I designed a 
prospective observational study in patients with an acute psychosis, where primary polydipsia has 
mainly been described (CoPsych Trial, NCT03235908). I planned the study, initiated the collaboration 
with the psychiatry department with Professor Stefan Borgwardt and Jennifer Küster, wrote the ethical 
proposal, and performed the patients’ visits. I finished recruitment of this study in July 2019 after 
including 73 patients and will continue with the one-year follow-up until July 2020. Thereafter, I will 
analyze the data and write the manuscript in collaboration with Professor Stefan Borgwardt and 
Jennifer Küster.  
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I was also involved in a study investigating the differential diagnosis of the polyuria-polydipsia 
syndrome. This study showed that copeptin measurement after arginine infusion can differentiate 
between patients with primary polydipsia and central diabetes insipidus [51].  
I was co-investigator of a randomized controlled trial investigating glucagon-like peptide 1 (GLP-1) 
receptor agonists as a potential treatment option for patients with primary polydipsia (GOLD-trial, 
NCT02770885). After finishing the recruitment, I am currently writing the manuscript with the help of 
Dr Bettina Winzeler and Professor Mirjam Christ-Crain. As part of the study, I initiated a sub-study in 
15 patients with primary polydipsia and 15 healthy matched controls to investigate neuronal changes 
using a functional magnet resonance imaging. Here, I wrote the amendment, coordinated the study 
set up with the radiology department, and set up the paradigm. I recruited patients and controls and 
performed patients’ visit. Recruitment ended in summer 2019 and I am currently analyzing the 
functional magnet resonance images using the software package FMRIB Software Library (FSL).  
Furthermore, I was the principle investigator in a randomized cross-over study investigating the 
influence of alcohol consumption with and without additional fluid and sodium on copeptin levels in 
ten healthy men. Here, I designed and planned the trial, drafted the ethical proposal, recruited 
patients, and performed patients’ visits. After the data analysis, I wrote the manuscript [52]. As part 
of this project, I supervised a master student and gained valuable leadership skills. 
Additionally, I recruited and performed regular study visits in a randomized, placebo-controlled trial 
investigating empagliflozin as treatment option for patients with the syndrome of inappropriate 
antidiuresis [53]. I presented this study at the local scientific meeting and was awarded with the second 
price for the oral presentation.  
Overall, I have gained many valuable skills during my MD-PhD that are necessary for clinical research. 
I was involved from the beginning of a new research project to the presentation of the data and writing 
of the manuscript. I learned basic and advanced statistical skills as well as leadership, teambuilding, 
and communication skills.   
Inaugural dissertation – Dr med. Clara Odilia Sailer 15 
Review: Primary polydipsia in the medical and psychiatric 
patient: characteristics, complications and therapy 
 
Sailer Clara O.ab, Winzeler Bettinaab, Christ-Crain Mirjamab 
 
aEndocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland 
bDepartment of Clinical Research, University Hospital Basel, Switzerland 
 
 
 
Published in “Swiss Medical Weekly”  
Publication Date: November 01, 2017; DOI: https://doi.org/10.4414/smw.2017.14514 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
--------------------------------- 
Clara O. Sailer and Bettina Winzeler contributed equally to this work 
  
Inaugural dissertation – Dr med. Clara Odilia Sailer 16 
Abstract 
Primary polydipsia (PP) has been defined as excessive intake of fluids. However, the pathogenesis of 
PP remains unexplored. Different theories include a dysfunction in the thirst mechanism, involvement 
of the hippocampus, stress-reducing behaviour and lesion occurrences in specific areas of the brain. 
Most studies have been performed in the psychiatric setting, indicating that PP coincides with 
schizophrenia, anxiety disorder and depression. However, an increasing number of case reports 
emphasise the incidence of PP in non-psychiatric patients. As often recommended by healthcare 
professions and in life-style programmes, the phenomenon of excessive fluid intake appears to be 
growing, especially in health-conscious and active people. PP is part of the polyuria-polydipsia 
syndrome, so the differential diagnosis diabetes insipidus (central or nephrogenic) must be excluded. 
The gold standard when differentiating between these disorders has been the water deprivation test. 
However, new options for distinguishing between these entities have been proposed e.g., 
measurement of copeptin, a reliable surrogate marker of the hormone arginine vasopressin (AVP). The 
major risk of excessive drinking is the development of hyponatraemia and the ensuing complications. 
In patients with PP, factors reducing the renal excretory capacity of the kidney such as acute illness, 
medications or low solute intake may accumulate in hyponatraemia. Treatment options for PP remain 
scarce. Different medication and behavioural therapy have been investigated, but never on a large 
scale and rarely in non-psychiatric patients. This review provides an overview of the pathophysiology, 
characteristics, complications, and outcomes of patients with PP in the medical and psychiatric patient. 
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Introduction 
Primary polydipsia (PP) is characterised by an increased fluid intake and consistent excretion of 
profound quantities 
of dilute urine exceeding 40–50 ml/kg body weight (e.g., 3000 ml/day for a person of 60 kg) over an 
extended period, excluding reasons for secondary polydipsia [1–3]. It has most commonly been 
described in patients with schizophrenia spectrum disorder with an incidence of 11 to 20%, and has 
therefore been named psychogenic polydipsia [1–3,5]. With the increasing popularity of lifestyle 
programmes and the common conception that consuming several litres of fluid per day is healthy, the 
prevalence of this phenomenon is increasing, particularly outside of the psychiatric setting. However, 
the prevalence in the overall population is unknown and has yet to be studied. Presumably, a lack of 
knowledge regarding the burden, consequences and treatment options for this disorder has limited 
studies in this field until now. 
A comparable disorder is beer potomania, which is also characterised by increased intake of beer, but 
in this condition urine output may be below the above-mentioned polyuria definition [54–57]. 
The most common and potentially severe complication of excessive fluid intake is the occurrence of 
hyponatraemia [1,5,26,30]. Hyponatraemia is associated with increased morbidity and mortality and 
should therefore be prevented [31,46,58,59]. Different risk factors are thought to be associated with 
the development of hyponatraemia in PP such as medication, physical or psychological stress, and 
acute consumption of copious quantities of fluids [1,5,30]. 
Several treatment options for PP have been investigated, ranging from different medication to 
behavioural therapy [36–39,60,61]. Unfortunately, most studies were using explorative study designs, 
small sample sizes with limited success, and low generalisability. 
This review is intended to give an overview of the current stage of research in the field of PP. We will 
describe causes, associated comorbidities, complications, and will discuss the diagnostic and 
therapeutic issues of this syndrome. 
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Pathophysiology 
Maintaining a stable fluid level is a primary human need [6,7]. Water balance is an incessant 
equilibrium of water intake and excretion through the kidneys, the lungs, the bowels and the skin. This 
balance, in order to keep plasma osmolality within a close range, is primarily regulated by the interplay 
of thirst and the hormone arginine vasopressin (AVP)[8]. AVP, promoting water retention in the kidney, 
is released upon two main stimuli namely high serum osmolality and low arterial blood volume [6,8,9] 
(fig. 1).  
 
In healthy people, drinking leads to a pleasant feeling in response to thirst with an activation of the 
prefrontal cortex, the pleasure and reward centre of the brain, as shown in functional magnet 
resonance imaging (fMRI) experiments. In contrast, increased drinking after thirst has been satisfied 
results in an unpleasant or even aversive sensation, which then stops the healthy participant from 
further fluid intake [11,12]. 
The pathogenesis of insatiable thirst and excessive fluid intake as seen in PP remains largely unknown. 
According to the underlying or associated conditions, PP may be classified in two main categories, 
whereby different causal mechanisms are discussed: psychogenic polydipsia and dipsogenic polydipsia 
[2,9,19,48] (table 1). A related disorder is beer potomania, which is characterised by the chronic or 
acute consumption of large amounts of beer [56,62].  
 
 
 
intake and excretion through the kidneys, the lungs, the
bowels and the skin. This balance, in order to keep plasma
osmolality within a close range, is primarily regulated by
the interplay of thirst and the hormone arginine vaso-
pressin (AVP) [23]. AVP, promoting water retention in the
kidney, is released upon two main stimuli namely high
serum osmolality and low arterial blood volume [21, 23,
24] (fig. 1).
In healthy people, drinking leads to a pleasant feeling in re-
sponse to thirst with an activation of the prefrontal cortex,
the pleasure and reward centre of the brain, as shown in
functional magnet resonance imaging (fMRI) experiments.
In contrast, increased drinking after thirst has been satis-
fied results in an unpleasant or even aversive sensation,
which then stops the healthy participant from further fluid
intake [26, 27].
The pathogenesis of insatiable thirst and excessive fluid in-
take as seen in PP remains largely unknown. According to
the underlying or associated conditions, PP may be clas-
sified in two main categories, whereby different causal
mechanisms are discussed: psychogenic polydipsia and
dipsogenic polydipsia [2, 24, 28, 29] (table 1). A related
disorder is beer potomania, which is characterised by the
chronic or acute consumption of large amounts of beer [7,
30].
Most research has been done in patients with schizophrenia
spectrum disorders and psychogenic polydipsia. In both, a
central defect of thirst and a dysfunction in AVP regula-
Figure 1: Physiology of thirst regulation. In the case of in-
creased plasma osmolality, osmoreceptors in the hypothalamus
are activated, which leads to secretion of the hormone arginine va-
sopressin (AVP). AVP thereafter stimulates water retention in the
kidneys receptors. On the other hand, thirst is stimulated and
leads to drinking.Adapted from Knepper et al. (2015) [25].
tion has been suggested [31, 32]. During acute psychotic
episodes, worsening of polydiptic behaviour and increased
levels of AVP have been observed [9]. It is speculated that
during acute psychosis, the activation of the hypothalamic-
pituitary-adrenal axis and AVP secretion influences behav-
ioural traits and vice versa – probably through hippocam-
pal involvement [9, 23, 33–37]. Interestingly, in cranial
MRI, the hippocampus was found to have a diminished
volume in patients with schizophrenia spectrum disorder
and PP compared to those without PP [35].
Furthermore, a stress-induced increase in dopamine levels
may also play a role in acute psychotic patients. This hy-
pothesis has been tested in animal studies, which showed
that exogenous dopamine initiated drinking and increased
AVP levels [38–41].
Other psychiatric conditions such as affective and depen-
dency disorder (e.g., smoking, alcoholism) and anorexia
nervosa also appear frequently in PP [29]. In these dis-
eases, drinking might be perceived as a coping strategy
to deal with psychological stress or, especially in patients
with anorexia nervosa, increased liquid consumption may
compensate for low food intake and to decrease the sensa-
tion of hunger [32, 42, 43].
Dipsogenic polydipsia includes patients with an increased
sensation of thirst due to hypothalamic lesions and subjects
with habitual polydipsia, which is typically seen in life-
style conscious men and women, which is the use of water
to detox the body. Abnormally high water consumption
is also seen in people who perform excessive amounts
of sport [44–48]. Alongside hypothalamic affection after
traumatic brain injuries, vascular or infiltrative diseases
(e.g., sarcoidosis) may lead to dipsogenic polydipsia [24,
49–52]. In habitual polydipsia, social conditioning with
constant motivation to drink may modify drinking behav-
iour relative to actual water deficit, thus resulting in a
downward resetting of the thirst threshold [26, 27].
Finally, while in beer potomania the underlying disorder is
alcohol dependency, the motivation to drink is the effect
of alcohol and thus different from other forms of primary
polydipsia [5–8]. Psychogenic and dipsogenic polydipsia
seem to occur preferentially in women, whereas beer poto-
mania is more often seen in men [1, 4, 11, 29].
Diagnosis and differential diagnosis of PP
The differential diagnoses of primary polydipsia (PP) are
central and nephrogenic diabetes insipidus (DI). While PP
is primarily characterised by increased fluid intake, DI is
determined by polyuria due to impaired AVP secretion
Table 1: Causes of primary polydipsia.<su>Table-Small</su>
Primary polydipsia (excessive water intake)
Psychogenic polydipsia (e.g., in patients with acute psychosis, chronic schizophrenia spectrum disorder, anxiety disorder, depression, anorexia nervosa and depen-
dency disorder)
Dipsogenic polydipsia
Habitual polydipsia
Health-conscious men and women
Sporty people
Somatic (damage of thirst centre)
Cerebral lesion
Granulomatous (sarcoidosis)
Infectious (tuberculous meningitis)
Vascular (vasculitis)
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Most research has been done in patients with schizophrenia spectrum disorders and psychogenic 
polydipsia. In both, a central defect of thirst and a dysfunction in AVP regulation has been suggested 
[25,63]. During acute psychotic episodes, worsening of polydiptic behaviour and increased levels of 
AVP have been observed [30]. It is speculated that during acute psychosis, the activation of the 
hypothalamic-pituitary-adrenal axis and AVP secretion influences behavioural traits and vice versa – 
probably through hippocampal involvement [8,30,64–68]. Interestingly, in cranial MRI, the 
hippocampus was found to have a diminished volume in patients with schizophrenia spectrum 
disorder and PP compared to those without PP [66]. 
Furthermore, a stress-induced increase in dopamine levels may also play a role in acute psychotic 
patients. This hypothesis has been tested in animal studies, which showed that exogenous dopamine 
initiated drinking and increased AVP levels [69–72]. 
Other psychiatric conditions such as affective and dependency disorder (e.g., smoking, alcoholism) and 
anorexia nervosa also appear frequently in PP [48]. In these diseases, drinking might be perceived as 
a coping strategy to deal with psychological stress or, especially in patients with anorexia nervosa, 
increased fluid intake may compensate for low food intake and to decrease the sensation of hunger 
[63,73,74]. 
Dipsogenic polydipsia includes patients with an increased sensation of thirst due to hypothalamic 
lesions and subjects with habitual polydipsia, which is typically seen in lifestyle conscious men and 
women, which is the use of water to detox the body. Abnormally high water consumption is also seen 
Table 1 Causes of primary polydipsia 
Primary Polydipsia (excessive water intake) 
      Psychogenic Polydipsia (e.g. in patients with acute psychosis, chronic 
schizophrenia spectrum disorder, anxiety disorder, depression, anorexia 
nervosa and dependency disorder) 
 Dipsogenic Polydipsia 
 Habitual polydipsia 
 Health conscious men and women 
 Athletics 
 Somatic (damage of thirst centre) 
 Cerebral lesion 
 Granulomatous (sarcoidosis) 
 Infectious (tuberculous meningitis) 
 Vascular (vasculitis) 
 Beer potomania (excessive beer intake) 
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in people who perform excessive amounts of sport [75–79]. Alongside hypothalamic affection after 
traumatic brain injuries, vascular or infiltrative diseases (e.g., sarcoidosis) may lead to dipsogenic 
polydipsia [9,13,80–82]. In habitual polydipsia, social conditioning with constant motivation to drink 
may modify drinking behaviour relative to actual water deficit, thus resulting in a downward resetting 
of the thirst threshold[11,12]. Finally, while in beer potomania the underlying disorder is alcohol 
dependency, the motivation to drink is the effect of alcohol and thus different from other forms of 
primary polydipsia[54–57]. Psychogenic and dipsogenic polydipsia seem to occur preferentially in 
women, whereas beer potomania is more often seen in men [1,5,31,48]. 
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Diagnosis and differential diagnosis of PP 
The differential diagnoses of primary polydipsia (PP) are central and nephrogenic diabetes insipidus 
(DI). While PP is primarily characterised by increased fluid intake, DI is determined by polyuria due to 
impaired AVP secretion (central DI) or AVP resistance in the kidneys (nephrogenic DI) [9]. Central DI 
may be acquired after e.g., pituitary trauma (surgery), infections, auto-immune disease or congenital 
factors [2,3,9,83]. Nephrogenic DI can be due to inherited mutations in the AVP-receptor-2 and 
aquaporine-2 gene, or acquired (e.g., chronic lithium use or metabolic/vascular kidney injuries) [3,83]. 
The first step in the diagnosis and differential diagnosis of PP is a thorough history, including medical 
and psychiatric comorbidities and medication. Compared to patients with DI, polydiptic patients 
typically report a less acute onset and often deny nocturia and drinking during the night [9]. The next 
diagnostic step is to exclude other forms of polyuria (e.g., diabetes mellitus) and to measure plasma, 
urine osmolality and electrolytes. Low normal plasma sodium in the presence of a low urine osmolality 
is indicative of PP. The widely accepted gold standard for the differential diagnosis of PP is the indirect 
water deprivation test, introduced in 1964 [15]. The test indirectly assesses AVP activity by 
measurement of urinary osmolality, and thus the concentration capacity of the kidneys, during a 
prolonged dehydration period, and finishes by assessing the response (increase in urinary osmolality 
in %) to the administration of exogenous vasopressin (desmopressin) [84–86]. 
However, this procedure is limited by poor diagnostic accuracy of 70% overall and an especially poor 
diagnostic performance of only 41% for PP [2,87]. Therefore, other methods have been studied. Direct 
measurement of AVP was used with initially promising results [18]. However, due to measuring 
difficulties and the instability of AVP, direct measurement of AVP has never entered everyday practice 
[28,88,89]. 
Copeptin, the c-terminal part of the AVP precursor peptide, was found to be a stable, sensitive and 
easily measured surrogate marker for AVP [88,90,91]. Copeptin has been shown to accurately 
discriminate between PP and DI [91,92]. Without prior thirsting, a single basal copeptin value >21.4 
pmol/l differentiates nephrogenic DI from other aetiologies with a high sensitivity and specificity. If 
the basal copeptin value is below this cut-off, an osmotic stimulation (plasma sodium >147 mmol/l) 
either by fluid restriction or the administration of a hypertonic saline infusion is necessary for 
differentiation between central DI and PP [92]. An osmotically stimulated copeptin value ≥4.9 pmol/l 
differentiates between patients with PP and central DI with high diagnostic accuracy (fig. 2). 
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(central DI) or AVP resistance in the kidneys (nephrogenic
DI) [24]. Central DI may be acquired after e.g., pituitary
trauma (surgery), infections, auto-immune disease or con-
genital factors [2, 3, 24, 53]. Nephrogenic DI can be due
to inherited mutations in the AVP-receptor-2 and aquapor-
ine-2 gene, or acquired (e.g., chronic lithium use or meta-
bolic/vascular kidney injuries) [3, 53].
The first step in the diagnosis and differential diagnosis of
PP is a thorough history, including medical and psychiatric
comorbidities and medication. Compared to patients with
DI, polydiptic patients typically report a less acute onset
and often deny nocturia and drinking during the night [24].
The next diagnostic step is to exclude other forms of
polyuria (e.g., diabetes mellitus) and to measure plasma,
urine osmolality and electrolytes. Low normal plasma
sodium in the presence of a low urine osmolality is in-
dicative of PP. The widely accepted gold standard for the
differential diagnosis of PP is the indirect water depriva-
tion test, introduced in 1964 [54]. The test indirectly as-
sesses AVP activity by measurement of urinary osmolality,
and thus the concentration capacity of the kidneys, during
a prolonged dehydration period, and finishes by assessing
the response (increase in urinary osmolality in %) to the
administration of exogenous vasopressin (desmopressin)
[55–57].
However, this procedure is limited by poor diagnostic ac-
curacy of 70% overall and an especially poor diagnostic
performance of only 41% for PP [2, 58]. Therefore, other
methods have been studied. Direct measurement of AVP
was used with initially promising results [59]. However,
due to measuring difficulties and the instability of AVP, di-
rect measurement of AVP has never entered everyday prac-
tice [60–62].
Copeptin, the c-terminal part of the AVP precursor peptide,
was found to be a stable, sensitive and easily measured
surrogate marker for AVP [61, 63, 64]. Copeptin has been
shown to accurately discriminate between PP and DI [28,
64]. Without prior thirsting, a single basal copeptin value
>21.4 pmol/l differentiates nephrogenic DI from other ae-
tiologies with a high sensitivity and specificity. If the basal
copeptin value is below this cut-off, an osmotic stimulation
(plasma sodium >147 mmol/l) either by fluid restriction or
the administration of a hypertonic saline infusion is neces-
sary for differentiation between central DI and PP [28]. An
osmotically stimulated copeptin value ≥4.9 pmol/l differ-
entiates between patients with PP and central DI with high
diagnostic accuracy (fig. 2).
Complications of PP
The most common and severe acute complication of PP is
the development of hyponatraemia [10, 11, 30, 65]. Hy-
ponatraemia in PP occurs when free fluid intake exceeds
free fluid excretion [31, 60, 66]. The normal excretory ca-
pacity of the kidneys can compensate for liquid intake up
to 15-18l/day (considering a maximum urine diluting ca-
pacity of 50mmol/l and an excretion of 900mmol/24h), but
this system may be altered by several factors [66]. Be-
side chronic and acute ingestion of excessive quantities of
fluids, conditions impairing urine dilution capacity predis-
pose hyponatraemia - primarily increased AVP release [1,
10, 11, 31, 65–71]. Risk factors for hyponatraemia are dis-
played in table 2.
About 20% of patients with schizophrenia and PP develop
hyponatraemia [4, 9, 11]. As AVP is known to be a stress
hormone, an acute psychotic episode increases the activity
of AVP, leading to water retention and potentially hypona-
traemia, especially if polydiptic behaviour persists [9, 60,
72]. Similarly, somatic stress (e.g., acute diseases, pain)
stimulates AVP secretion [73]. Recent case reports have
Figure 2: Diagnostic algorithm of copeptin in the differential diagnosis of patients with PP, central and nephrogenic DI. A basal
copeptin value of ≥21.4 pmol/l confirms the diagnosis of nephrogenic DI. A basal copeptin value of <21.4 pmol/l needs an osmotic stimulation
(water deprivation or hypertonic saline infusion) to differentiate between central DI and PP. An osmotically stimulated copeptin value ≥4.9
pmol/l differentiates between patients with central DI and PP with a high diagnostic accuracy [28].Adapted from Christ-Crain and Fenske
(2016) [53].
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Complications of PP 
The most common and severe acute complication of PP is the development of hyponatraemia 
[26,31,62,93]. Hyponatraemia in PP occurs when free fluid intake exceeds free fluid excretion 
[25,27,28]. The normal excretory capacity of the kidneys can compensate for liquid intake up to 15-
18l/day (considering a maximum urine diluting capacity of 50mmol/l and an excretion of 
900mmol/24h), but this system may be altered by several factors [27]. Beside chronic and acute 
ingestion of excessive quantities of fluids, conditions impairing urine dilution capacity predispose 
hyponatraemia - primarily increased AVP release [1,25–27,31,93–98]. Risk factors for hyponatraemia 
are displayed in table 2. 
 
Table 2 Factors predisposing hyponatremia in primary polydipsia 
Acute fluid intake of high amount 
Impaired water excretion 
 Low solute intake 
 Malnutrition 
 Anorexia nervosa 
 Beer potomania 
 Concomitant AVP stimulus 
 Medication (e.g. antidepressants, antipsychotics, diuretics) 
 Acute infection (e.g. pneumonia, urogenital tract infection) or other 
acute diseases (e.g. stroke, myocardial infarction) 
 Psychological stress (e.g. acute psychosis) 
 
About 20% of patients with schizophrenia and PP develop hyponatraemia [5,30,31]. As AVP is known 
to be a stress hormone, an acute psychotic episode increases the activity of AVP, leading to water 
retention and potentially hyponatraemia, especially if polydiptic behaviour persists [28,30,99]. 
Similarly, somatic stress (e.g., acute diseases, pain) stimulates AVP secretion [100]. Recent case reports 
have shown an association between acute infection and hyponatraemia. Particularly in urinary tract 
infections when both the infection per se and stress-induced AVP release reduce the renal excretory 
capacity, a combined with medical advice to increase fluid intake, patients in general and especially 
with PP are at risk of the development of hyponatraemia [101–104]. 
Several medications may promote hyponatraemia by stimulating AVP release or increasing the 
sensitivity of the kidneys to AVP: thiazide diuretics, antipsychotic drugs, antidepressant drugs, 
antiepileptic drugs, and lithium [94,96,98,105–108]. Furthermore, the anticholinergic side effects of 
antidepressant drugs may result in an elevated sensation of thirst and hence lead to increased drinking. 
Inaugural dissertation – Dr med. Clara Odilia Sailer 24 
In patients with beer potomania, patients with PP and malnutrition or anorexia nervosa, low solute 
intake plays a major role in the development of hyponatraemia [62]. The amount of solute intake 
defines the maximum dilution capacity of the kidneys as free fluid without solutes cannot be excreted. 
Thus, if solute intake decreases, the kidneys’ excretory capacity of water may decrease from around 
15 l/d to 4 l/d, a threshold that is quickly passed in patients with chronic polydipsia and beer potomania 
[27]. Hyponatraemia may lead to several serious consequences. In the acute setting, if hyponatraemia 
treatment is delayed or inadequate, complications include brain oedema, seizures, falls and fractures 
as well as rhabdomyolysis and central pontine myelinolysis [31,109–113]. In the long-term, 
hyponatraemia is associated with increased rehospitalisation rates, morbidity and mortality [58,114]. 
Importantly, the risk of hyponatraemia seems to increase with duration of the underlying disease of 
PP[5]. It is speculated that excessive fluid intake over a long period may modulate drinking behaviour 
relative to actual water deficit and lead to a disturbance in the osmoregulation. Hence, over time, 
subjects declare thirst and keep drinking even in the presence of reduced serum osmolality 
[28,32,115]. Similarly, a downward resetting of the osmostat results in delayed or incomplete 
suppression of AVP and hence impairs water excretion. 
Beside hyponatraemia, other complications of chronic excessive fluid consumption exist. Renal 
concentration capacity may diminish through a washout mechanism and downregulation of 
aquaporine-2 water channels, as shown in rodents [116]. Furthermore, malnutrition, gastrointestinal 
distress, bladder dilatation, hydronephrosis, renal failure, congestive heart failure, osteopenia and 
central nervous system dysfunction have been discussed [35,37,46,117]. These data, however, mostly 
derive from case reports and retrospective studies and therefore provide low evidence. 
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Treating primary polydipsia and its complications 
Treatment options for PP are scarce. Voluntary reduction of water intake would be the ideal therapy 
for PP, however, it often fails due to non-compliance of the polydiptic patient who suffers from thirst 
and compulsive drinking behaviour [29,32,33,118]. Supportive measures to avoid hyponatraemia are 
the following: ingestion of a balanced diet, avoidance of drugs that may cause a dry mouth, hence 
increasing drinking, and frequent weighing to detect water retention. Studies have investigated 
behavioural therapy such as disease education, relaxation training using biofeedback, conditioning of 
desired behaviour, group therapy and others [34–37] and have shown variable results. However, the 
feasibility of behavioural treatments, requiring substantial time and manpower, are limited in an 
outpatient setting [37]. 
Different medications have been suggested to improve polydiptic behaviour and prevent 
hyponatraemia. As PP has mainly been studied in acutely psychotic patients, it is not surprising that 
most drugs studied are antipsychotic drugs and mood stabilisers such as olanzapine, lithium, 
risperidone, aripiprazole and clozapine [36,38–43,119]. The question however remains whether these 
drugs are treating the urge to drink, or if they are simply reducing acute psychosis and thus treat PP 
that might be a symptom of acute psychosis. Other medications that have been found to reduce 
polydiptic behaviour are phenytoin, bupropion, and propranolol [44,45,120]. All therapeutic options 
studied are considered low evidence, as these are descriptions of case reports, small case series or 
small casecontrol group studies. In conclusion, the wide spread of different medication used 
underlines the difficulty in treating this disorder and the need for better options. 
Acute treatment of hyponatraemia in PP primarily consists of fluid restriction. In cases of profound and 
symptomatic hyponatraemia, a 3% saline infusion may be used. Overcorrection of hyponatraemia 
(increase of serum sodium >12 mmol/24h) has been described in patients with PP, fortunately without 
neurological complications [111,121,122]. Nevertheless, treating physicians should be aware of the 
risk of overcorrection and consequently pontine myelinolysis. 
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Conclusion 
In conclusion, the pathophysiology of PP is complex and poorly understood. PP is associated with a 
wide spectrum of psychiatric comorbidities beyond schizophrenia. Moreover, habitual polydipsia 
appears to be increasing in prevalence in lifestyle conscious healthy people. Several factors impairing 
water excretion exist and may promote hyponatraemia in PP, a condition linked to substantial 
morbidity and mortality. 
Fluid restriction is a successful measure to correct the complication of acute hyponatraemia, however, 
in the long run treatment options for this typically chronic condition are scarce. Studies elaborating 
novel therapeutic approaches would be desirable. But most importantly, educational measures in the 
general population might be needed to rationalise the prevalent advice to “drink enough”. 
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Abstract 
Objective Hyponatraemia due to excessive fluid intake (ie primary polydipsia [PP]) is common. It may 
culminate in profound hyponatraemia—carrying considerable risk of morbidity. However, data on 
patients with PP leading to hyponatraemia are lacking. Herein, we describe the characteristics of 
polydiptic patients hospitalized with profound hyponatraemia and assess 1-year outcomes. 
Design Substudy of the prospective observational Co-MED Study. 
Patients: Patients with an episode of profound hyponatraemia (≤125 mmol/L) due to PP in the medical 
emergency were eligible and classified into psychogenic polydipsia (PsyP), dipsogenic polydipsia (DiP) 
and beer potomania (BP). 
Measurements Symptoms, laboratory findings and factors contributing to hyponatraemia 
(comorbidities, medication and liquid intake) were assessed. A 1-year follow-up was performed to 
evaluate recurrence of hyponatraemia, readmission rate and mortality. 
Results Twenty-three patients were included (median age 56 years [IQR 50-65], 74% female), seven 
had PsyP, eight had DiP and eight had BP. Median serum sodium of all patients was 121 mmol/L (IQR 
114-123), median urine osmolality 167 mmol/L (IQR 105-184) and median copeptin 3.6 mmol/L (IQR 
1.9-5.5). Psychiatric diagnoses, particularly dependency disorder (43%) and depression (35%), were 
highly prevalent. Factors provoking hyponatraemia were found in all patients (eg acute water load, 
medication, stress). 
During the follow-up period, 67% of patients were readmitted, 52% of these with rehyponatraemia, 
and three patients (38%) with BP died. 
Conclusion Patients with PP are more likely to be female and to have addictive and affective disorders. 
Given the high recurrence, rehospitalization and mortality rate, careful monitoring and long-term 
follow-up including controls of serum sodium, education and behavioural therapy are needed. 
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Introduction  
Primary polydipsia (PP) is defined as excessive ingestion of fluids (>3000 mL/d) and consecutive 
excretion of profound quantities of dilute urine [5]. PP was first described in patients with 
schizophrenia and has therefore been named “psychogenic polydipsia” (PsyP) [5]. Further categories 
have been reported as: individuals who voluntarily drink excessive fluids without psychiatric 
comorbidities (“dipsogenic polydipsia” [DiP]), individuals who increase drinking after receiving medical 
advice (“iatrogenic polydipsia”) and PP resulting from a brain injury or a pathological process in the 
hypothalamus or the pituitary gland (eg sarcoidosis or traumatic brain injury) [13,82,103,123]. A 
comparable pathology, seen in alcoholics and beer-binge drinkers, is characterized by the chronic or 
acute consumption of large amounts of beer and has been described as “beer potomania” (BP) [56]. 
As underlying pathophysiology, a dysfunction in the dopaminergic and cholinergic system has been 
discussed, resulting in a dysregulation of the thirst centre, as well as an involvement of the 
hippocampal region, leading to “bizarre behaviours” such as constant drinking [7,65,72,124]. 
Excessive fluid intake results in a decrease in serum osmolality and by inhibiting the release of the 
hormone arginine vasopressin (AVP) leads to hypotonic polyuria. The normal excretory capacity of the 
kidneys is about 12 L/d and can thus, in normal circumstances, compensate for the increased liquid 
intake [27]. However, this system might be influenced and changed by external factors. A potentially 
severe complication of excessive fluid intake is the onset of hyponatraemia [95]; 20%-30% of patients 
with schizophrenia and PP develop episodic or chronic hyponatraemia, which is mostly mild and 
oligosymptomatic [5,125]. Nevertheless, some patients may present with profound symptomatic 
hyponatraemia and neurological complications [31]. Several risk factors are thought to predispose 
hyponatraemia: chronicity of PP, acute ingestion of excessive quantities of water exceeding the 
maximum excretory function of the kidney per hour, nonosmotic AVP stimulation (eg psychosis, acute 
stress), smoking and drugs (eg antidepressants, antipsychotics, diuretics) [93,95,126]. A contributing 
factor is the low solute intake, which is typically observed in BP and malnourished people, leading to 
the reduction in the renal excretory capacity from 12 L/d to 8 L/d or less [27,62]. 
Little is known about chronic complications of continuous excessive fluid consumption, but bladder 
dilatation, hydronephrosis, renal failure, congestive heart failure, gastrointestinal dilatation and 
osteopenia with increased risk of fractures have been described [117]. 
Taken together, PP is thought to be associated with substantial morbidity, mortality and health service 
utilization [31,46]. However, consistent clinical data on patients with PP leading to hyponatraemia are 
lacking, information regarding presentation and outcomes being scarce. Most of the existing data arise 
from case reports and retrospective studies within a psychiatric setting. 
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The aim of this prospective study was therefore to describe clinical characteristics of patients with PP 
hospitalized in a general hospital with profound hyponatraemia and to assess outcomes 1-year post 
initial hospitalization. 
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Materials and methods 
Study design 
This is a predefined secondary analysis of a prospective multicentre observational study (Co-MED 
Study) including patients with profound hyponatraemia (≤125 mmol/L) in the medical emergency 
department of two tertiary care centres in Switzerland from June 2011 until August 2013 [127]. Of a 
total of 298 patients with profound hyponatraemia, we enclosed all patients in whom hyponatraemia 
was predominant due to PP (N=23). 
Inclusion criteria were full legal age, profound hyponatraemia and diagnosis of PP, performed by 
experienced board-certified endocrinologists based on medical history (especially drinking habits), 
laboratory findings (serum <125 mmol/L and urinary osmolality <200 mmol/L), clinical examination 
and therapy response. Patients with secondary polydipsia (eg hyperglycaemia) were excluded. Patients 
were divided into the following groups: patients with primarily nonalcoholic fluid intake were 
diagnosed as PP and those consuming large amounts of beer as BP. Patients with PP were further 
classified as PsyP in the presence of psychiatric comorbidities and as DiP in the absence of psychiatric 
comorbidities. 
Informed consent was obtained from all participants. The Ethics Committees of Basel and Aarau 
approved the study protocol. The study was preregistered on clinicaltrials.gov and was conducted per 
the current version of the Declaration of Helsinki, the ICH-GCP and all national legal regulatory 
requirements. 
 
Clinical variables and follow-up: data collection 
Medical history and symptoms related to hyponatraemia were recorded in specified bedside 
interviews. A clinical examination was performed, and data on vital parameters, electrolytes, current 
medication, comorbidities and social status were obtained immediately upon hospitalization. Therapy 
of PP, the course of serum sodium levels, ICU admission and mortality were assessed during the 
hospital stay. The ward physician not involved in the study was responsible for treatment of patients 
during hospitalization. 
Follow-up was performed using a structured telephone interview and revising medical records 1 year 
after initial hospitalization to evaluate readmission rate, recurrence of hyponatraemia and mortality. 
 
Study objectives 
This study was intended to describe clinical and laboratory characteristics of patients hospitalized with 
profound hyponatraemia due to PP in a prospectively enrolled group. Special attention was paid to 
potential risk factors predisposing hyponatraemia, acute symptoms and complications related to 
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hyponatraemia, treatment and outcome 1 year after initial hospitalization. Defined outcome measures 
were readmission rate, recurrence of hyponatraemia and mortality. 
 
Statistical analysis 
All relevant clinical and laboratory parameters obtained by interview, clinical testing and review of 
medical records were entered for statistical analysis into an Excel database. Analyses were performed 
using R (Version 3.3.2 GUI 1.68 Mavericks build [7288], S. Urbanek & H.J. Bibiko, @ R Foundation for 
Statistical Computing, 2016). 
Discrete variables are expressed as frequencies (percentage and number of participants, n), 
continuous variables as median and interquartile range (IQR 25th-75th percentiles), unless stated 
otherwise. Intergroup comparisons were performed using the Kruskal-Wallis or the Fisher’s exact test, 
as appropriate. The significance level was set at P<.05. 
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Results 
Baseline characteristics 
Median age of all participants was 56 years (IQR 50-65), 74% were female. Sixty-five per cent were 
classified as primary polydipsia (PP) and 35% as beer potomania (BP), with 47% of PP patients being 
further classified as psychogenic polydipsia (PsyP) and the remaining 53% as dipsogenic polydipsia 
(DiP). All patients with PsyP and DiP were female (P<.001) and tended to be older (median age 60 years 
[IQR 52-69]) than patients with BP (median age 53 years [IQR 50-57], 25% female). The median 
reported fluid intake was 4350 mL/d (IQR 3000-5000) overall, 4000 mL/d (IQR 4000-5000) for patients 
with PsyP, 3000 mL/d (IQR 2000-3500) for patients with DiP and 5000 mL/d (IQR 4875-5250) for 
patients with BP. 
Laboratory findings on hospital admission of all patients were as follows: median serum sodium of 121 
mmol/L (IQR 114-123), median plasma osmolality of 256 mmol/L (IQR 248-261), median urinary 
osmolality of 167 mmol/L (IQR 105-184) and median urinary sodium of 21.5 mmol/L (IQR 14.3-37). The 
median copeptin level was 3.6 pmol/L (IQR 1.9-5.5). (Table 1). 
 
Comorbidities and medication  
Comorbidities of the study population are provided in Table 2. The most common comorbidities were 
psychiatric disorders (65%) such as substance dependency disorder (43%), depression (35%), 
schizophrenia (13%) and anorexia nervosa (13%). Substance use was ubiquitous within this population: 
together with alcohol dependency, all patients with BP were smokers, which is significantly higher 
compared to the other two groups with 29% smokers in the PsyP group and 38% in the DiP group 
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2.4 | Statistical analysis
All	relevant	clinical	and	laboratory	parameters	obtained	by	interview,	
clinical	testing	and	review	of	medical	records	were	entered	for	statis-
tical	analysis	into	an	Excel	database.	Analyses	were	performed	using	
R	(Version	3.3.2	GUI	1.68	Mavericks	build	[7288],	S.	Urbanek	&	H.J.	
Bibiko,	@	R	Foundation	for	Statistical	Computing,	2016).
Discrete	 variables	 are	 expressed	 as	 frequencies	 (percentage	 and	
number	of	participants,	n),	 continuous	variables	as	median	and	 inter-
quartile	 range	 (IQR	 25th-	75th	 percentiles),	 unless	 stated	 otherwise.	
Intergroup	comparisons	were	performed	using	the	Kruskal-	Wallis	or	the	
Fisher’s	exact	test,	as	appropriate.	The	significance	level	was	set	at	P<.5.
3  | RESULTS
3.1 | Baseline characteristics
Median	age	of	all	participants	was	56	years	(IQR	50-	65),	74%	were	fe-
male.	Sixty-	five	per	cent	were	classified	as	primary	polydipsia	(PP)	and	
35%	as	beer	potomania	(BP),	with	47%	of	PP	patients	being	further	
classified	 as	 psychogenic	 polydipsia	 (PsyP)	 and	 the	 remaining	 53%	
as	dipsogenic	polydipsia	 (DiP).	All	patients	with	PsyP	and	DiP	were	
female	 (P<.001)	 and	 tended	 to	 be	 older	 (median	 age	 60	years	 [IQR	
52-	69])	than	patients	with	BP	(median	age	53	years	[IQR	50-	57],	25%	
female).	The	median	reported	fluid	intake	was	4350	mL/d	(IQR	3000-	
5000)	 overall,	 4000	mL/d	 (IQR	 4000-	5000)	 for	 patients	with	 PsyP,	
3000	mL/d	 (IQR	 2000-	3500)	 for	 patients	with	DiP	 and	 5000	mL/d	
(IQR	4875-	5250)	for	patients	with	BP.
Laboratory	findings	on	hospital	admission	of	all	patients	were	as	
follows:	median	serum	sodium	of	121	mmol/L	(IQR	114-	123),	median	
plasma	osmolality	of	256	mmol/L	(IQR	248-	261),	median	urinary	os-
molality	of	167	mmol/L	(IQR	105-	184)	and	median	urinary	sodium	of	
21.5	mmol/L	(IQR	14.3-	37).	The	median	copeptin	level	was	3.6	pmol/L	
(IQR	1.9-	5.5).	(Table	1).
3.2 | Comorbidities and medication
Comorbidities	of	the	study	population	are	provided	 in	Table	2.	The	
most	common	comorbidities	were	psychiatric	disorders	 (65%)	such	
as	substance	dependency	disorder	(43%),	depression	(35%),	schizo-
phrenia	(13%)	and	anorexia	nervosa	(13%).	Substance	use	was	ubiq-
uitous	within	this	population:	together	with	alcohol	dependency,	all	
patients	with	 BP	were	 smokers,	which	 is	 significantly	 higher	 com-
pared	to	the	other	two	groups	with	29%	smokers	in	the	PsyP	group	
and	38%	in	the	DiP	group	respectively	(P-	value	.007).	One	person	per	
group	was	known	to	have	been	using	illicit	drugs	in	the	past.	Further	
comorbidities	 included	epilepsy	 (26%),	 renal	 (17%)	and	cardiac	dis-
eases	 (13%).	Fifty-	seven	per	cent	with	PsyP,	25%	with	DiP,	and	all	
patients	with	BP	had	experienced	hyponatraemia	in	the	past	(P-	value	
.013)	(Table	2).
The	following	medications	were	recorded	upon	hospital	admission	
known	 to	predispose	hyponatraemia:	benzodiazepine	 (43%),	 antide-
pressant	drugs	(39%),	diuretics	(30%),	antipsychotic	drugs	(26%),	an-
tiepileptic	drugs	(22%)	and	opioids	(13%).	Drug	use	was	higher	in	the	
patient	group	with	PsyP	than	with	DiP	or	BP.	Eighty-	three	per	cent	of	
all	patients	had	at	least	one	of	these	medications	(Table	2).
TABLE  1 Baseline	characteristics	of	23	patients,	classified	as	patients	with	psychogenic,	dipsogenic	polydipsia	and	beer	potomania
Characteristics
All  
participants
Psychogenic  
polydipsia
Dipsogenic  
polydipsia
Beer  
potomania
P- 
value
n 23 7 8 8
Age	(yrs),	median	(IQR) 56	(50-	65) 60	(52-	63) 60	(53-	73) 53	(50-	57) .55
Female,	%	(n) 74	(17) 100	(7) 100	(8) 25	(2) <.001
Systolic	blood	pressure	(mm	Hg),	median	(IQR) 122	(110-	144) 114	(107-	126) 116	(103-	144) 136	(122-	147) .26
Heart	rate	(beats	per	minute),	median	(IQR) 87	(76-	96) 84	(68-	94) 90	(83-	94) 85	(76-	99) .73
Body	temperature	(°C),	median	(IQR) 37	(36.5-	37.4) 37.2	(36.7-	37.5) 37.1	(36.8-	37.6) 36.9	(36.4-	37.0) .46
GCS,	min-	max 15	(13-	15) 15	(15-	15) 15	(15-	15) 15	(13-	15) .06
BMI	(kg/m2),	median	(IQR) 22.6	(16.8-	29.1) 16.2	(13.8-	22.6) 23.5	(22.7-	25.1) 29	(19.2-	32) .15
Reported	amount	of	drinking/d	(mL),	median	(IQR) 4350	(3000-	5000) 4000	(4000-	5000) 3000	(2000-	3500) 5000	(4875-	5250) .02
Laboratory	findings
Serum	sodium	(mmol/L),	median	(IQR) 121	(114-	123) 122	(120-	123) 121	(119-	123) 114	(111-	123) .61
Serum	potassium	(mmol/L),	median	(IQR) 3.9	(3.35-	4.4) 3.9	(3.5-	4.1) 3.7	(3.1-	3.8) 4.6	(4.3-	4.9) .01
Plasma	osmolality	(mmol/L),	median	(IQR) 256	(248-	261) 255	(249-	258) 254	(247-	261) 258	(240-	276) .47
Copeptin	(pmol/L),	median	(IQR) 3.6	(1.9-	5.5) 2.3	(1.8-	3.1) 2.5	(1.4-	5.1) 4.2	(3.7-	7.3) .19
Urinary	sodium	(mmol/L),	median	(IQR) 21.5	(14.3-	37.3) 31.0	(18.8-	41.8) 21.5	(13.0-	29.8) 17.0	(13.8-	35.8) .47
Urine	osmolality	(mmol/L),	median	(IQR) 167	(105-	184) 138	(94-	180) 137	(93-	187) 178	(130-	184) .53
CI,	confidence	interval;	GCS,	Glasgow	Coma	Scale;	BMI,	body	mass	index.
Data	are	presented	as	%	(n)	and	median	(IQR:	25th	-	75th).	Intergroup	comparisons	were	made	using	the	Kruskal-	Wallis	test	for	continuous	and	the	Fisher’s	
Exact	test	for	binomial	outcome.	Bold	P	values	represent	statistically	significant	results.
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respectively (P-value .007). One person per group was known to have been using illicit drugs in the 
past. Further comorbidities included epilepsy (26%), renal (17%) and cardiac diseases (13%). Fifty-
seven per cent with PsyP, 25% with DiP, and all patients with BP had experienced hyponatraemia in 
the past (P-value .013) (Table 2).  
The following medications were recorded upon hospital admission known to predispose 
hyponatraemia: benzodiazepine (43%), antidepressant drugs (39%), diuretics (30%), antipsychotic 
drugs (26%), antiepileptic drugs (22%) and opioids (13%). Drug use was higher in the patient group 
with PsyP than with DiP or BP. Eighty-three per cent of all patients had at least one of these 
medications (Table 2).  
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3.3 | Symptoms and therapy
The	most	common	symptoms	in	our	population	were	generalized	weak-
ness	(65%),	sensation	of	thirst	(61%),	nocturia	(48%),	nausea	(39%)	and	
gait	disturbance	(26%).	Gait	disturbance	occurred	significantly	more	often	
in	patients	with	BP	compared	to	the	other	groups	(P=.012)	(Table	3).
All	participants	received	an	initial	treatment	of	free	fluid	restriction,	
combined	with	0.9%	saline	in	57%.	No	patient	received	3%	saline.	Median	
correction	rate	within	the	first	24	h	was	6	mmol/L	(IQR	4-	10),	two	ex-
perienced	overcorrection	(increase	of	serum	sodium	level	by	14	mmol/L	
and	 20	mmol/L),	 nevertheless	 without	 clinical	 signs	 of	 pontine	 my-
elinolysis.	 Median	 serum	 sodium	 level	 at	 discharge	 was	 135	mmol/L	
(IQR	132-	138	mmol/L).	Forty-	eight	per	cent	of	all	participants	(41%	of	
PP	and	66%	of	BP)	were	discharged	before	a	normal	 sodium	 level	of	
>135	mmol/L	was	reached.	Twenty-	two	per	cent	had	to	be	admitted	to	
the	 intensive	care	unit	 (ICU),	14%	with	PsyP,	none	with	DiP	and	50%	
with	BP.	Reasons	for	ICU	admission	were	symptomatic	hyponatraemia,	
a	bone	fracture	due	to	an	acute	fall,	alcohol	abstinence	delirium	and	re-
spiratory	problems.	One	patient	of	the	group	of	BP	died	during	the	initial	
hospitalization	due	to	sepsis	caused	by	aspiration	pneumonia	(Table	3).
Two	participants	(29%)	with	PsyP	had	to	be	transferred	to	a	psychi-
atric	hospital	for	further	treatment	after	correction	of	hyponatraemia.
3.4 | Factors contributing to the development of 
hyponatraemia
Possible	 factors	 contributing	 to	 the	development	of	 hyponatraemia	
were	 found	 in	 every	 patient.	 Besides	 an	 impaired	 water	 excretory	
TABLE  2 Comorbidities	and	medication	of	23	patients,	classified	as	patients	with	psychogenic	polydipsia,	dipsogenic	polydipsia	and	beer	
potomania
All  
participants
Psychogenic  
polydipsia
Dipsogenic  
polydipsia
Beer  
potomania P- value
n 23 7 8 8
Comorbidities
Psychiatric	disorder,	%	(n) 65	(15) 100	(7) 0	(0) 100	(8) <.001
Dependency	disorder,	%	(n) 48	(11) 43	(3) 0	(0) 100	(8) .01
Depression,	%	(n) 39	(9) 86	(6) 0	(0) 38	(3) .14
Personality	disorder,	%	(n) 17	(4) 57	(4) 0	(0) 0	(0) .004
Schizophrenia,	%	(n) 13	(3) 29	(2) 0	(0) 13	(1) .27
Anorexia	nervosa,	%	(n) 13	(3) 43	(3) 0	(0) 0	(0) .02
Anxiety	disorder,	%	(n) 9	(2) 0	(0) 0	(0) 25	(2) .3
Bipolar	disorder,	%	(n) 4	(1) 0	(0) 0	(0) 13	(1) 1
Epilepsy,	%	(n) 26	(6) 29	(2) 38	(3) 13	(1) .62
Pulmonary	disease,	%	(n) 17	(4) 14	(1) 13	(1) 25	(2) 1
Renal	disease,	%	(n) 17	(4) 0	(0) 25	(2) 25	(2) .49
Cardiac	insufficiency,	%	(n) 13	(3) 14	(1) 0	(0) 25	(2) .49
Hypertension,	%	(n) 48	(11) 29	(2) 38	(3) 75	(6) .2
Hyponatraemia	in	the	past,	%	(n) 61	(14) 57	(4) 25	(2) 100	(8) .013
Smoking,	%	(n) 57	(13) 29	(2) 38	(3) 100	(8) .007
Smoking	amount	(py),	median	(IQR) 40	(20-	60) 20	(15-	30) 20	(12-	25) 59	(49-	60) <.001
Alcohol	consumption,	%	(n) 57	(13) 29	(2) 38	(3) 100	(8) .007
Medication
Benzodiazepine,	%	(n) 43	(10) 57	(4) 25	(2) 50	(4) .57
Benzodiazepine	abuse,	%	(n) 17	(4) 29	(2) 0	(0) 25	(2) .41
Antidepressant	drugs,	%	(n) 39	(9) 86	(6) 0	(0) 38	(3) .002
Antipsychotic	drugs,	%	(n) 26	(6) 43	(3) 13	(1) 25	(2) .43
Antiepileptic	drug,	%	(n) 22	(5) 29	(2) 25	(2) 13	(1) .84
Opioids,	%	(n) 13	(3) 29	(2) 0	(0) 13	(1) .27
Diuretics,	%	(n) 26	(6) 29	(2) 25	(2) 38	(2) 1
No	medication,	%	(n) 17	(4) 0	(0) 38	(3) 13	(1) .27
IQR,	interquartile	range;	py,	pack	years.
Data	are	presented	as	%	(n)	and	median	(IQR:	25th	-	75th).	Intergroup	comparisons	were	made	using	the	Kruskal-	Wallis	test	for	continuous	and	the	Fisher’s	
Exact	test	for	binomial	outcome.	Bold	P	values	represent	statistically	significant	results.
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Symptoms and therapy  
The most common symptoms in our population were generalized weakness (65%), sensation of thirst 
(61%), nocturia (48%), nausea (39%) and gait disturbance (26%). Gait disturbance occurred significantly 
more often in patients with BP compared to the other groups (P=.012) (Table 3).  
All participants received an initial treatment of free fluid restriction, combined with 0.9% saline in 57%. 
No patient received 3% saline. Median correction rate within the first 24 h was 6 mmol/L (IQR 4-10), 
two participants experienced overcorrection (increase of serum sodium level by 14 mmol/L and 20 
mmol/L), nevertheless without clinical signs of pontine myelinolysis. Median serum sodium level at 
discharge was 135 mmol/L (IQR 132-138 mmol/L). Forty-eight per cent of all participants (41% of PP 
and 66% of BP) were discharged before a normal sodium level of >135 mmol/L was reached. Twenty-
two per cent had to be admitted to the intensive care unit (ICU), 14% with PsyP, none with DiP and 
50% with BP. Reasons for ICU admission were symptomatic hyponatraemia, a bone fracture due to an 
acute fall, alcohol abstinence delirium and respiratory problems. One patient of the group of BP died 
during the initial hospitalization due to sepsis caused by aspiration pneumonia (Table 3).  
Two participants (29%) with PsyP had to be transferred to a psychiatric hospital for further treatment 
after correction of hyponatraemia.       |  5SAILER Et AL.
capacity	due	to	malnutrition,	the	main	reason	was	a	concomitant	stim-
ulus	for	AVP.	All	patients	with	PsyP,	75%	with	DiP	and	63%	with	BP	
were	found	to	have	medications	potentially	stimulating	AVP.	Another	
common	nonosmotic	AVP	stimulus	was	an	acute	infection	(pneumo-
nia	or	urogenital	tract	infection)	in	50%	of	patients	with	DiP	and	38%	
with	BP.	Further	trigger	factors	for	AVP	were	nausea	(39%),	reduced	
GCS,	 a	 transitory	 ischaemic	attack	 (TIA)	 and	a	 seizure.	None	of	 the	
patients	suffered	from	an	acute	psychotic	episode	(Table	4).
3.5 | One- year follow- up of primary polydipsia
Complete	 follow-	up	 data	 were	 available	 for	 21	 participants	 (91%).	
Sixty-	six	per	cent	of	the	patients	with	PsyP	were	readmitted	to	the	
hospital,	 25%	 at	 least	 twice	 and	 50%	 experienced	 another	 episode	
of	hyponatraemia.	In	the	patient’s	group	with	DiP,	43%	were	rehos-
pitalized:	33%	more	than	once	and	66%	with	another	episode	of	hy-
ponatraemia.	 All	 patients	with	 BP	were	 readmitted	 to	 the	 hospital,	
57%	more	than	once	and	all	had	another	episode	of	hyponatraemia.	
Mortality	rate	in	BP	was	38%:	one	patient	died	during	the	initial	hos-
pitalization,	 two	 more	 throughout	 the	 follow-	up	 year,	 one	 due	 to	
complications	 of	 an	 abdominal	 surgery	 and	 the	 other	 for	 unknown	
reasons.	None	of	 the	patients	 seemed	 to	have	died	directly	 due	 to	
hyponatraemia	(Table	5).
4  | DISCUSSION
To	our	knowledge,	this	is	the	first	prospective	study	on	patients	with	
increased	 fluid	 consumption	 leading	 to	 hyponatraemia	 in	 a	medical	
emergency	 setting.	We	 herein	 present	 the	 following	main	 findings:	
first,	patients	with	excessive	fluid	 intake	exhibit	a	wide	spectrum	of	
mostly	psychiatric	comorbidities.	Second,	 in	hyponatraemic	patients	
with	polydipsia	several	risk	factors	impairing	water	excretion	and	pro-
moting	 hyponatraemia,	 respectively,	 are	 present.	 Third,	 compulsive	
fluid	 ingestion	 is	 a	 chronic	 disorder	 and	 associated	with	 substantial	
morbidity	and	mortality.
TABLE  3 Symptoms	at	admission	and	therapy	of	23	patients	and	subclassification	as	patients	with	psychogenic	polydipsia,	dipsogenic	
polydipsia	and	patients	with	beer	potomania
All  
participants
Psychogenic  
polydipsia
Dipsogenic  
polydipsia
Beer  
potomania P- value
n 23 7 8 8
Symptoms
Generalized	weakness,	%	(n) 65	(15) 71	(5) 50	(4) 75	(6) .66
Sensation	of	thirst,	%	(n) 61	(14) 71	(5) 63	(5) 50	(4) .87
Nocturia,	%	(n) 43	(10) 57	(4) 38	(3) 38	(3) .76
Concentration	disorder,	%	(n) 39	(9) 29	(2) 38	(3) 50	(4) .87
Headache,	%	(n) 30	(7) 14	(1) 50	(4) 25	(2) .4
Nausea,	%	(n) 39	(9) 43	(3) 38	(3) 38	(3) 1
Vomitus,	%	(n) 26	(6) 29	(2) 38	(3) 13	(1) .62
Diarrhoea,	%	(n) 39	(9) 29	(2) 50	(4) 38	(3) .87
Gait	disturbance,	%	(n) 26	(6) 14	(1) 0	(0) 63	(5) .012
Recurrent	falls,	%	(n) 17	(4) 14	(1) 0	(0) 38	(3) .17
Acute	fall,	%	(n) 9	(2) 14	(1) 0	(0) 13	(1) .75
Bone	fracture,	%	(n) 4	(1) 14	(1) 0	(0) 0	(0) .3
Muscle	cramp,	%	(n) 17	(4) 14	(1) 13	(1) 25	(2) 1
Seizure,	%	(n) 4	(1) 0	(0) 13	(1) 0	(0) 1
Therapy 1
Free	fluid	restriction,	%	(n) 100	(23) 100	(7) 100	(8) 100	(8) .1
Amount	of	drinking	d	1	(mL/d),	median	(IQR) 1500	(1000-	1800) 1000	(820-	1375) 1500	(850-	1500) 1800	(1500-	2500) .49
Substitution	of	isotonic	solution	(0.9%),	%	(n) 57	(13) 43	(3) 50	(4) 75	(6) .049
ICU	admission,	%	(n) 22	(5) 14	(1) 0	(0) 50	(4) .09
Time	until	Na>130	mmol/L	(d),	median	(IQR) 3	(2-	4) 2.5	(1.3-	8.25) 2	(1-	3) 4	(2.8-	6.3) .27
Natrium	at	discharge	(mmol/L) 135	(133-	139) 137	(133-	140) 135	(134-	139) 133	(130-	138) .66
Natrium	>135	mmol/L	at	discharge,	%	(n) 74	(17) 86	(6) 75	(6) 63	(5) .87
ICU,	intensive	care	unit;	IQR,	interquartile	range.
Data	are	presented	as	%	(n)	and	median	(IQR:	25th	-	75th).	Intergroup	comparisons	were	made	using	the	Kruskal-	Wallis	test	for	continuous	and	the	Fisher’s	
Exact	test	for	binomial	outcome.	Bold	P	values	represent	statistically	significant	results.
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Factors contributing to the development of hyponatraemia  
Possible factors contributing to the development of hyponatraemia were found in every patient. 
Besides an impaired water excretory capacity due to malnutrition, the main reason was a concomitant 
stimulus for AVP. All patients with PsyP, 75% with DiP and 63% with BP were found to have medications 
potentially stimulating AVP. Another common nonosmotic AVP stimulus was an acute infection 
(pneumonia or urogenital tract infection) in 50% of patients with DiP and 38% with BP. Further trigger 
factors for AVP were nausea (39%), reduced GCS, a transitory ischaemic attack (TIA) and a seizure. 
None of the patients suffered from an acute psychotic episode (Table 4).  
 
One-year follow-up of primary polydipsia  
Complete follow-up data were available for 21 participants (91%). Sixty-six per cent of the patients 
with PsyP were readmitted to the hospital, 25% at least twice and 50% experienced another episode 
of hyponatraemia. In the patient’s group with DiP, 43% were rehospitalized: 33% more than once and 
66% with another episode of hyponatraemia. All patients with BP were readmitted to the hospital, 
57% more than once and all had another episode of hyponatraemia. Mortality rate in BP was 38%: one 
patient died during the initial hospitalization, two more throughout the follow-up year, one due to 
complications of an abdominal surgery and the other for unknown reasons. None of the patients 
seemed to have died directly due to hyponatraemia (Table 5).  
 
 
  
6  |     SAILER Et AL.
In	our	population,	psychiatric	diagnoses	were	prevalent	in	patients	
with	PsyP	and	BP.	Of	note,	 all	patients	with	PsyP	and	DiP	were	 fe-
male,	while	patients	with	BP	were	mostly	male.	Psychiatric	patients	
especially	with	chronic	schizophrenia	are	known	to	be	at	risk	of	suf-
fering	from	PsyP.14,21,22	Here,	only	few	patients	had	such	a	diagnosis.	
In	contrast,	the	most	prevalent	psychiatric	disorder	was	dependency	
disorder.	Given	that	compulsive	fluid	 ingestion	per	se	could	be	seen	
as	an	addictive	behaviour,	this	seems	likely	and	is	supported	by	a	high	
prevalence	of	smoking	in	this	and	other	studies.14
Another	 frequent	psychiatric	 disorder	was	depression.	Only	one	
case	report	describes	PsyP	in	the	context	of	depression.23	The	asso-
ciation	of	depression	and	PsyP	could	be	explained	by	a	hippocampal	
involvement,	 a	 brain	 region	 involved	 in	 affective	 disorders,	 which	
modulates	the	AVP	response	to	stress.10,24,25	An	alternative	 xplana-
tion	could	be	the	anticholinergic	side	effects	of	antidepressants	caus-
ing	an	elevated	sensation	of	thirst.
Interestingly,	three	patients	with	PsyP	had	a	diagnosis	of	anorexia	
nervosa.	Further,	two	patients	had	a	BMI	<17.5	kg/m2.	Patients	with	
anorexia	nervosa	may	increase	liquid	consumption	to	compensate	for	
low	food	intake	and	to	decrease	the	sensation	of	hunger.	Similarities	
of	anorexia	nervosa	and	BP—characterized	by	malnutrition	with	 low	
protein	 and	 high	 liquid	 intake—are	 striking.	 A	 minimum	 of	 solutes	 
(50-	60	mmol/L)	is	necessary	for	a	normal	renal	function	with	adequate	
water	clearance.	Hence,	 in	people	with	anorexia,	BP	or	malnutrition,	
the	low	solute	intake	increases	the	risk	of	hyponatraemia,11	especially	
when	combined	with	high	fluid	ingestion.
Surprisingly,	 one-	third	 of	 the	 patients	 had	 no	 psychiatric	 comor-
bidity	and	were	categorized	into	the	DiP	group.	This	 is	an	interesting	
finding,	because	until	now,	polydipsia	has	mainly	been	studied	in	the	
psychiatric	setting.	Although	most	DiP	patients	might	not	experience	
hyponatraemia,	 special	 situations	 associated	 with	 (AVP-	stimulating)	
stress,	such	as	acute	illness,	may	put	them	at	risk	to	develop	hypona-
traemia.	Interestingly,	there	is	an	increasing	number	of	case	reports	de-
scribing	patients	with	DiP	who	develop	hyponatraemia	during	an	acute	
infection	(eg	pneumonia,	urogenital	tract	infection).26,27	Educative	mea-
sures	in	the	general	population	might	be	needed	to	rationalize	the	prev-
alent	advice	to	“drink	a	lot	in	acute	illnesses,”	and	the	required	amount	
of	drinking,	especially	in	acute	illnesses,	should	be	further	investigated.
TABLE  4 Possible	factors	contributing	to	the	development	of	hyponatraemia	of	23	patients,	classified	as	patients	with	psychogenic,	
dipsogenic	polydipsia	and	beer	potomania
Factor causing  
hyponatraemia
All  
participants
Psychogenic  
polydipsia
Dipsogenic  
polydipsia
Beer  
potomania P- value
n 23 7 8 8
Acute	fluid	intake,	%	(n) 13	(3) 14	(1) 0	(0) 25	(2) .494
Impaired	water	excretion,	%	(n) 100	(23) 100	(7) 100	(8) 100	(8) 1
Low	solute	intake,	n	(%) 52	(12) 57	(4) 0	(0) 100	(8) <.001
Concomitant	AVP	stimulus,	n	(%) 100	(23) 100	(7) 100	(8) 100	(8) 1
Medication,	n	(%) 78	(18) 100	(7) 75	(6) 63	(5) .3
Pneumonia/COPD	exacerbation,	n	(%) 17	(4) 0	(0) 13	(1) 38	(3) .27
UGT	infection,	n	(%) 17	(4) 14	(1) 38	(3) 0	(0) .17
Nausea/Vomitus,	n	(%) 39	(9) 43	(3) 38	(3) 38	(3) 1
Acute	psychosis,	n	(%) 0	(0) 0	(0) 0	(0) 0	(0) 1
AVP,	vasopressin;	COPD,	chronic	obstructive	pulmonary	disease;	UGT,	urogenital	tract.
Data	are	presented	as	%	(n)	and	median	(IQR:	25th	-	75th).	Intergroup	comparisons	were	made	using	the	Kruskal-	Wallis	test	for	continuous	and	the	Fisher’s	
Exact	test	for	binomial	outcome.	Bold	P	values	represent	statistically	significant	results.
TABLE  5 One-	year	follow-	up	of	23	patients	and	subclassifications	as	psychogenic	polydipsia,	dipsogenic	polydipsia	and	beer	potomania
Follow- up
All  
participants
Psychogenic  
polydipsia
Dipsogenic  
polydipsia
Beer  
potomania P- value
n 21 6 7 8
Rehospitalization,	%	(n) 67	(14) 66	(4) 43	(3) 88	(7) .21
Recurrent	rehospitalization,	%	(n) 43	(6) 25	(1) 33	(1) 57	(4) .28
Rehyponatraemia,	%	(n) 79	(11) 50	(2) 66	(2) 100	(7) .47
Profound	hyponatraemia	(<125	mm l/L),	%	(n) 36	(5) 25	(1) 0	(0) 57	(4) .08
Time	until	first	rehospitalization,	%	(n) 66	(29-	125) 108	(27-	142) 110	(80-	138) 57	(25-	95) .55
Mortality	rate,	%	(n) 14	(3) 0	(0) 0	(0) 38	(3) .08
Data	are	presented	as	%	(n)	and	median	(IQR:	25th	-	75th).	Intergroup	comparisons	were	made	using	the	Kruskal-	Wallis	test	for	continuous	and	the	Fisher’s	
Exact	test	for	binomial	outcome.	Bold	P	values	represent	statistically	significant	results.
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Discussion 
To our knowledge, this is the first prospective study on patients with increased fluid consumption 
leading to hyponatraemia in a medical emergency setting. We herein present the following main 
findings: first, patients with excessive fluid intake exhibit a wide spectrum of mostly psychiatric 
comorbidities. Second, in hyponatraemic patients with polydipsia several risk factors impairing water 
excretion and promoting hyponatraemia, respectively, are present. Third, compulsive fluid ingestion 
is a chronic disorder and associated with substantial morbidity and mortality.  
In our population, psychiatric diagnoses were prevalent in patients with PsyP and BP. Of note, all 
patients with PsyP and DiP were female, while patients with BP were mostly male. Psychiatric patients 
especially with chronic schizophrenia are known to be at risk of suffering from PsyP [30,31,128]. Here, 
only few patients had such a diagnosis. In contrast, the most prevalent psychiatric disorder was 
dependency disorder. Given that compulsive fluid ingestion per se could be seen as an addictive 
behaviour, this seems likely and is supported by a high prevalence of smoking in this and other studies 
[31].  
Another frequent psychiatric disorder was depression. Only one case report describes PsyP in the 
context of depression [129]. The association of depression and PsyP could be explained by a 
hippocampal involvement, a brain region involved in affective disorders, which modulates the AVP 
response to stress[25,65,130]. An alternative explanation could be the anticholinergic side effects of 
antidepressants causing an elevated sensation of thirst.  
Interestingly, three patients with PsyP had a diagnosis of anorexia nervosa. Further, two patients had 
a BMI <17.5 kg/m2. Patients with anorexia nervosa may increase liquid consumption to compensate 
for low food intake and to decrease the sensation of hunger. Similarities of anorexia nervosa and BP—
characterized by malnutrition with low protein and high liquid intake—are striking. A minimum of 
solutes (50-60 mmol/L) is necessary for a normal renal function with adequate water clearance. Hence, 
in people with anorexia, BP or malnutrition, the low solute intake increases the risk of hyponatraemia 
[27], especially when combined with high fluid ingestion.  
Surprisingly, one-third of the patients had no psychiatric comorbidity and were categorized into the 
DiP group. This is an interesting finding, because until now, polydipsia has mainly been studied in the 
psychiatric setting. Although most DiP patients might not experience hyponatraemia, special situations 
associated with (AVP-stimulating) stress, such as acute illness, may put them at risk to develop 
hyponatraemia. Interestingly, there is an increasing number of case reports describing patients with 
DiP who develop hyponatraemia during an acute infection (eg pneumonia, urogenital tract infection) 
[101,102]. Educative measures in the general population might be needed to rationalize the prevalent 
advice to “drink a lot in acute illnesses” and the required amount of drinking, especially in acute 
illnesses, should be further investigated.  
Inaugural dissertation – Dr med. Clara Odilia Sailer 39 
In all groups, patients with the diagnosis of epilepsy were present. One of these patients experienced 
an acute seizure presumably due to hyponatraemia [131]. Beyond this acute complication, a probable 
association of temporal epilepsy and peri-ictal water consumption has been suggested [132]. The 
development of hyponatraemia in these patients might also be due to antiepileptic drugs.  
Even in the presence of profound hyponatraemia, patients declared a sensation of thirst. This 
emphasizes that PP is caused by a dysfunction in the thirst centre [124], and that the osmotic threshold 
of thirst perception is depressed below the osmotic threshold for AVP secretion [133]. Alternatively, it 
might mirror a behavioural misperception associated with the chronic urge to drink. Suppression of 
AVP and thus maximally suppressed urine osmolality are expected during increased consumption of 
liquid. In our study, urine osmolality remained unexpectedly high. It has been shown that patients with 
PP who become hyponatraemic have a higher urine osmolality than patients with PP who remain 
normonatraemic, indicating insufficient AVP suppression [28,30]. Underlining the nonosmotic AVP 
stimulus in our patients, we found nonsuppressed copeptin levels. Copeptin, a stable and reliable 
surrogate marker of AVP [134], has been shown to be high in other aetiologies of hyponatraemia in 
the Co-MED study: the median copeptin values were 36.7 pmol/L (IQR 12.09-88.30 pmol/L) in 
hypovolaemic hyponatraemia, 28.15 pmol/L (IQR 12.42-64.45 pmol/L) in hypervolaemic 
hyponatraemia and 11.87 pmol/L (IQR 5.35-27.20 pmol/L) in SIADH (syndrome of inappropriate 
antidiuretic hormone secretion) [127]. We hypothesize that for patients with PP to become 
hyponatraemic, a certain AVP stimulus is needed. Such a stimulus could be physical (eg acute infection) 
or psychological stress (eg acute psychosis), drugs (eg antidepressants, antipsychotics) or smoking. 
Every patient had at least one of these stimuli.  
Copeptin levels were slightly higher in BP compared to the other two groups. As copeptin is also a 
stress hormone, the more severe illness in BP patients (more comorbidity and reduced GCS) could be 
one explanation. Alternatively, the predominance of male gender could explain the higher copeptin 
levels, as men generally show higher copeptin values than women.  
Therapy with fluid restriction was successful in all patients to raise sodium levels; none needed 
treatment with hypertonic saline. Some patients were admitted to the ICU for close monitoring of 
sodium levels, while other patients were admitted to the ICU not due to their hyponatraemia 
symptoms but because of comorbidities.  
Our third main finding is an unfavourable 1-year outcome, particularly in patients with BP. Within 1 
year, most patients had to be rehospitalized at least once, and recurrent hyponatraemia was common.  
In patients with BP the mortality rate was high, although cause of death seemed not directly related 
to hyponatraemia itself. The electrolyte disturbance may also be interpreted as marker of disease 
severity in this context [58].  
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The high recurrence of hyponatraemia and rehospitalization rate highlights the chronicity of PP and 
illustrates that simply correcting hyponatraemia is insufficient in these patients. Patients with PP may 
benefit from a longer follow-up with focus on cognitive behavioural therapy to treat excessive fluid 
intake and identification of hyponatraemia predisposing factors (eg concomitant drugs, comorbidities, 
behavioural misconceptions in the general population) to prevent development of hyponatraemia.  
 
Strengths and limitations  
Several limitations should be considered for the interpretation of our results. First, the design of a 
secondary analysis of an observational study increases the risk of biases. Second, the limited number 
of people with PP should be considered when extrapolating the results to the population. Third, to 
discriminate PP from SIADH, a cut-off limit for urinary osmolality of 100 mmol/l is proposed in the 
current guidelines for hyponatraemia [135,136]. We and others [123] use a higher cut-off of 200 
mmol/L which might have led to misclassification. Nevertheless, final diagnosis of PP was not only 
based on urinary osmolality, but included all available clinical and laboratory information. We believe 
that the predominant cause in our patients was polydipsia, but an additional component of a SIADH 
might have been present. Fourth, the half-life of copeptin is not known but supposed to be longer than 
the half-life of AVP; thus, we cannot exclude that the nonsuppressed copeptin levels in the presence 
of acute water load seen in our patients are explained by its longer half-life. Fifth, most of the patients 
did not have a cerebral imaging, and thus we might have underestimated patients with 
hypothalamic/pituitary lesions. Fifth, we probably underestimated the proportion of psychotic 
patients, as they might have been treated in a psychiatric hospital. Strengths of our study include the 
prospective design, which allowed us to carefully diagnose and characterize patients with PsyP, DiP 
and BP, and the investigation of polydiptic patients outside a psychiatric setting.  
 
Conclusion 
Excessive fluid intake is a complex medical condition, which may lead to life-threatening 
hyponatraemia especially when exposed to AVP stimulus and/or reduced renal excretory capacity. 
Primary polydipsia is not only present in patients with schizophrenia spectrum disorder but also in a 
wider range of psychiatric diagnosis. Specifically, we found a high prevalence of addictive and affective 
disorders in our patients—the interplay between these disorders with PP and hyponatraemia should 
be elucidated in further studies. Nevertheless, one-third did not suffer from a psychiatric disorder. 
Given the high recurrence, rehospitalization and mortality rate especially in patients with BP, longer 
follow-up, including controls of serum sodium, education (regarding eating and drinking habits) and 
behavioural therapy must be integrated in current therapeutic approaches.  
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Abstract  
Context Hyponatremia is the most common electrolyte disturbance in hospitalized patients. Known 
risk factors are heart or renal failure, excessive drinking, or the use of diuretics. The incidence of 
hyponatremia may also be influenced by climate.  
Objective Analyzing the influence of outdoor temperature and relative humidity on the incidence and 
etiology of hyponatremia.  
Design: Cohort A: cross-sectional study from January 2011 to December 2016. Cohort B: prospective 
observational study from June 2011 to August 2013.  
Setting Emergency departments of two tertiary centers. 
Patients Cohort A: patients with plasma sodium £145 mmol/L (n = 222,217). Cohort B: consecutive 
patients (n = 294) with profound hyponatremia (plasma sodium £125 mmol/L).  
Main Outcome Measure The effects of outdoor temperature and relative humidity on the incidence 
of mild (sodium 126 to 134 mmol/L) and profound hyponatremia (sodium £125 mmol/L) were 
investigated via logistic regression models. The effects of outdoor temperature and relative humidity 
on hyponatremia etiology were evaluated.  
Results In cohort A, 9.9% had mild and 1.08% had profound hyponatremia. Outdoor temperature was 
significantly associated with the incidence of profound but not mild hyponatremia (P < 0.01, P = 0.3). 
Relative humidity was not associated with the incidence of hyponatremia. In cohort B, diuretic-induced 
hyponatremia occurred more frequently with higher outdoor temperatures, whereas other etiologies 
showed no clear variation with outdoor temperature or relative humidity.  
Conclusions Higher outdoor temperature, but not relative humidity, seems to be associated with the 
incidence of profound hyponatremia. Our data suggest that diuretics should be used with caution 
during hot weather.  
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Introduction  
Hyponatremia is the most common electrolyte disorder and is associated with increased morbidity and 
mortality [58,135,137]. The incidence of mild hyponatremia (plasma sodium 126 to 134 mmol/L) 
ranges from 10% to 30%, and the incidence of profound hyponatremia (plasma sodium £125 mmol/L) 
ranges from 1% to 5% [137–141]. Risk factors for hyponatremia, such as heart or liver failure, excessive 
drinking, dehydration, drugs, intense physical activity, and age, have been identified [135,141–143]. It 
has also been speculated that the incidence of hyponatremia varies with climate factors (eg, outdoor 
temperature, relative humidity) [144–147]. In line with this speculation, the highest incidence of 
hyponatremia has been reported in tropical Asia and Australia [140,141]. In Europe, two retrospective 
observational studies found a higher incidence of profound hyponatremia cases in the summer 
compared with the winter [144,146]. Another study showed a higher incidence of hyponatremia in 
older adults in the summer [145], and two other studies found higher rates of hyponatremia during 
heatwaves [148,149]. 
However, these studies focused mostly on a small or specific group (eg, profound hyponatremia, older 
adults), and the etiology of hyponatremia [ie, syndrome of inappropriate antidiuresis (SIAD), diuretic-
induced hyponatremia, primary polydipsia-induced hyponatremia] in association with outdoor 
temperature or relative humidity has not yet been studied prospectively. Climate change has increased 
outdoor temperature and the frequency of weather extremes [150]. A possible association between 
climate and the incidence of hyponatremia might therefore become even more important in the 
future. 
Therefore, the current study aimed at investigating the potential influence of outdoor temperature 
and relative humidity on the incidence of mild and profound hyponatremia in a broad general medical 
collective and the impact of outdoor temperature and relative humidity on the etiology of 
hyponatremia. 
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Materials and methods  
Study design  
We analyzed data from two patient cohorts.  
 
Cohort A  
A cross-sectional study included patients with a plasma sodium measured in the emergency 
departments of two tertiary care centers in Switzerland between January 2011 and December 2016. 
We defined normonatremia as plasma sodium levels between 135 and 145 mmol/L, mild 
hyponatremia as plasma sodium levels between 126 and 134 mmol/L, and profound hyponatremia as 
plasma sodium levels £125 mmol/L. We excluded patients with hypernatremia (plasma sodium >145 
mmol/L).  
 
Cohort B  
A prospective observational study included consecutive patients with profound hyponatremia (plasma 
sodium £125 mmol/L) admitted to the medical emergency department of the same two centers in 
Switzerland from June 2011 to August 2013.  
The Ethics Committees of Basel and Aarau approved the study protocol (NCT01456533). The study was 
registered on clinicaltrials.gov. All participants in cohort B gave written informed consent before study 
inclusion, as recommended by the Declaration of Helsinki. The study was conducted according to the 
International Conference on Harmonisation–Good Clinical Practice and all national legal regulatory 
requirements. 
 
Data collection  
Cohort A  
The following data were obtained from an electronic registry: date of admission to the emergency 
department, age, sex, and initial plasma sodium level.  
 
Cohort B  
Collected data included medical history, symptoms related to profound hyponatremia, vital 
parameters, volume status, blood sampling, medication, and comorbidities. Based on the collected 
clinical data, the etiology of profound hyponatremia was determined by experienced, board-certified 
endocrinologists in a structured and standardized fashion. Hyponatremia was classified as SIAD, 
diuretic-induced hyponatremia, hypovolemic hyponatremia (dehydration), hypervolemic 
hyponatremia (heart and liver failure), and primary polydipsia-induced hyponatremia.  
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Meteorological data  
We received mean daily outdoor temperature and mean daily relative humidity from the official 
weather services of Switzerland and the open data repository of the Federal Office of Meteorology 
and Climatology MeteoSwiss (Bundesamt für Meteorologie und Klimatologie MeteoSchweiz). The 
measurements were recorded within 3.4 km and 2.5 km of the participating hospitals, respectively.  
 
Study objective and outcome measures  
The main objective was to investigate the association of outdoor temperature and relative humidity 
with the incidence of mild and profound hyponatremia and with the etiology of hyponatremia. 
Outcome measures were mean daily outdoor temperature and mean daily relative humidity and, in 
view of seasonal variation, mean monthly outdoor temperature and mean monthly relative humidity.  
 
Statistical analysis  
Discrete variables are expressed as frequencies (percentage and number of participants, n), 
continuous variables as median and interquartile range (IQR, 25th to 75th percentiles). Univariate 
logistic regression models were used to assess the association between mean daily outdoor 
temperature and mean daily relative humidity on the incidence of mild and profound hyponatremia 
and on the etiology of profound hyponatremia. A multiple logistic regression model was used for mild 
and profound hyponatremia adjusted for age and sex. The continuous variables outdoor temperature, 
relative humidity, and age were centered on the respective mean. To assess the seasonal variation, we 
computed the incidence of hyponatremia per month and the mean monthly outdoor temperature and 
mean monthly relative humidity (mean of mean daily outdoor temperature and relative humidity).  
Graphical analysis was done via locally estimated scatterplot smoothing (LOESS) to correlate outdoor 
temperature with the incidence of mild and profound hyponatremia.  
Statistical significance was considered for a two-sided P value <0.05. Analyses were performed in R 
statistical software (MathSoft, Seattle, WA).  
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Results  
Baseline characteristics  
Cohort A  
A total of 222,217 patients [median age 58 years (IQR 40 to 75), 47.8% female] with a measurement 
of plasma sodium £145 mmol/L were included in the analysis (Table 1). The incidence of mild 
hyponatremia was 9.9%, patients had a median plasma sodium of 132 mmol/L (IQR 130 to 134) and a 
median age of 71 years (IQR 57 to 81), and 51.2% were women. The incidence of profound 
hyponatremia was 1.08%, patients had a median plasma sodium of 122 mmol/L (IQR 119 to 124) and 
a median age of 72 years (IQR 60 to 81), and 58.4% were women. Mean daily outdoor temperature 
was 12.5°C for patients with mild hyponatremia and 14.2°C for patients with profound hyponatremia. 
Mean daily relative humidity was 79% for patients with mild hyponatremia and 77% for patients with 
profound hyponatremia (Table 1).  
 
Cohort B  
A total of 294 participants were included in this 
analysis [127]. Patients had a median plasma 
sodium of 120 mmol/L (IQR 116 to 123) and a 
median age of 71 years (IQR 60 to 80), and 65.6% 
were women (Table 2). The most common 
etiology of hyponatremia was SIAD with 35.7% (n 
= 105), followed by diuretic-induced 
hyponatremia with 24.1% (n = 71), hypovolemic 
hyponatremia with 21.1% (n = 62), hypervolemic 
hyponatremia with 10.9% (n = 32), and primary 
polydipsia-induced hyponatremia with 8.2% (n = 
24).  
 
Results
Baseline characteristics
Cohort A
A total of 222,217 patients [median age 58 years (IQR 40
to 75), 47.8% female] with a measurement of plasma
sodium #145 mmol/L were included in the analysis
(Table 1). The incidence of mild hyponatremia was 9.9%,
patients had a median plasma sodium of 132 mmol/L (IQR
130 to 134) and a median age of 71 years (IQR 57 to 81),
and 51.2% were women. The incidence of profound
hyponatremia was 1.08%, patients had a median plasma
sodium of 122 mmol/L (IQR 119 to 124) and a median
age of 72 years (IQR 60 to 81), and 58.4% were women.
Mean daily outdoor temperature was 12.5°C for patients
with mild hyponatremia and 14.2°C for patients with
prof und hyponatremia. Mean daily relativ humidity
was 79% for patients with mild hyponatremia and 77%
for patients with profound hyponatremia (Table 1).
Cohort B
A total of 294 participants were included in this analysis
(17). Patients had a median plasma sodium of 120 mmol/L
(IQR 116 to 123) and a median age of 71 years (IQR 60 to
80), and 65.6% were women (Table 2). The most common
etiology of hyponatremia was SIAD with 35.7% (n = 105),
followed by diuretic-induced hyponatremia with 24.1% (n =
71), hypovolemic hyponatremia with 21.1% (n = 62),
hypervolemic hyponatremia with 10.9% (n = 32), and
primary polydipsia-induced hyponatremia with 8.2%
(n = 24).
Association of hyponatremia with outdoor
temperature and relative humidity
Cohort A
The incidence ofmild hyponatremia did not significantly
correlate with outdoor temperature (OR 1, P = 0.9) or with
relative humidity (OR 0.99, P = 0.07), in a univariate or a
multiple logistic regression model adjusted for age and sex
(Table 3, Figs. 1A, 2A).
Considering the incidence of profound hyponatremia,
the univariate logistic regression model indicated a statis-
tically significant positive correlation of outdoor temper-
ature with a 1.2% increased risk per degree Celsius (OR
1.012, P , 0.001) and a statistically significant negative
correlation of relative humidity with a 1% decreased risk
per percentage point of relative humidity (OR 0.99, P ,
0.001; Fig. 1B, Fig. 2B). Temperature remained statistically
significant in themultiple regressionmodel adjusted for age
and sex, whereas relative humidity did not (Table 4).
Mean monthly outdoor temperature in the winter was
about 3°C and increased in summer to 22°C. Conversely,
mean relative humidity in the winter was about 85% and
decreased in summer to 69%. Investigating the monthly
incidence of hyponatremia, we observed no clear change
of mild hyponatremia but a clear increase of profound
hyponatremia during the summer (June, July, August) and a
Table 1. Cohort A Baseline Characteristics
Cohort A Total Normonatremia
Mild
Hyponatremia
Profound
Hyponatremia P
N (%) 222,217 (100) 197,890 (89) 21,928 (9.9) 2399 (1.08)
Age, median (IQR) 58 (40–75) 56 (38–74) 71 (57–81) 72 (60–81) <0.001
Female sex, n (%) 106,214 (47.8) 93,591 (47.3) 11,222 (51.2) 1401 (58.4) <0.001
Median plasma sodium, mmol/L,
median (IQR)
139 (137–141) 140 (138–141) 132 (130–134) 122 (119–124) <0.001
Mean daily outdoor temperature,
°C, median (IQR)
12.8 (5.9–18.7) 12.8 (5.9–18.6) 12.5 (5.9–18.8) 14.2 (6.2–19.6) <0.001
Mean daily relative humidity, %,
median (IQR)
78 (68–85) 78 (68–85) 79 (69–87) 77 (67–85) <0.001
Three-group comparison between normonatremia, mild hyponatremia, and profound hyponatremia was done with the Kruskal-Wallis test. A two-sided
P , 0.05 was considered statistically significant and appears in boldface.
Table 2. Cohort B Baseline Characteristics
Cohort B Total
n 294
Age, y, median (IQR) 71 (60–80)
Female sex, n (%) 193 (65.6)
Median plasma sodium, mmol/L,
median (IQR)
120 (116–123)
Mean daily outdoor temperature,
°C, median (IQR)
13.9 (5.6–20.8)
Mean daily relative humidity, %,
median (IQR)
76 (68–85)
Etiology of profound hyponatremia
SIAD, n (%, 95% CI) 105 (35.7, 30.1–41.5)
Diuretic-induced hyponatremia,
n (%, 95% CI)
71 (24.1, 19.5–29.5)
Hypovolemic hyponatremia,
n (%, 95% CI)
61 (21.1, 16.7–26.3)
Hypervolemic hyponatremia,
n (%, 95% CI)
32 (10.9, 7.7–15.2)
Primary polydipsia-induced
hyponatremia, n (%, 95% CI)
24 (8.2, 5.4–12.1)
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Results
Baseline characteristics
Cohort A
A total of 222,217 patients [median age 58 years (IQR 40
to 75), 47.8% female] with a measurement of plasma
sodium #145 mmol/L were included in the analysis
(Table 1). The incidence of mild hyponatremia was 9.9%,
patients had a median plasma sodium of 132 mmol/L (IQR
130 to 134) and a edian age of 71 years (IQR 57 to 8 ),
and 51.2% were women. The incidence of profound
hyponatremia was 1.08%, patients had a median plasma
sodium of 122 mmol/L (IQR 119 to 124) and a median
ag of 72 years (IQR 60 to 81), and 58.4% were women.
Mean daily outdoor temperature was 12.5°C for patients
with mild hyponatremia and 14.2°C for atients with
profound hyponatremia. Mean daily relative humidity
was 79% for patients with mild hyponatremia and 77%
for patients with profound hyponatremia (Table 1).
Cohort B
A total of 294 participants were included in this analysis
(17). Patients had a median plasma sodium of 120 mmol/L
(IQR 116 to 123) and a median age of 71 years (IQR 60 to
80), and 65.6% were women (Table 2). The most common
etiology of hyponatremia was SIAD with 35.7% (n = 105),
followed by diuretic-induced hyponatremia with 24.1% (n =
71), hypovolemic hyponatremia with 21.1% (n = 62),
hypervolemic hyponatremia with 10.9% (n = 32), and
primary pol dipsi -induced hyponatremia with 8.2%
(n = 24).
Association of hyponatremia with outdoor
temperature and relative humidity
Cohort A
The incidence ofmild hyponatremia did not sig ificantly
correlate with outdoor temperature (OR 1, P = 0.9) or with
relative humidity (OR 0.99, P = 0.07), in a univariate or a
multiple logistic regression model adjusted for age and sex
(Table 3, Figs. 1A, 2A).
Considering the incidence of profound hyponatremia,
the univariate logistic regression model indicated a statis-
tically significant positive correlation of outdoor temper-
ature with a 1.2% increased risk per degree Celsius (OR
1.012, P , 0.001) and a statistically significant negative
correlation of relative humidity with a % decreased risk
per percentage point of relative humidity (OR 0.99, P ,
0.001; Fig. 1B, Fig. 2B). Temperature remained statistically
significant in themultiple regressionmodel adjusted for age
and sex, whereas relative humidity did not (Table 4).
Mean monthly outdoor temperature in the winter was
about 3°C and increased in summer to 22°C. Conversely,
mean relative humidity in the winter was about 85% and
decreased in summer to 69%. Investigating the monthly
incidence of hyponatremia, we observed no clear change
of mild hyponatremia but a clear increase of profound
hyponatremia during the su mer (June, July, Au ust) and a
Table 1. Cohort A Baseline Characteristics
Cohort A Total Normonatremia
Mild
Hyponatremia
Profound
Hyponatremia P
N (%) 222,217 (100) 197,890 (89) 21,928 (9.9) 2399 (1.08)
Age, median (IQR) 58 (40–75) 56 (38–74) 71 (57–81) 72 (60–81) <0.001
Female sex, n (%) 106,214 (47.8) 93,591 (47.3) 11,22 (51.2) 140 (58.4) <0.001
Median plasma sodium, mmol/L,
median (IQR)
139 (137–141) 140 (138–141) 132 (130–134) 122 (119–124) <0.001
Mean daily outdoor temperature,
°C, median (IQR)
12.8 (5.9–18.7) 12.8 (5.9–18.6) 12.5 (5.9–18.8) 14.2 (6.2–19.6) <0.001
Mean daily relative humidity, %,
median (IQR)
78 (68–85) 78 (68–85) 79 (69–87) 77 (67–85) <0.001
Three-group comparison between normonatremia, mild hyponatremia, and profound hyponatremia was done with the Kruskal-Wallis test. A two-sided
P , 0.05 was considered statistically significant and appears in boldface.
Table 2. Cohort B Baseline Characteristics
Cohort B Total
n 294
Age, y, median (IQR) 71 (60–80)
Female sex, n (%) 193 (65.6)
Median plasma sodium, mmol/L,
median (IQR)
120 (116–123)
Mean daily outdoor temperatur ,
°C, median (IQR)
13.9 (5.6–20.8)
Mean daily relative humidity, %,
median (IQR)
76 (68–85)
Etiology of profound hyponatr ia
SIAD, n (%, 95% CI) 105 (35.7, 30.1–41.5)
Diuretic-induced hyponatremia,
n (%, 95% CI)
71 (24.1, 19.5–29.5)
Hypovolemic hyponatremia,
n (%, 95% CI)
61 (21.1, 16.7–26.3)
Hypervolemic hyponatremia,
n (%, 95% CI)
32 (10.9, 7.7–15.2)
Primary poly ips a-induced
hyponatremia, n (%, 95% CI)
24 (8.2, 5.4–12.1)
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Association of hyponatremia with outdoor temperature and relative humidity  
Cohort A  
The incidence of mild hyponatremia did not significantly correlate with outdoor temperature (OR 1, P 
= 0.9) or with relative humidity (OR 0.99, P = 0.07), in a univariate or a multiple logistic regression 
model adjusted for age and sex (Table 3, Figs. 1A, 2A). 
  slight increase in profound hyponatremia in November
(Fig. 3).
Association of the etiology of hyponatremia with
outdoor temperature and relative humidity
Cohort B
The etiology of profound hyponatremia according to
outdoor temperature is displayed in Fig. 4. The occurrence
of diuretic-induced hyponatremia (n = 71) increased sig-
nificantly, by 4% per degree Celsius of outdoor temper-
ature (OR 1.04, P = 0.02). Primary polydipsia-induced
hyponatremia seemed to be more common when outdoor
temper ture ranged from 17°C to 22°C, but the associ-
ation did not reach statistical significance. The other eti-
ologies showed no clear difference with change in outdoor
temperature. Considering relative humidity, no clear dif-
ference in etiology distribution of profound hyponatremia
was found (data not shown).
Discussion
The study has several findings. First, we found a positive
correlation between outdoor temperature and the in-
cidence of profound hyponatremia, with a seasonal in-
crease in summer. Second, mild hyponatremia did not
correlate with outdoor temperature, and no seasonal
variation was detected. Third, hyponatremia due to di-
uretics was more frequently observed with higher outdoor
temperatures. Fourth, humidity did not consistently cor-
relate with the incidence of hyponatremia.
Table 3. Univariate and Multiple Logistic Regression Analysis for Incidence of Mild Hyponatremia
Univariate Logistic Regression Analysis Multiple Logistic Regression Analysis
OR (95% CI) P OR (95% CI) P
Outdoor temperature 1 (0.998–1.002) 0.9 1.001 (1–1.003) 0.31
Relative humidity 0.99 (0.998–1.00) 0.07 0.999 (0.997–1.0) 0.07
Age 1.029 (1.028–1.029) <0.001 1.029 (1.028–1.029) <0.001
Female sex 1.16 (1.13–1.19) <0.001 1.08 (1.054–1.12) <0.001
A two-sided P ,0.05 was considered statistically significant and appears in boldface.
Figure 1. Incidence of mild and profound hyponatremia with outdoor temperature. Incidence (%) of (A) mild hyponatremia (plasma sodium 126
to 134 mmol/L) and (B) profound hyponatremia (plasma sodium #125 mmol/L) over mean daily outdoor temperature according to the LOESS
method of smoothing.
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slight increase in profound hyponatremia in November
(Fig. 3).
Association of the etiology of hyponatremia with
outdoor temperature and relative humidity
Cohort B
The etiology of profound hyponatremia according to
outdoor temperature is displayed in Fig. 4. The occurrence
of diuretic-induced hyponatremia (n = 71) increased sig-
nificantly, by 4% per degree Celsius of outdoor temper-
ature (OR 1.04, P = 0.02). Primary polydipsia-induced
hyp natremia seemed to be ore common when outdoor
temperatures ranged from 17°C to 22°C, but the associ-
ation did not reach statistical significance. The other eti-
ologies showed no clear difference with change in outdoor
temperature. Considering relative humidity, no clear dif-
ference in etiology distribution of profound hyponatremia
was found (data not shown).
Discussion
The study has several findings. First, we found a positive
correlation between outdoor temperature and the in-
cidence of profound hyponatremia, with a seasonal in-
crease in summer. Second, mild hyponatremia did not
correlate with outdoor temperature, and no seasonal
variation was d tected. Third, hyponatremia due to di-
uretics was more frequently observed with higher outdoor
temperatures. Fourth, humidity did not consistently cor-
relate with the incidence of hyponatremia.
Table 3. Univariate and Multiple Logistic Regression Analysis for Incidence of Mild Hyponatremia
Univariate Logistic Regression Analysis Multiple Logistic Regression Analysis
OR (95% CI) P OR (95% CI) P
Outdoor temperature 1 (0.998–1.002) 0.9 1.001 (1–1.003) 0.31
Relative humidity 0.99 (0.998–1.00) 0.07 0.999 (0.997–1.0) 0.07
Age 1.029 (1.028–1.029) <0.001 1.029 (1.028–1.029) <0.001
Female sex 1.16 (1.13–1.19) <0.001 1.08 (1.054–1.12) <0.001
A two-sided P ,0.05 was considered statistically significant and appears in boldface.
Figure 1. Incidence of mild and profound hyponatremia with outdoor temperature. Incidence (%) of (A) mild hyponatremia (plasma sodium 126
to 134 mmol/L) and (B) profound hyponatremia (plasma sodium #125 mmol/L) over mean daily outdoor temperature according to the LOESS
method of smoothing.
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Considering the incidence of profound hyponatremia, the univariate logistic regression model 
indicated a statistically significant positive correlation of outdoor temperature with a 1.2% increased 
risk per degree Celsius (OR 1.012, P , 0.001) and a statistically significant negative correlation of relative 
humidity with a 1% decreased risk per percentage point of relative humidity (OR 0.99, P , 0.001; Fig. 
2B, Fig. 2B). Temperature remained statistically significant in the multiple regression model adjusted 
for age and sex, whereas relative humidity did not (Table 4). 
  
In line with previous studies, we hereby confirm in a
large multicenter study that the incidence of profound
hyponatremia increases with rising outdoor temperature
(10, 11). One study from Switzerland showed a higher
incidence of profound hyponatremia during hot weather
(10), and one study from India indicated a higher incidence
of profound hyponatremia during the warmer season (12).
Interestingly, mild hyponatremia seems less associatedwith
outdoor temperature. The association of outdoor tem-
perature and mild hyponatremia has been investigated in
only one study from southern Europe, showing an in-
creased prevalence of mild hyponatremia in older adults in
summer (11). To explain this difference, one might argue
that patients with profound hyponatremia are generally
sicker and more vulnerable to external stressors such as
extreme outdoor temperatures. Indeed, according to the
j-shaped curve in Fig. 2B and the slight increase in hypo-
natremia incidence in November, our data suggest that
profound hyponatremia increases with not only high
temperatures but to a certain extent also with low tem-
peratures. Another explanation might be that the etiologies
of mild and profound hyponatremia differ (2) and that
the various underlying diseases are differently susceptible
to outdoor temperature. According to a previous publi-
cation, milder hyponatremia is often caused by heart or
liver failure, whereas more profound hyponatremia seems
mostly drug-induced (2).
In line with the latter finding, our results suggest that
diuretic-induced profound hyponatremia occurs more
frequentlywith increased outdoor temperature. In contrast,
Figure 2. Incidence of mild and profound hyponatremia with relative humidity. Incidence (%) of (A) mild hyponatremia (plasma sodium 126 to
134 mmol/L) and (B) profound hyponatremia (plasma sodium #125 mmol/L) over mean daily relative humidity according to the LOESS method
of smoothing.
Table 4. Univariate and Multiple Logistic Regression Analysis for Incidence of Profound Hyponatremia
Univariate Logistic Regression Analysis Multiple Logistic Regression Analysis
OR (95% CI) P OR (95% CI) P
Outdoor temperature 1.012 (1.007–1.017) <0.001 1.012 (1.006–1.017) <0.001
Relative humidity 0.99 (0.99––0.997) <0.001 0.997 (0.99–1.00) 0.1
Age 1.033 (1.031––1.036) <0.001 1.032 (1.030–1.035) <0.001
Female sex 1.54 (1.42––1.67) <0.001 1.41 (1.3–1.5) <0.001
A two-sided P ,0.05 was considered statistically significant and appears in boldface.
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In line with previous studies, we hereby confirm in a
large multicenter study that the incidence of profound
hyponatremia increases with rising outdoor temperature
(10, 11). One study from Switzerland showed a higher
incidence of profound hyponatremia during hot weather
(10), and one study from India indicated a higher incidence
of profound hyponatremia during the warmer season (12).
Interestingly, mild hyponatremia seems less associatedwith
outdoor temperature. The association of outdoor tem-
perature and mild hyponatremia has been investigated in
only one study from southern Europe, showing an in-
creased prevalence of mild hyponatremia in older adults in
sum er (11). To explain this difference, one might argue
that patients with profound hyponatremia are generally
sicker and more vulnerable to external stressors such as
extreme outdoor temperatures. Indeed, according to the
j-shaped curve in Fig. 2B and the slight increase in hypo-
natremia incidence in November, our data suggest that
profound hyponatremia increases with not only high
temperatures but to a certain extent also with low tem-
peratures. Another explanation might be that the etiologies
of mild and profound hyponatremia differ (2) and that
the various underlying diseases are differently susceptible
to outdoor temperature. According to a previous publi-
cation, milder hyponatremia is often caused by heart or
liver failure, whereas more profound hyponatremia seems
mostly drug-induced (2).
In line with the latter findin , ur results suggest that
diuretic-induced profound hyponatremia occurs more
frequentlywith increased outdoor temperature. In contrast,
Figure 2. Incidence of mild and profound hyponatremia with relative humidity. Incidence (%) of (A) mild hyponatremia (plasma sodium 126 to
134 mmol/L) and (B) profound hyponatremia (plasma sodium #125 mmol/L) over mean daily relative humidity according to the LOESS method
of smoothing.
Table 4. Univari t and Multiple L gistic Regression Analysis for Incide ce of Profound Hyponatremi
Univariate Logistic Regression Analysis Multiple Logistic Regression Analysis
OR (95% CI) P OR (95% CI) P
Outdoor temperature 1.012 (1.007–1.017) <0.001 1.012 (1.006–1.017) <0.001
Relative humidity 0.99 (0.99––0.997) <0.001 0.997 (0.99–1.00) 0.1
Age 1.033 (1.031––1.036) <0.001 1.032 (1.030–1.035) <0.001
Female sex 1.54 (1.42––1.67) <0.001 1.41 (1.3–1.5) <0.001
A two-sided P ,0.05 was considered statistically significant and appears in boldface.
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Mean monthly outdoor temperature in the winter was about 3°C and increased in summer to 22°C. 
Conversely, mean relative humidity in the winter was about 85% and decreased in summer to 69%. 
Investigating the monthly incidence of hyponatremia, we observed no clear change of mild 
hyponatremia but a clear increase of profound hyponatremia during the summer (June, July, August) 
and a slight increase in profound hyponatremia in November (Fig. 3). 
 
 
 
  
we did not find a temperature dependence of hypervolemic
or hypovolemic hyponatremia or of SIAD. Similarly,
Huwyler et al. (10) and Jo¨nsson et al. (13) showed an
association between diuretic and drug use and the devel-
opment of hyponatremiawith higher outdoor temperature;
however, others could not find a seasonal variation of
diuretic-induced hyponatremia (18). Diuretics are known
to influence water metabolism and lead to a loss of fluid
and relatively more electrolytes, especially if drinking is
insufficient or if fluids low in electrolytes are consumed
(9). At higher outdoor temperatures the combination
of sweating, low fluid and solute intake, or consumption
of primarily hypotonic fluids, together with the use of
diuretics, may increase the risk of hyponatremia (13).
Primary polydipsia-induced hyponatremia also tends to
be more common with higher outdoor temperature, even
though this association was not statistically significant.
Interestingly, Huwyler et al. (10) found an association
between psychiatric diseases and increased hyponatremia
incidence with higher outdoor temperature. Patients with
primary polydipsia, which is typically caused by a psy-
chiatric disorder, may follow a doctor’s advice to drink
plenty of water and further increase their already excessive
(mostly hypotonic) fluid intake during hot weather. Ac-
cordingly, they are at risk for water intoxication and
hyponatremia, especially when combined with a concom-
itant stimulus (eg, psychiatric exacerbation, drugs) (19).
Our data showed no clear correlation between relative
humidity and hyponatremia. Of note, in Switzerland rel-
ative humidity remains nearly constant throughout the year
and inversely correlates with outdoor temperature (relative
humidity is lowest when outdoor temperature is highest). In
tropical regions, the mean monthly outdoor temperature
is .23°C, and the humidity is higher compared with
Europe (20). Studies from Asia and northern Australia
indicated a higher incidence of hyponatremia during the
year and especially during the wet season (6, 7, 12).
Whether the increased incidence in these regions is caused
by increased outdoor temperature or relative humidity has
not yet been investigated.
Figure 3. Seasonal variation of mild and profound hyponatremia. Monthly incidence of (A) mild hyponatremia and (B) profound hyponatremia
over the study period of 7 y. The black curve and squares show the incidence of hyponatremia (%), the dark gray curve and triangles show the
mean monthly outdoor temperature (°C), and the gray curve and round dots show the mean monthly relative humidity (%).
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Association of the etiology of hyponatremia with outdoor temperature and relative humidity  
Cohort B  
The etiology of profound hyponatremia according to outdoor temperature is displayed in Fig. 4. The 
occurrence of diuretic-induced hyponatremia (n = 71) increased significantly, by 4% per degree Celsius 
of outdoor temperature (OR 1.04, P = 0.02). Primary polydipsia-induced hyponatremia seemed to be 
more common when outdoor temperatures ranged from 17°C to 22°C, but the association did not 
reach statistical significance. The other etiologies showed no clear difference with change in outdoor 
temperature. Considering relative humidity, no clear difference in etiology distribution of profound 
hyponatremia was found (data not shown).  
We confirm in the current study that, independent of
outdoor temperature or relative humidity, age is signif-
icantly correlated to hyponatremia. Aging is associated
with a decreased capacity to cope with environmental
and disease-related stressors, which influences the so-
dium and water balance (21, 22). Older adults have a
reduced renal function, decreased total body water, and
lower renal sodium-conserving ability (23, 24). Addi-
tionally, drugs inducing hyponatremia (eg, diuretics and
psychotropics) are prescribed more frequently (9), and
the aging population suffers more often from cardio-
vascular and malignant disorders, which influences
electrolyte homeostasis (25, 26). Moreover, thirst per-
ception changes with age and often leads to reduced fluid
intake, which might be especially important with in-
creased outdoor temperatures (23, 27, 28). Along the
same lines, malnutrition might play a role as age leads to
reduced appetite and thus reduced solute and protein
intake, which influences water excretion and the risk of
hyponatremia (29, 30). In summary, it seems likely that a
combination of these factors is the cause of the described
phenomenon.
As shown in other studies, our results suggest thatwomen
aremore susceptible to hyponatremia thanmen (3, 7). So far,
the reason for this sex difference is unclear. A possible ex-
planation might be the higher expression of aquaporin-2
and a higher sensitivity to endogenous vasopressin inwomen
(31).With the reduced renal function in age, this may lead to
an increased incidence of hyponatremia in women.
Strength and limitations
Some limitations of our study need to bementioned. First,
the study was performed in Switzerland, where outdoor
temperature and relative humidity extremes are less com-
mon; nevertheless, observing a correlation between profound
hyponatremia and outdoor temperature with a moderate
average outdoor temperature supports the hypothesis that
outdoor temperature influences the incidence of hypona-
tremia, but this correlation should be investigated within
different and especially hot and humid climate zones.
Figure 4. Etiology of profound hyponatremia according to outdoor temperature. The etiologies of hyponatremia in 5 categories of outdoor
temperature. The red part represents patients with SIAD, the blue part represents patients with primary polydipsia-induced hyponatremia, the
yellow part represents patients with hypovolemic hyponatremia, the violet part represents hypervolemic hyponatremia, and the green part
represents diuretic-induced hyponatremia.
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Discussion  
The study has several findings. First, we found a positive correlation between outdoor temperature 
and the incidence of profound hyponatremia, with a seasonal increase in summer. Second, mild 
hyponatremia did not correlate with outdoor temperature, and no seasonal variation was detected. 
Third, hyponatremia due to diuretics was more frequently observed with higher outdoor 
temperatures. Fourth, humidity did not consistently correlate with the incidence of hyponatremia. 
In line with previous studies, we hereby confirm in a large multicenter study that the incidence of 
profound hyponatremia increases with rising outdoor temperature [144,145]. One study from 
Switzerland showed a higher incidence of profound hyponatremia during hot weather [144], and one 
study from India indicated a higher incidence of profound hyponatremia during the warmer season 
[146]. Interestingly, mild hyponatremia seems less associated with outdoor temperature. The 
association of outdoor temperature and mild hyponatremia has been investigated in only one study 
from southern Europe, showing an increased prevalence of mild hyponatremia in older adults in 
summer [145]. To explain this difference, one might argue that patients with profound hyponatremia 
are generally sicker and more vulnerable to external stressors such as  
extreme outdoor temperatures. Indeed, according to the j-shaped curve in Fig. 2B and the slight 
increase in hyponatremia incidence in November, our data suggest that profound hyponatremia 
increases with not only high temperatures but to a certain extent also with low temperatures. Another 
explanation might be that the etiologies of mild and profound hyponatremia differ [58] and that the 
various underlying diseases are differently susceptible to outdoor temperature. According to a 
previous publication, milder hyponatremia is often caused by heart or liver failure, whereas more 
profound hyponatremia seems mostly drug-induced [58].  
In line with the latter finding, our results suggest that diuretic-induced profound hyponatremia occurs 
more frequently with increased outdoor temperature. In contrast, we did not find a temperature 
dependence of hypervolemic or hypovolemic hyponatremia or of SIAD. Similarly, Huwyler et al. [144] 
and Jönsson et al. [147] showed an association between diuretic and drug use and the development 
of hyponatremia with higher outdoor temperature; however, others could not find a seasonal variation 
of diuretic-induced hyponatremia [151]. Diuretics are known to influence water metabolism and lead 
to a loss of fluid and relatively more electrolytes, especially if drinking is insufficient or if fluids low in 
electrolytes are consumed [143]. At higher outdoor temperatures the combination of sweating, low 
fluid and solute intake, or consumption of primarily hypotonic fluids, together with the use of diuretics, 
may increase the risk of hyponatremia [147].  
Primary polydipsia-induced hyponatremia also tends to be more common with higher outdoor 
temperature, even though this association was not statistically significant. Interestingly, Huwyler et al. 
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[144] found an association between psychiatric diseases and increased hyponatremia incidence with 
higher outdoor temperature. Patients with  
primary polydipsia, which is typically caused by a psychiatric disorder, may follow a doctor’s advice to 
drink plenty of water and further increase their already excessive (mostly hypotonic) fluid intake during 
hot weather. Accordingly, they are at risk for water intoxication and hyponatremia, especially when 
combined with a concomitant stimulus (eg, psychiatric exacerbation, drugs) [48].  
Our data showed no clear correlation between relative humidity and hyponatremia. Of note, in 
Switzerland relative humidity remains nearly constant throughout the year and inversely correlates 
with outdoor temperature (relative humidity is lowest when outdoor temperature is highest). In 
tropical regions, the mean monthly outdoor temperature is .23°C, and the humidity is higher compared 
with Europe [152]. Studies from Asia and northern Australia indicated a higher incidence of 
hyponatremia during the year and especially during the wet season [140,141,146]. Whether the 
increased incidence in these regions is caused by increased outdoor temperature or relative humidity 
has not yet been investigated.  
We confirm in the current study that, independent of outdoor temperature or relative humidity, age 
is significantly correlated to hyponatremia. Aging is associated with a decreased capacity to cope with 
environmental and disease-related stressors, which influences the sodium and water balance [95,153]. 
Older adults have a reduced renal function, decreased total body water, and lower renal sodium-
conserving ability [154,155]. Additionally, drugs inducing hyponatremia (eg, diuretics and 
psychotropics) are prescribed more frequently [143], and the aging population suffers more often from 
cardiovascular and malignant disorders, which influences electrolyte homeostasis [156,157]. 
Moreover, thirst perception changes with age and often leads to reduced fluid intake, which might be 
especially important with increased outdoor temperatures [154,158,159]. Along the same lines, 
malnutrition might play a role as age leads to reduced appetite and thus reduced solute and protein 
intake, which influences water excretion and the risk of hyponatremia [48,160]. In summary, it seems 
likely that a combination of these factors is the cause of the described phenomenon.  
As shown in other studies, our results suggest that women are more susceptible to hyponatremia than 
men [137,141]. So far, the reason for this sex difference is unclear. A possible explanation might be 
the higher expression of aquaporin-2 and a higher sensitivity to endogenous vasopressin in women 
[161]. With the reduced renal function in age, this may lead to an increased incidence of hyponatremia 
in women.  
 
Strength and limitations  
Some limitations of our study need to be mentioned. First, the study was performed in Switzerland, 
where outdoor temperature and relative humidity extremes are less common; nevertheless, observing 
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a correlation between profound hyponatremia and outdoor temperature with a moderate average 
outdoor temperature supports the hypothesis that outdoor temperature influences the incidence of 
hyponatremia, but this correlation should be investigated within different and especially hot and 
humid climate zones.  
Additionally, the etiologies of hyponatremia and the comorbidities of cohort A are unknown because 
data were collected from an electronic registry not indicating this information. Furthermore, we have 
no objective data on thirst control and the amount of prehospital fluid, salt, and nutrient intake. Cohort 
B, where the underlying etiology was identified, is small, limiting the power to show a statistically 
significant association between hyponatremia and outdoor temperature and relative humidity. 
Furthermore, although our study shows an association, we cannot infer a causal link between outdoor 
temperature and profound hyponatremia. This study is an exploratory analysis, and thus the findings 
are hypothesis generating, which should be kept in mind when the results are interpreted. 
The main strengths of this study are the large number of investigated patients, the long observation 
period, and the multicenter design. In contrast to previous smaller studies investigating the seasonal 
or monthly differences in the incidence of mainly profound hyponatremia and older adults, we studied 
the mean daily outdoor temperature and the mean daily relative humidity with the incidence of mild 
and profound hyponatremia over all age groups, providing more detailed insight. Additionally, this 
study investigated the etiology of hyponatremia in correlation to outdoor temperature and relative 
humidity in a prospective way. 
In summary, our data show that higher outdoor temperature is associated with an increased incidence 
of profound hyponatremia, whereas mild hyponatremia is not. Relative humidity seems not to be 
associated with the incidence of hyponatremia. Diuretic-induced hyponatremia is more commonly 
seen with higher outdoor temperatures, whereas the distribution of other hyponatremia etiologies is 
equally distributed. Our data indicate that diuretics should be used with caution during hot weather 
and especially in older adults and women, who are more susceptible to developing hyponatremia. 
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Abstract 
Context: Hyponatremia is the most prevalent electrolyte disturbance in hospitalized patients. Previous 
studies have shown a seasonal variation of profound hyponatremia with higher prevalence during 
warmer months.  
Objective: This study aimed at analyzing the seasonal prevalence, sex and age-specific differences of 
hyponatremia in medical inpatients. 
Design: Nationwide cohort study from January 2009 and December 2015 using prospective 
administrative data. 
Setting: Medical inpatients. 
Patients: Diagnosis of hypoosmolar hyponatremia.  
Main outcome measures: The primary outcome was the monthly alteration in hyponatremia 
prevalence. Secondary outcomes were the association of outdoor temperature with hyponatremia 
prevalence and differences among sex and age groups. 
Results: Of 2,426,722 medical inpatients, 84,210 were diagnosed with hypoosmolar hyponatremia, of 
whom 61% (n=51,262) were female. The highest overall prevalence of hyponatremia was observed in 
July (4.5%, n=8,976), it was lowest in December (2.7%, n=6,530). The overall prevalence of 
hyponatremia in women compared to men was higher by 58% (OR 1.58 [95% CI 1.56 to 1.60]). The sex-
specific difference was most pronounced in the warmest month of July (mean temperature 20.1°C, OR 
1.76 [95% CI 1.68 to 1.84]). We observed the strongest association between seasonality and 
hyponatremia in elderly (>80 years) female inpatients admitted during the month of July (OR 2.40 [95% 
CI 2.20 to 2.62]). 
Conclusion The prevalence of diagnosed hypoosmolar hyponatremia in medical inpatients increases 
during summer months with higher outdoor temperature. Elderly female inpatients were most 
susceptible to the seasonal rise in hyponatremia prevalence. 
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Introduction 
Hyponatremia is the most prevalent electrolyte disbalance affecting 10-15% of hospitalized patients 
and is associated with a poor clinical outcome [58,135,137,138]. Predisposing risk factors for 
hyponatremia are disease stress-related drive of arginine vasopressin [162,163], heart failure, liver 
cirrhosis or renal failure causing volume-overload, dehydration with sodium loss (e.g. infection), and 
medications (e.g. diuretics and antidepressant). A meta-analysis of 81 studies including 147,948 
participants found that already mild hyponatremia is significantly associated with overall mortality 
[164] and is associated with a worse prognosis in multimorbid patients, e.g. disease of the liver, heart, 
kidney, brain and lungs [165–168]. Importantly, in-hospital health care providers are frequently faced 
with this burdensome electrolyte disorder and a season-dependent variation may alter in-hospital 
resource allocation accordingly.  
A season-dependent variation in the hyponatremia prevalence has recently been described in the 
emergency department setting [49,144–146]. In particular, the prevalence of profound hyponatremia 
has been associated with outdoor temperature and has been shown to be increased during summer 
months [49,145]. However, these studies focus on patients in the emergency department and 
information on medical inpatients are scarce. Thus, large scale data are needed not only to validate 
previous findings from the emergency department setting but also to identify nationwide 
epidemiological variations within hyponatremic medical inpatients. Furthermore, previous studies 
suggest that women and elderly patients are more susceptible towards developing hyponatremia 
[49,141,145,169,170]. However, whether these associations alter throughout the year with changing 
outdoor temperature is poorly explored [49,145]. 
Therefore, the aim of this study was to investigate in-hospital hyponatremia prevalence throughout 
the year stratified for sex and age groups. 
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Materials and Methods 
Participants, Data Sources, and Study Variables 
In this nationwide cohort study, we performed a cross-sectional analysis using prospective 
administrative data from January 1, 2009 to December 31, 2015 provided by the Swiss Federal 
Statistical Office.  
The database includes all Swiss hospitalization records from acute care, general, and specialty 
hospitals, excluding hospital units of post–acute care institutions. Non-medical, psychiatric, and 
nonadult (<18 years of age) patients were excluded from the final analysis. Medical cases were defined 
as encoded by the Federal Statistical Office. Thus, gynecology and obstetrics, pediatrics, 
ophthalmology, intensive care, otolaryngology, surgery, psychiatry, dermatology and venerology, 
radiology, geriatrics, rehabilitation and emergency-center patient records were excluded.  
To qualify for inclusion in this study cohort, hospitalized patients had a primary or secondary discharge 
record of hypoosmolar hyponatremia diagnosis according to the International Classification of 
Diseases, 10th Revision German Version (ICD-10-GM): E87.1 (hypoosmolar hyponatremia) or E22.2 
(syndrome of inappropriate antidiuresis), respectively. Patients without clear diagnosis of 
hyponatremia were not included in the analysis. 
Data on mean daily outdoor temperature were gathered from the open data repository of the Federal 
Office of Meteorology and Climatology MeteoSwiss (Bundesamt fuer Meteorologie und Klimatologie 
MeteoSchweiz). 
The institutional review board of Northwestern and Central Switzerland approved of this study and 
waived patients’ informed consent owing to the use of deidentified data. This study followed the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline 
[171]. 
 
Outcomes 
The primary outcome was the monthly alteration in hypoosmolar hyponatremia prevalence among 
medical inpatients. Secondary outcomes were sex and age specific monthly variations in hypoosmolar 
hyponatremia prevalence in these patients. Outcome measures were mean monthly odds ratio of 
hypoosmolar hyponatremia diagnosis and mean monthly outdoor temperature. 
 
Statistical analysis 
Unless stated otherwise, categorical variables are expressed as number (percentage) and continuous 
variables as mean (standard deviation, SD). Subgroup analyses were performed for sex (male, female) 
and for pre-defined age groups (based on quartiles of all hospitalized patients: ≤55 years, 56 to 70 
years, 71 to 80 years and >80 years). Furthermore, sensitivity analyses were performed for the 
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diagnoses of hypoosmolar hyponatremia (E87.1) and syndrome of inappropriate antidiuresis (E22.2) 
separately. 
We used univariable and multivariable logistic regression models to calculate odds ratio (OR) and 95% 
confidence intervals (CI) for the hypoosmolar hyponatremia diagnosis. The multivariable models were 
adjusted for age, nationality, hospital teaching status, type and date (month and year) of admission, 
disease severity score (Charlson Comorbidity Index), type of admission (planned versus unplanned), 
and main comorbidities. Monthly prevalence rates were calculated and compared among the 
predefined sex and age subgroups. 
The significance level was set as α = 5%. All p-values are two-sided and have not been adjusted for 
multiple testing. Statistical analyses were performed using Stata 15.1 (StataCorp. 2015. College 
Station, TX, USA: StataCorp LP). 
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Results 
Baseline characteristics 
Of 2,426,722 medical inpatients included in this study, 84,210 (3.5%) were diagnosed with 
hypoosmolar hyponatremia, of whom 51,262 (61%) were female. Among inpatients with a diagnosis 
of hypoosmolar hyponatremia, the majority was admitted through the emergency department and 
around 88% were community-dwelling. Patients with hypoosmolar hyponatremia had a high burden 
of comorbidities such as heart failure, chronic kidney disease, pneumonia, and liver failure. The mean 
[SD] Charlson Comorbidity Index was significantly higher in patients diagnosed with hypoosmolar 
hyponatremia as compared to medical controls at the same time of hospitalization (1.9 [2.6] vs. 1.5 
[2.3], p-value < 0.001) (Table 1).  
 
Table 1 Baseline Characteristics 
 Hyponatremia Medical controls p-value 
    
Socio-demographics 
Hospitalizations, n 84`210 234`2512  
Sex, female, n (%) 51`262 (60.9) 1`114`006 (47.6) <0.001 
Age groups, n (%)   <0.001 
<56 years 10`713 (12.7) 584`615 (25.0)  
56 to 70 years 21`620 (25.7) 627`761 (26.8)  
71 to 80 years 23`094 (27.4) 565`363 (24.1)  
>80 years 28`783 (34.2) 564`773 (24.1)  
Swiss residents, n (%) 74`796 (88.8) 1`940`162 (82.8) <0.001 
Hospital teaching level, n (%)    
Tertiary care hospital 55`162 (65.5) 1`535`222 (65.5) 0.85 
Hospital admission   <0.001 
Emergency admission 73`718 (87.5) 1`647`354 (70.3)  
Elective admission 9`687 (11.5) 662`611 (28.3)  
Others 805 (1.0) 32`547 (1.4)  
Living situation, n (%) 
Before admission     
At home 73`880 (87.7) 2`041`444 (87.1) <0.001 
Comorbidities, n (%) 
Diabetes mellitus 15`227 (18.1) 366`271 (15.6) <0.001 
Arterial hypertension 45`795 (54.4) 916`926 (39.1) <0.001 
Coronary artery disease 12`770 (15.2) 497`689 (21.2) <0.001 
Cerebrovascular disease 4`646 (5.5) 153`786 (6.6) <0.001 
Heart failure 20`255 (24.1) 426`973 (18.2) <0.001 
Cancer 14`507 (17.2) 337`744 (14.4) <0.001 
Chronic kidney disease 22`249 (26.4) 408`818 (17.5) <0.001 
Chronic obstructive pulmonary disease 11`418 (13.6) 226`501 (9.7) <0.001 
Pneumonia 10`694 (12.7) 177`656 (7.6) <0.001 
Liver failure 6`707 (8.0) 79`419 (3.4) <0.001 
Severity index, mean (SD) 
Charlson Comorbidity Index 1.9 (2.6) 1.5 (2.3) <0.001 
COPD, Chronic obstructive pulmonary disease; n, number; SD, standard deviation. 
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Seasonal variation of hypoosmolar hyponatremia 
We found a strong seasonal variation in the prevalence of hypoosmolar hyponatremia (R2 = 0.56, p-
values = 0.005). While the highest overall prevalence of hypoosmolar hyponatremia was noted in the 
month of July (n=8,976, 4.5%), it was lowest in the month of December (n=6,530, 2.7%). We observed 
a gradual increase in hypoosmolar hyponatremia from the month of January to the month of July, 
followed by a gradual decrease thereafter. This was paralleled with a gradual increase in mean monthly 
outdoor temperature from the months of January to the month of July with a mean [SD] monthly 
outdoor temperature in January of 1.4°C [1.6] to July of 20°C [1.8] and followed by a continued 
decrease in mean monthly outdoor temperature, respectively (Table 2, Figure 1). In the sensitivity 
analyses for the respective diagnosis of hypoosmolar hyponatremia (E87.1) and syndrome of 
inappropriate antidiuresis (E22.2), there were no significant differences in the temporal dynamics 
throughout the year (Figure 2 A and B). 
 
Table 2 Mean monthly outdoor temperature and prevalence of hyponatremia among hospitalized 
male and female patients 
C°, degrees Celsius; n, number; SD, standard deviation 
Month of  
hospital admission 
Outdoor temperature (C°), 
mean (SD) 
Total prevalence of 
hyponatremia, n (%) 
Prevalence of hyponatremia 
in male patients, n (%) 
Prevalence of hyponatremia 
in female patients, n (%) 
  
January 1.4 (1.6) 6`747 (3.2) 2`688 (2.4) 4`059 (4.0) 
February 1.3 (2.1) 6`262 (3.2) 2`547 (2.5) 3`715 (4.0) 
March 6.5 (1.5) 6`787 (3.2) 2`691 (2.5) 4`096 (4.1) 
April 11.1 (1.2) 6`407 (3.3) 2`597 (2.6) 3`810 (4.1) 
May 14.3 (1.6) 6`541 (3.4) 2`520 (2.5) 4`021 (4.3) 
June 18.0 (0.7) 7`309 (3.8) 2`886 (2.9) 4`423 (4.8) 
July 20.1 (1.8) 8`976 (4.5) 3`182 (3.1) 5`794 (6.1) 
August 19.6 (1.2) 8`212 (4.3) 3`126 (3.1) 5`086 (5.5) 
September 15.5 (1.1) 7`116 (3.7) 2`720 (2.7) 4`396 (4.7) 
October 11.0 (1.2) 6`928 (3.5) 2`763 (2.7) 4`165 (4.3) 
November 6.6 (1.0) 6`395 (3.2) 2`602 (2.5) 3`793 (4.0) 
December 2.6 (1.4) 6`530 (2.7) 2`626 (2.1) 3`904 (3.4) 
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Figure 1: Association of hyponatremia in hospitalized patients, month of admission, sex, and 
stratified by age groups. 
 
Figure 2: Mean monthly prevalence of hyponatremia stratified for sex 
Seasonal variation of hypoosmolar hyponatremia stratified by sex and age categories 
The overall prevalence of hypoosmolar hyponatremia was higher in women as compared to men (OR 
1.72 [95%-CI 1.69 to 1.74], p<0.001). This remained statistically significant when adjusting for 
comorbidities such as heart failure, chronic kidney disease, pneumonia and liver failure (OR 1.58 [95%-
CI 1.56 to 1.60], p<0.001) (Table 3). Sex-specific differences in hypoosmolar hyponatremia increased 
in parallel with the mean monthly outdoor temperature (Figure 1). While in January 2.4% men and 4% 
women were diagnosed with hypoosmolar hyponatremia (OR 1.54 [95%-CI 1.46 to 1.62], p<0.001), 
3.1% men and 6.1% women were diagnosed with hypoosmolar hyponatremia in July (OR 1.76 [95%-CI 
1.68 to 1.84]) (Tables 2 and 3).  
The in-hospital prevalence of hypoosmolar hyponatremia increased with increasing age. The overall 
prevalence of hypoosmolar hyponatremia for patients <56 years was 1.8% and increased for the age 
rage 56 to 70 years to 3.3% and for the age range 70 to 80 years to 3.9% and was 4.9% for patients >80 
years (data not shown separately) (Figure 3).  
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Whereas the overall prevalence of hyponatremia was higher in women as compared to men, we did 
not find such a significant difference after stratification for month. In older patients, however, we did 
observe month-stratified differences in the prevalence of hypoosmolar hyponatremia in hospitalized 
medical patients (Table 3). These associations are visualized in Figure 3. Based on terms of interaction 
we found age to be a strong effect modifier in the association between sex and the prevalence of in-
hospital hyponatremia.  
To exclude that these findings are due to an increased admission rate of female and elderly patients 
during summer months, we investigated the monthly admission rate of these patients and found that 
there was no seasonal difference in admission rates throughout the year (data not shown). 
 
Figure 3: Mean monthly prevalence of (A) hypoosmolar hyponatremia (ICD code E87.1) and (B) 
syndrome of inappropriate antidiuresis (ICD code E22.2) stratified for sex 
 
 
 
 
 
 
Table 3 Association of monthly-stratified hyponatremia in hospitalized patients among sex and age groups 
 
 Overall <56 years 56 to 70 years 71 to 80 years >80 years 
 
Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value 
           
Overall           
Male patients reference  reference  reference  reference  reference  
Female patients 1.58 (1.56-1.60) 
<0.001 1.04 (1.00-
1.09) 
0.035 1.24 (1.20-
1.27) 
<0.001 1.78 (1.73-
1.83) 
<0.001 2.14 (2.08-
2.21) 
<0.001 
January           
Male patients reference  reference  reference  reference  reference  
Female patients 1.54 (1.46-1.62) 
<0.001 1.09 (0.96-
1.24) 
0.197 1.21 (1.10-
1.34) 
<0.001 1.69 (1.53-
1.87) 
<0.001 2.21 (1.99-
2.44) 
<0.001 
February           
Male patients reference  reference  reference  reference  reference  
Female patients 1.51 (1.43-1.59) 
<0.001 1.04 (0.90-
1.20) 
0.583 1.26 (1.14-
1.39) 
<0.001 1.78 (1.60-
1.98) 
<0.001 1.91 (1.73-
2.11) 
<0.001 
March           
Male patients reference  reference  reference  reference  reference  
Female patients 1.54 (1.47-1.62) 
<0.001 1.07 (0.93-
1.27) 
0.341 1.19 (1.08-
1.31) 
0.001 1.73 (1.58-
1.91) 
<0.001 2.17 (1.96-
2.40) 
<0.001 
April           
Male patients reference  reference  reference  reference  reference  
Female patients 1.49 (1.41-1.57) 
<0.001 1.02 (0.86-
1.17) 
0.790 1.17 (1.06-
1.30) 
0.002 1.61 (1.45-
1.78) 
<0.001 2.06 (1.86-
2.28) 
<0.001 
May           
Male patients reference  reference  reference  reference  reference  
Female patients 1.63 (1.55-1.72) 
<0.001 0.94 (0.82-
1.09) 
0.420 1.46 (1.32-
1.61) 
<0.001 1.71 (1.55-
1.89) 
<0.001 2.30 (2.07-
2.55) 
<0.001 
June           
Male patients reference  reference  reference  reference  reference  
Female patients 1.57 (1.50-1.65) 
<0.001 1.09 (0.95-
1.25) 
0.220 1.18 (1.08-
1.30) 
0.001 1.82 (1.66-
2.01) 
<0.001 2.06 (1.88-
2.27) 
<0.001 
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OR, odds ratio; CI, confidence interval 
 Overall <56 years 56 to 70 years 71 to 80 years >80 years 
 
Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value 
           
July           
Male patients reference  reference  reference  reference  reference  
Female patients 1.76 (1.68-1.84) 
<0.001 1.05 (0.92-
1.19) 
0.508 1.33 (1.22-
1.46) 
<0.001 1.98 (1.81-
2.16) 
<0.001 2.40 (2.20-
2.62) 
<0.001 
August           
Male patients reference  reference  reference  reference  reference  
Female patients 1.64 (1.57-1.72) 
<0.001 1.04 (0.91-
1.18) 
0.568 1.29 (1.17-
1.41) 
<0.001 1.87 (1.71-
2.05) 
<0.001 2.17 (1.99-
2.37) 
<0.001 
September           
Male patients reference  reference  reference  reference  reference  
Female patients 1.62 (1.54-1.70) 
<0.001 1.13 (0.99-
1.30) 
0.075 1.24 (1.12-
1.37) 
<0.001 1.81 (1.64-
1.99) 
<0.001 2.16 (1.96-
2.38) 
<0.001 
October           
Male patients reference  reference  reference  reference  reference  
Female patients 1.52 (1.44-1.60) 
<0.001 0.97 (0.85-
1.11) 
0.648 1.12 (1.01-
1.23) 
0.030 1.77 (1.61-
1.95) 
<0.001 2.15 (1.95-
2.38) 
<0.001 
November           
Male patients reference  reference  reference  reference  reference  
Female patients 1.48 (1.40-1.56) 
<0.001 1.04 (0.90-
1.20) 
0.594 1.17 (1.06-
1.29) 
0.002 1.68 (1.52-
1.86) 
<0.001 1.94 (1.75-
2.15) 
<0.001 
December           
Male patients reference  reference  reference  reference  reference  
Female patients 1.57 (1.49-1.66) 
<0.001 1.05 (0.91-
1.21) 
0.487 1.21 (1.10-
1.34) 
<0.001 1.78 (1.61-
1.96) 
<0.001 2.08 (1.88-
2.30) 
<0.001 
Discussion 
Key findings of this study are threefold: First, the prevalence of hyponatremia in medical inpatients 
increases during summer months and is strongly associated with warmer outdoor temperature. 
Second, hyponatremia was more common in women, especially during summer months. Third, 
increasing age was associated with a higher in-hospital prevalence of hyponatremia, and again, this 
finding was most pronounced during summer months.  
Our nationwide cohort data conclusively confirm a seasonal variation of the prevalence of 
hyponatremia being highest during summer months [49,144,145]. While previous studies investigated 
smaller patient numbers or focused on emergency department setting, the present study expands the 
findings to a large medical inpatient population. The overall prevalence of hypoosmolar hyponatremia 
in hospitalized patients of 3.5% is lower as compared to 10-15% prevalence reported in previous 
studies [58,135,137,138]. This could possibly be due to an underreporting of hyponatremia and that 
our data represent the more profound and symptomatic cases of hyponatremia. This would in fact be 
in line with data from the outpatient setting that indicated a season dependent effect in particular for 
patients with profound hyponatremia [49,145].  
Reasons for the increased prevalence of hyponatremia during summer months with increased outdoor 
temperature may be attributed to several predisposing factors. Our data suggest that hypoosmolar 
hyponatremia overall as well as syndrome of inappropriate antidiuresis taken as single diagnosis 
increase in parallel during summer months. Hypoosmolar hyponatremia may be caused by diuretic-
induced hyponatremia, primary polydipsia, or volume overload due to heart or renal failure, 
respectively. Even though our data cannot differentiate between the different hypoosmolar 
hyponatremia etiologies, previous studies have described increased diuretic-induced hyponatremia 
during summer months [49,172]. The pathophysiological reasoning is that diuretics lead to a relative 
renal salt loss and when combined with dehydration, as during months with higher outdoor 
temperature, hyponatremia might develop. With regard to hyponatremia caused by heart or renal 
failure, studies suggest that they are more commonly decompensated and thus of a higher severity 
during summer months which could as well lead to hyponatremia [173]. The distribution of 
hyponatremia prevalence due to the syndrome of inappropriate antidiuresis increases according to 
our results during summer months. A hypothetical explanation is that increased outdoor temperature 
is a stimulus for arginine vasopressin. We speculate that in combination with increased fluid intake this 
might lead to hyponatremia, especially when consuming hypotonic fluids [48,49,174]. Additionally, 
idiopathic syndrome of inappropriate antidiuresis, especially in the elderly, could be increased during 
summer months but further prospective studies are needed to validate this hypothesis. 
As known from previous studies, women tend to have a higher prevalence of hyponatremia in general 
[49,137]. Our results are in line with those findings, suggesting that women are prone to develop 
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hyponatremia [145]. Interestingly, we show that this effect is highest with higher outdoor 
temperature. It is possible that the increased outdoor temperature influences sex hormones 
differently, making women more susceptible to develop hyponatremia during increased outdoor 
temperatures. It was shown that estrogen affects aquaporin-4 expression regulating water 
homeostasis [175] and that aquaporin-2 expression is higher and more sensitive to endogenous 
arginine vasopressin in women [176]. Lastly, it is speculated that women tend to drink generally more 
fluids than men and primary polydipsia is also more common in women [17,47,48]. This might lead to 
a volume overload and relative salt deficit, especially when renal function is impaired, and may result 
in hyponatremia [48].  
Ageing has been described as independent risk factor for electrolyte disturbances, especially 
hyponatremia [141]. We here confirm that ageing is associated with an increased prevalence of 
hyponatremia and show that this effect is also more pronounced with higher outdoor temperature. 
Ageing is associated with maladaptation to stress and decreased capacity to cope with environmental, 
disease-related, and iatrogenic stress [153,177]. Common factors predisposing hyponatremia in the 
elderly are an impaired renal function, increased consumption of hyponatremia-inducing drugs (e.g., 
diuretics and psychotropics), increased occurrence of cardiac and pulmonary diseases and increased 
idiopathic syndrome of inappropriate antidiuresis which all influence the water homeostasis [143,154–
157]. Our results indicate that patients with hyponatremia had higher rates of cardiac and pulmonary 
diseases. Additionally, it has been shown that thirst perception is decreased with age [154,158,159]. It 
could therefore be that the reduced thirst perception in the elderly in combination with medication 
and fluid loss (e.g., sweating, vomitus, diarrhea) results in dehydration hyponatremia, especially during 
higher outdoor temperature.  
These data will have to be interpreted in the context of the study design. First, using administrative 
data is prone to confounding due to the risk of misclassification and underreporting of hyponatremia 
and lack of validating diagnosis with laboratory measurements. In fact, merely 3.5% of all included 
hospitalized patients were diagnosed with hyponatremia, although evidence suggests a much higher 
prevalence in hospitalized patients [135]. We expect our data to still be representable as rate of 
ascertainment is expected to be constant throughout the year. Second, our data do not differentiate 
between hyponatremia on admission versus hospital-acquired hyponatremia. ICD-10 coding is 
generally done at the time of discharge or death. Consequently, some of the patients may have 
developed hyponatremia during hospitalization, rather than on admission. Assuming a constant rate 
of hospital-acquired hyponatremia throughout the year, the observed seasonal variation would 
however be explained by varying hyponatremia prevalence on admission. Our data are based on 
hospital claims data of ICD coded diagnoses “hypoosmolar hyponatremia” and “syndrome of 
inappropriate antidiuresis”, but exact laboratory measurements were not available. Third, the non-
Inaugural dissertation – Dr med. Clara Odilia Sailer 69 
experimental design of our study limits the ability to draw causal links between the prevalence of 
hyponatremia, seasonality, sex- and age-specific variations. Fourth, since we do not have information 
on clinical symptoms and severity of hyponatremia, we are unable to account for unmeasured (and 
unmeasurable) residual confounding (e.g., etiology of hyponatremia, thirst perception, volume status).  
However, our study has several strengths: the large nationwide data, the high representability, and 
the long study period. All analyses were adjusted for multiple comorbidities and possible confounders. 
Furthermore, this is the first study to date focusing on medical inpatients and thus provides 
information about a patient population which has been poorly studied so far. 
In conclusion, in medical inpatients, hyponatremia is increased during summer months with higher 
outdoor temperature. Female and elderly are at higher risk to develop hyponatremia and this effect is 
enforced during summer months.  
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Abstract  
Background Primary polydipsia is part of the polyuria-polydipsia syndrome and characterized by 
increased fluid intake. Excessive fluid may lead to complications such as hyponatremia. However, 
besides behavioral therapy, treatment options are scarce. Glucagon-like peptide-1 (GLP-1) receptor 
agonists reduce appetite and energy intake and could play a role in drinking and water homeostasis. 
The purpose of this study was to investigate whether GLP-1 receptor agonists reduce fluid intake in 
patients with primary polydipsia. 
Method In this three-week double-blind, placebo-controlled, randomized, cross-over trial, 34 patients 
with primary polydipsia received weekly dulaglutide (TrulicityÒ) 1.5mg and placebo (0.9% sodium 
chloride). During the third week, patients attended an 8-hour evaluation visit with free water access. 
The primary endpoint was total fluid intake during the evaluation visit. The treatment effect was 
estimated using a mixed-effects model, accounting for treatment sequence and patient. 
Results Median [IQR] age of participants (23 (67.6%) female) was 29.5 years [26.0, 38.8]. We found 
that median [IQR] total fluid intake was lower in patients treated with dulaglutide as compared to 
placebo: 2250 ml [1600-2600] versus 2400 ml [1850-3400]. Two third of patients on dulaglutide had a 
reduced fluid intake by -453 ml [95% CI -851, -54], p=0.033, corresponding to a 15% relative reduction. 
Thirst perception was slightly reduced in patients receiving dulaglutide, and electrolytes were similar 
between the two groups at the beginning of the evaluation visit.  
Conclusion This study suggests that GLP-1 receptor agonists reduce fluid intake in patients with 
primary polydipsia and could therefore be a new treatment option for these patients. 
  
Inaugural dissertation – Dr med. Clara Odilia Sailer 72 
Introduction  
Primary polydipsia is characterized by excess water intake and consecutive excretion of profound 
quantities of dilute urine [14,28]. This disorder has most often been described in psychiatric patients 
(psychogenic polydipsia) but can also be seen in subjects with a defective thirst mechanism or health 
conscious people with voluntary increased fluid intake (habitual polydipsia) [13,14,47,178]. In contrast 
to the common believe, increased fluid intake is not without complication but may lead to 
hyponatremia with symptoms such as nausea, falls, seizures and even death [48]. However, treatment 
options for primary polydipsia are scarce. While voluntary fluid reduction would be the ideal 
treatment, it is often unsuccessful because of continuous thirst and compulsive drinking behavior 
[29,33,118]. Some medications have been studied to improve polydipsic behavior such as olanzapine, 
lithium, aripiprazole and clozapine [36,38–40,42]. These drugs are mainly used to treat psychotic 
symptoms and in schizophrenic patients and might therefore reduce polydipsic behavior in these 
patients. However, they have unfavorable side effects such as weight gain and type 2 diabetes and are 
therefore no suitable option for otherwise healthy people with primary polydipsia. A medication with 
primarily thirst reducing action would be desirable. 
The hormone glucagon-like peptide-1 (GLP-1) is released in response to food intake [179,180] and is 
involved in the regulation of appetite and energy intake [179,181–184]. GLP-1 receptor agonists are 
widely used for the treatment of type 2 diabetes mellitus and weight management in obese patients 
[185]. These satiating properties make GLP-1 and its receptor agonists an interesting therapeutic 
target in the regulation of thirst and drinking. Studies investigating GLP-1 receptor agonists on food 
intake revealed a concomitant reduction of fluid intake both in humans and rats in the presence and 
absence of food [186,187].  
The aim of this study was therefore to investigate whether GLP-1 receptor agonists as compared to 
placebo reduce fluid intake and thirst perception in patients with primary polydipsia. 
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Materials and methods  
Study design and participants 
This is a single center, randomized, double blind, placebo controlled, 3-week crossover trial in 34 
patients with primary polydipsia. The trial was conducted at the University Hospital Basel, Switzerland. 
Inclusion criteria were age between 18 and 65 years, polyuria > 50 ml/kg body weight per day and 
polydipsia of > 3 liters per day. Exclusion criteria were central or nephrogenic diabetes insipidus, 
secondary polyuria (e.g., diabetes mellitus, hypokalemia, hypercalcemia), history of pancreatitis and 
previous treatment with GLP-1 receptor agonists within the last 3 months. The study protocol and 
study medication were approved by both the local ethic committee and the national agency for the 
authorization and supervision of therapeutic products (Swissmedic). Written informed consent has 
been obtained from each participant after full explanation of the purpose and nature of all procedures 
used. The study was registered on ClinicalTrials.gov (NCT02770885). 
 
Study objective and outcomes  
The objective of this study was to explore whether a three-week treatment with GLP-1 receptor 
agonist dulaglutide (Trulicity®) as compared to placebo reduces fluid intake in patients with primary 
polydipsia. The primary outcome was total fluid intake (ml) during an 8-hour evaluation visit.  
Further outcomes were thirst perception during the preceding week and during the evaluation visit, 
24-hour urine output during the evaluation visit and the following 16 hours, day and nighttime urinary 
frequency, quality of life, serum and urine electrolytes and osmolality, and adverse effects e.g. 
gastrointestinal symptoms.  
 
Study intervention 
The procedures and timeline of the study are schematically displayed in figure 1. 
All study participants received in random order a 3-week treatment with either dulaglutide (Trulicity®) 
1.5 mg or placebo (0,9% sodium chloride) subcutaneously once weekly. After a wash-out period of at 
least 3 weeks, participants received the complementary treatment. 
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Figure 1: Flow Chart 
 
Assessment of fluid intake and urinary output 
Patients attended an 8-hour evaluation visit (8 am to 4 pm) at the study site after an overnight fast (no 
food and drinks) for 12 hours within 7 days following the third study drug injection. At arrival, 
participants were requested to void their bladders and a 24-hours urine collection was started. Clinical 
parameters, symptoms and adverse effects were assessed at 8 am, noon and 4 pm. Symptoms and 
adverse effects (thirst, hunger, nausea, abdominal pain) were assessed using the a 10-point numerous 
rating scale (e.g., 0 = no thirst, 10 = extreme thirst). 
At 8.30 am (breakfast) and at noon (lunch) standardized, savory meals were served (consisting of 116g 
carbohydrates, 60g fat, 25g proteins, 12g fibers, 5.7g salt and 1284kcal in total). To control for food 
intake, participants were requested to consume the entire meals on both evaluation visits, irrespective 
of their appetite. Starting at 8.30 am, a water dispenser with a content of 10 liters was provided and 
refilled if necessary. The amount of water in the dispenser was unknown to the participants. 
Participants were invited to drink freely from the dispenser during the evaluation visit. Besides the 
provided meals and water no other food or drinks were allowed. At 4 pm, participants were asked to 
void their bladders and instructed to collect their urine until 8 am the following day.  
 
Assessment of polydipsic behavior  
Thirst perception was assessed in different ways during our study: First, we assessed thirst perception 
at each study visit using a 10-point numerous rating scale. Patients were asked to indicate their average 
thirst perception during the preceding week. Second, at the evaluation visit, patients were asked at 8 
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am, noon, 1pm and 4 pm to indicate their current thirst perception. Furthermore, at the weekly visits, 
reported average daily fluid intake during the day, emictions per day and at night were assessed.  
 
Assessment of quality of life 
We assessed quality of life in our patients in two ways: First, patients were asked to rate their perceived 
reduced quality of life by the polyuria-polydipsia symptoms on a 10-point rating scale during the 
preceding week (e.g., 0 = quality of life not reduced, 10 = quality of life maximally reduced). Second, 
patients answered the standardized short form 12 (SF-12) questionnaire (Quelle), a standardized 
questionnaire to assess quality of life, at each study visit. 
 
Assessment of electrolytes 
At the screening visit, patients had a basal blood draw for serum electrolytes and osmolality, serum 
glucose, urinary electrolytes and osmolality. At the beginning of the 8-hour the evaluation visits an 
intravenous line was placed into the antecubital vein for blood sampling. Blood and urine samples 
were collected at 8 am, noon and 4 pm for the measurement of the above-mentioned laboratory 
values. 
 
Assessment of adverse effects 
At every weekly visit and during the evaluation visit, gastrointestinal symptoms, e.g. nausea, 
abdominal pain, and diarrhea were assessed on a 10-point numerous rating scale (e.g., 0 = no nausea, 
10 = unbearable nausea). Other adverse effects were recorded free text.  
 
Statistical analysis 
For the analysis of the primary endpoint, total water intake during the evaluation visit, a linear mixed-
effect model was used. The model included study arm, sequence and their interaction term as 
predictors (fixed effects). Further, a random intercept was fitted for patient (random effect). Model 
residual distribution was inspected visually. 95% confidence intervals were computed using the profile 
method. P-values were calculated using the Satterwaite’s method for deriving degrees of freedom and 
t-statistics (implemented in the R package lmerTest). The estimated difference in the primary endpoint 
between dulaglutide and placebo is indicated with 95% confidence interval and interpreted regarding 
its clinical relevance and regarding the assumed effect for sample size estimation (13% reduction of 
dulaglutide versus placebo). As sensitivity analysis, the primary analysis was repeated on the per 
protocol set and including adverse effects at the beginning and at any time-point during the evaluation 
visit. 
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All secondary analyses in this study are exploratory and hypothesis generating. These tests of 
secondary outcomes all explore the general prediction that dulaglutide has hypodipsic properties. For 
all outcomes, descriptive summary statistics are reported for dulaglutide and placebo separately for 
each measurement time. For continuous variables the median and interquartile range is reported.  
Analysis were performed using the statistic program R [188].   
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Results 
Baseline characteristics  
The 34 included patients (67.6% female) had a median [IQR] age of 29.5 years [26.0, 38.8] and had a 
median [IQR] body mass index of 23.1 kg/m2 [20.7, 25.5]. At baseline, median [IQR] reported fluid 
intake was 4500 ml per day [3600, 5000] and median [IQR] 24h urine output was 4700 ml [3900, 5600]. 
Baseline characteristics are shown in Table 1. 
 
Table 1: Baseline Characteristics and polydipsic behavior 
Baseline characteristics 34 
Age (years), median (IQR) 29.5 (26.0, 38.8) 
Male gender, n (%)  11 (32.4) 
BMI (kg/m2), median (IQR) 23.1 (20.7, 25.5) 
Psychiatric comorbidities, n (%)  20 (58.8) 
Other comorbidities, n (%)  14 (41.2) 
Smoking, n (%)  14 (41.2) 
Polydipsic behavior  
Reported daily fluid intake (ml), median (IQR) 4500 (3600, 5000) 
24h urine output (ml), median (IQR) 4700 (3900, 5600) 
Time since onset of symptoms (months), median (IQR) 120.0 (61.0, 120.0) 
 
Fluid intake and 24-hour urine output 
Median [IQR] fluid intake during the 8-hour evaluation visit was lower on dulaglutide as compared to 
placebo treatment: 2250 ml [1600, 7400] versus 2400 ml [1850, 3400]), see Figure 2. The median [95%-
confidence interval] difference of fluid intake on dulaglutide compared to placebo treatment was -453 
ml [-851, -54] (p-value = 0.033), which correspond to a fluid reduction of 15%. Two third of participants 
drank less on dulaglutide than on placebo treatment as illustrated in the histogram (Figure 3). The 
sensitivity analyses confirmed these findings.  
24-hour urine output tended to be lower in patients treated with dulaglutide, median [IQR] 3250 ml 
[2288, 4362] compared to placebo, median [IQR] 4150 ml [3262, 5788]. The median [IQR] difference 
of urine output on dulaglutide compared to placebo treatment was -675 ml [-1391, 41] (p = 0.074). 
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Figure 2: Total voluntary water intake within 8 hours at the evaluation visit after treatment with 
placebo or dulaglutide. 
 
 
Figure 3: Within-patient differences in total voluntary water intake within 8 hours at the evaluation 
visit between treatment with dulaglutide versus placebo. Differences are calculated as the value under 
treatment with dulaglutide minus placebo, hence, negative differences indicate a reduced water intake 
under treatment with dulaglutide, while positive values indicate an increased or unaltered water 
intake under treatment with dulaglutide. 
 
Hypodipsic effect of dulaglutide 
After treatment with dulaglutide, acute thirst perception at every time point of the evaluation visit 
was slightly reduced (see figure 4). Overall thirst perception in the preceding weeks prior to the 
evaluation visit remained constant with dulaglutide and increased slightly with placebo treatment (see 
figure 5). 
Reported fluid intake decreased in patients receiving dulaglutide during the three weeks of treatment 
and was significantly lower preceding the evaluation visit (placebo: 4000 [3500, 5000], dulaglutide: 
3000 [2500, 3900], on average -1661 ml [-2346, -976] (p-value < 0.001)), figure 6. Less than half of 
patients reported drinking at night before treatment start.  
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Self-reported urinary emictions per day before the evaluation visit decreased with dulaglutide as 
compared to placebo treatment: -1.9 emictions per day [-3.4, -0.5] p = 0.014. During placebo 
treatment, 16 patients reported nycturia before start of treatment and only 1 patient reported 
improvement of symptoms. During dulaglutide treatment, 19 patients reported nycturia before 
treatment start. Of these, 7 patients reported no more nycturia at the evaluation visit. The patient who 
improved under placebo also improved under dulaglutide (p-value 0.0412).  
 
 
Figure 4: Time course of acute thirst perception (numerous rating scale 0–10) at the evaluation visit 
for each treatment. 
 
Figure 5: Time course of overall thirst perception during the preceding week for each treatment. 
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2.1 I Hypodipsic properties of Dulaglutide
2.1.1 ai: Overall thirst perception during preceding week under treatment
For the week immediately before the start of treatment (assessment at day 1), most
participants indicated an intermediate level of thirst perception (median NRS score
of 5; Figure 1 and Table 1). Under placebo treatment, we observe an increase in the
median by one NRS point for the first and second week of treatment (assessments at
day 7 and 14, respectively), but the interquartile ranges do not change much. Under
Dulaglutide, the median NRS score remains constant at 5 and we see no notable
change in the range of values.
Overall, our data do not indicate that Dulaglutide reduces overall thirst perception.
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Figure 1: Time c urse of overall thirst perception during the preceding week for each
treatment.
Table 1: Summary statistics for overall thirst perception (NRS 0–10) during the preced-
ing week under treament with Dulaglutide or placebo. Day = Days of treatment; N =
number of available measurements. The range between the first and the third quartile
is the inter-quartile range.
Day Treatment arm N Minimum First quartile Median Third quartile Maximum
1 Placebo 34 2.00 3.25 5.00 7.00 8.00
1 Dulaglutide 34 1.00 4.00 5.00 6.00 10.00
7 Placebo 34 2.00 4.25 6.00 7.00 8.00
7 Dulaglutide 34 1.00 3.25 5.00 6.00 8.00
14 Placebo 34 0.00 3.00 6.00 7.00 9.00
14 Dulaglutide 33 1.00 3.00 5.00 6.00 8.00
me14ChristCrain4AN2 (December 18, 2019, rev. 161187) 7 / 29
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Figure 6: Time course of self-reported average daily fluid intake during the preceding week under 
treatment with dulaglutide or placebo. Treatment duration was 14 days; the evaluation visit (EV) took 
place one to six days after the end of treatment (day 15 to 20).  
 
Quality of life 
At baseline, patients indicated that their quality of life was reduced by symptoms of polyuria-
polydipsia. At the evaluation visit, patients reported an improved quality of life in regard to polyuric-
polydipsic symptoms after treatment with dulaglutide as compared to placebo (estimated treatment 
difference [95%]: -1.6 [-2.9, -0.3], p-value = 0.019). 
At the evaluation visit the SF-12 physiological and mental subscores were similar between the two 
treatment groups at the evaluation visit (p-value = 0.87). 
 
Serum and urinary laboratory parameters 
At the beginning of the evaluation visit, patients’ serum sodium levels were in the normal range and 
did not differ between treatment with dulaglutide or placebo (median [IQR] serum sodium levels of 
140 mmol/l [138; 141] versus 140 mmol/l [138; 141]). As expected, serum glucose levels were lower 
on dulaglutide versus placebo treatment (estimated difference -0.63 [-0.86, -0.4] mmol/l, p-value 
<0.001) but without hypoglycemia. 
24-hour urine electrolytes were similar after treatment with dulaglutide as compared to placebo. 
Particularly, our data provide no evidence that urinary sodium excretion differs between the groups 
(estimated difference: -8.67 [-19.37, 1.82] mmol/l, p=0.12), see Table 2. 
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Table 2: Laboratory parameters at the beginning of the evaluation visit 
Blood parameters Placebo Dulaglutide 
Sodium (mmol/l), median (IQR) 140 (139-142) 140 (139-141) 
Osmolality (mosm/kg), median (IQR) 289 (286-292) 286 (284-293) 
Creatinine (mmol/l), median (IQR) 70 (62-81) 73 (62-82) 
Urea (mmol/l), median (IQR) 4.15 (3.32-5.15) 3.85 (3.12-5.0) 
Glucose (mmol/l), median (IQR) 4.8 (4.5-5.2) 4.4 (4.2-4.7) 
Urinary parameters  Placebo Dulaglutide 
Sodium (mmol/l), median (IQR)  38 (26-54) 40 (29-48) 
Osmolality (mosm/kg), median (IQR)  217 (154-269) 245 (170-270) 
Creatinine (mmol/l), median (IQR) 3.2 (1.9-4.1) 3.7 (2.5-5.0) 
Urea (mmol/l), median (IQR) 188 (129-313) 209 (66-282) 
Glucose (mmol/l), median (IQR) 0.1 (0-0.1) 0.1 (0-0.1) 
 
Adverse effects 
Observed adverse effects were mostly of gastrointestinal nature, e.g. nausea, abdominal pain and 
diarrhea (Table 3). After treatment with dulaglutide respectively placebo, 11 respectively 6 patients 
indicated nausea and 3 respectively 2 patients reported abdominal pain during the evaluation visit. 
Other gastrointestinal symptoms were reported by 2 per each group. Two patients developed mild 
hyponatremia during both evaluation visits (minimum plasma sodium of patient 1 under dulaglutide 
was 133 mmol/l, and under placebo 131 mmol/l, minimum plasma sodium of patient 2 under 
dulaglutide was 133 mmol/l, and under placebo 133 mmol/l).  
 
Table 3: Gastrointestinal symptoms and adverse effects during the evaluation visit 
Gastrointestinal symptoms Placebo Dulaglutide 
Nausea, n (%) 2 (6) 2 (6) 
Abdominal pain, n (%) 1 (3) 2 (6) 
Other gastrointestinal symptoms, n (%) 2 (6) 2 (6) 
Mild hyponatremia, n (%) 2 (6) 2 (6) 
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Discussion  
Our results indicate that the GLP-1 receptor agonist dulaglutide reduces fluid intake and thirst 
perception as compared to placebo in patients with primary polydipsia. Consequently, patients 
receiving dulaglutide were less constrained by drinking and urinary frequency.  
Patients with primary polydipsia are characterized by exaggerated thirst sensation and excessive 
drinking [47]. It may result in water intoxication and life-threatening hyponatremia, highlighting that 
this condition is not harmless as it is often believed [48,124]. Treatment options have been mainly 
studied in the psychiatric setting in polydipsic patients with chronic schizophrenia. Besides behavioral 
therapy [34,35], mainly antipsychotics have been described to be helpful [39,42,119]. However, 
antipsychotic medications are not a sensible treatment option for otherwise healthy patients, as they 
are associated with risks of obesity, type 2 diabetes and cardiovascular events [189,190].  
In our study median total fluid intake in patients with primary polydipsia was lower on dulaglutide as 
compared to placebo treatment. Concomitantly, further hypodipsic effects were evident such as 
reduced self-reported fluid intake, reduced daytime urinary frequency and reduced nycturia. GLP-1 
receptor agonists have mainly been studied in food intake, obesity and type 2 diabetes. Findings from 
rodents and humans have suggested a hypodipsic effect of GLP-1 receptor agonists in an acute setting 
after single doses of GLP-1 receptor agonists [22,23]. The reduced fluid intake was observed both in 
the presence and absence of food, indicating a food independent effect of dulaglutide on fluid intake 
[187]. Our results indicate a prolonged effect of GLP-1 receptor agonists in humans in a controlled 
setting. In addition, our results show for the first time besides reduced fluid intake effects of GLP-1 on 
urine output, daytime and nighttime urinary frequency. These results strengthen the observed 
hypodipsic effect of GLP-1 receptor agonists as an independent effect of food intake.  
The most common complication in patients with primary polydipsia is hyponatremia [26,42,48]. It has 
been described that profound hyponatremia (plasma sodium <125 mmol/l) occurs in patients with 
primary polydipsia either in the presence of factors impairing renal water excretion, such as 
medication, acute infection or stress in general, or if free fluid intake exceeds free fluid excretion 
[27,48,62]. In our cohort, two patients experienced mild hyponatremia in the afternoon in both 
treatment phases. Even though their fluid intake decreased under dulaglutide as compared to placebo 
(5400 ml vs 6500 ml and 6700 ml vs 7400 ml), their fluid intake was still very high. One patient received 
quetiapine, a neuroleptic known to induce hyponatremia, while no clear risk factor for hyponatremia 
could be identified in the other patient. We speculate that in patients with primary polydipsia, the risk 
of hyponatremia increases throughout the day with the consistent increase of fluid intake.  
The regulation of thirst and drinking is complex and only partly understood (18,19). To coordinate 
water intake and fluid balance, the brain has to integrate both homeostatic and behavioral signals (20). 
After salt ingestion an early signal to drink is sent to the brain in order to anticipate hyperosmolality. 
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Likewise, fluid intake is calibrated to match physiological need and drinking stops before osmolality 
and blood volume effectively change (21). A role for GLP-1 in this regulatory circuit has been suggested 
by a recent study in mice (20). The authors found enriched GLP-1 receptor expression in neurons of 
the lamina terminalis – a key brain structure for sensing and regulating water balance (18, 22). These 
neurons are believed to be activated by GLP-1 upon water intake and to confer rapid satiety of thirst 
during fluid ingestion (20). Furthermore, the authors observed a polydipsic overdrinking phenotype 
after ablation of these GLP-1 receptor expressing, thirst inhibitory neurons. In patients with primary 
polydipsia, it is speculated that a dysfunction in the brain leads to exaggerated thirst sensation and 
excessive drinking (23). Additionally, the compulsory fluid intake in primary polydipsia shares similar 
features with other addictive behaviors such as excessive eating or drug taking (26, 27). Interestingly, 
growing literature imply that GLP-1 is also involved in reward regulation and the pathophysiology of 
addiction (26). Indeed, GLP-1 receptors are expressed in brain areas related to reward processing such 
as hypothalamus, ventral tegmental area and nucleus accumbens (1, 2, 28) supporting this hypothesis. 
A treatment with GLP-1 receptor agonists holds, therefore, the potential to address addictive 
components of primary polydipsia while also modulating homeostatic and behavioral factors of thirst 
regulation. 
The main limitation of this study is the short observation period of 8 hours and the artificial setting 
used to assess the primary endpoint, water intake. Nevertheless, the reduced fluid intake in patients 
receiving dulaglutide is in line with findings from the literature, where fluid intake was reported 
alongside food intake. Self-reported fluid intake indicated a stronger effect of hypodipsic properties in 
patients receiving GLP-1 receptor agonists. The appetite and thirst satiating effects of GLP-1 receptor 
agonists may be linked to their well-known impact on nausea or taste aversion [191]. In our study, 
reported nausea and side effects during the evaluation visit were similar between the two groups and 
the model adjusting for side effects confirmed reduced fluid intake in patients receiving dulaglutide. 
This indicates that the observed hypodipsic effects of dulaglutide were independent of gastrointestinal 
side effects. Last but not least, we used dulaglutide as study drug and are not able to transfer these 
results to other GLP-1 receptor agonists. Dulaglutide is a large molecule (>50-60 kilo Dalton) and its 
size may hamper the access to the central nervous system [192]. The effect on fluid intake could be 
more pronounced with smaller GLP-1 receptor agonist molecules of enhanced blood brain barrier 
permeability and central activity (e.g. liraglutide, semaglutide or lixisenatide) [193].  
In summary, our data show that a 3-week treatment with the GLP-1 receptor agonist dulaglutide 
reduces fluid intake and polydipsic symptoms in patients with primary polydipsia. Further large scale 
and longer intervention studies also with other GLP-1 receptor agonists should be conducted to 
confirm our results. This study is a first approach to provide a new treatment option for patients with 
primary polydipsia, where currently no effective medical treatment options exist.   
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Effects of alcohol consumption on copeptin levels and sodium-water 
homeostasis 
 
Clara Odilia Sailer*, Julie Refardt*, Sarah Bissig, Katja Bologna, Cornelia Imber, Mirjam Christ-Crain 
 
Published in “American Journal of Physiology – Renal Physiology”; January 21, 2020 
--------------------------------- 
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Alcohol consumption influences the sodium-water homeostasis. However, the effect of alcohol on 
vasopressin levels is controversial. The aim of this study was to evaluate physiological changes of 
alcohol consumption on the stable vasopressin surrogate marker copeptin. In addition, we aimed at 
investigating the effect of additional sodium and/or water consumption on plasma sodium, osmolality 
and copeptin levels. Ten healthy men underwent four interventions in random order: a) beer 
consumption only, b) beer consumption with additional water or c) stock, d) water consumption only. 
Fluid consumption was equal between interventions and calculated to reach a blood alcohol 
concentration of 0.8‰ in the beer interventions. Blood and urinary samples were taken at six 
timepoints over the observation period of 720 minutes. The primary endpoint was the mean difference 
in copeptin levels 90 minutes after the start of fluid consumption, which showed no in-between groups 
differences (p=0.4). However, a higher total urinary volume excretion in all alcohol compared to water 
interventions was observed (p=0.01). Furthermore, plasma copeptin, sodium and urinary osmolality 
levels increased significantly at the end of the observation period in all alcohol compared to water only 
interventions (p=0.02). In conclusion, initial copeptin suppression does not differ between alcohol or 
water interventions but seems to be prolonged in the alcohol interventions. This leads to increased 
volume loss followed by a counter regulation with increased copeptin levels and water retention after 
720 minutes in the alcohol compared to interventions. Additional sodium and/or water consumption 
with alcohol did not change the observed alcohol-induced effects. 
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Mild to moderate hyponatremia at discharge is associated with increased risk 
of recurrence in patients with community-acquired pneumonia 
 
Laura Potasso⁎, Clara Odilia Sailer*, Claudine Angela Blum*, Nicole Cesana-Nigro, Philipp Schuetz, Beat 
Mueller, Mirjam Christ-Crain 
 
Published in “European Journal of Internal Medicine”; January 14, 2020 
--------------------------------- 
* L.P, C.O.S. and C.A.B. contributed equally contributing to this manuscript 
 
Background: Hyponatremia is the most common electrolyte disorder in hospitalized patients with 
pneumonia. Different studies have shown an association of hyponatremia on admission and worse 
patient's outcome. Yet, the impact of hyponatremia at discharge or of hyponatremia correction on 
patient's prognosis is unknown.  
Methods: This is a preplanned secondary data analysis from a double-blind, randomized, placebo-
controlled trial of hospitalized patients with community-acquired pneumonia and prednisone 
treatment. The primary outcome was the impact of hyponatremia on admission and at discharge on 
patient relevant outcomes (i.e. mortality, rehospitalization and recurrence rate) within 180 days.  
Results: Of the 708 included patients, 185 (26.1%) were hyponatremic on admission. Of these, 28 
(15.1%) were still hyponatremic at discharge. 34 (4.8%) patients developed hyponatremia during 
hospitalization despite being normonatremic on admission. Patients with hyponatremia at discharge 
had a higher rate of pneumonia recurrence as compared to normonatremic patients (OR 2.68; 95%-CI 
1.09–6.95; p = 0.037). Among patients with hyponatremia at discharge, patients who were already 
hyponatremic on admission showed the strongest association with increased recurrence rate (OR 4.01; 
95%-CI 1.08–12.64; p = 0.022). In contrast, recurrence rate was not affected in patients who were 
hyponatremic on admission but had normalized serum sodium levels at discharge (p = 0.73).  
Conclusion: Mild to moderate hyponatremia at discharge is associated with an increased risk of 
recurrence in hospitalized patients with pneumonia. This association is particularly strong for patients 
who are hyponatremic both on admission and at discharge, emphasizing the importance of 
hyponatremia correction during hospitalization.  
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Markers of systemic inflammation in response to osmotic stimulus in healthy 
volunteers 
 
Clara Odilia Sailer, Sophia Julia Wiedemann, Konrad Strauss, Ingeborg Schnyder, Wiebke Kristin Fenske 
and Mirjam Christ-Crain 
 
Published in “Endocrine Connections”; August 01, 2019  
 
Osmotic stimulus or stress results in vasopressin release. Animal and human in vitro studies have 
shown that inflammatory parameters, such as interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α), 
increase in parallel in the central nervous system and bronchial, corneal or intestinal epithelial cell 
lines in response to osmotic stimulus. Whether osmotic stimulus directly causes a systemic 
inflammatory response in humans is unknown. We therefore investigated the influence of osmotic 
stimulus on circulatory markers of systemic inflammation in healthy volunteers. In this prospective 
cohort study, 44 healthy volunteers underwent a standardized test protocol with an osmotic stimulus 
leading into the hyperosmotic/hypernatremic range (serum sodium ≥150 mmol/L) by hypertonic saline 
infusion. Copeptin – a marker indicating vasopressin activity – serum sodium and osmolality, plasma 
IL-8 and TNF-α were measured at baseline and directly after osmotic stimulus. Median (range) serum 
sodium increased from 141 mmol/L (136, 147) to 151 mmol/L (145, 154) (P < 0.01), serum osmolality 
increased from 295 mmol/L (281, 306) to 315 mmol/L (304, 325) (P < 0.01). Median (range) copeptin 
increased from 4.3 pg/L (1.1, 21.4) to 28.8 pg/L (19.9, 43.4) (P < 0.01). Median (range) IL-8 levels 
showed a trend to decrease from 0.79 pg/mL (0.37, 1.6) to 0.7 pg/mL (0.4, 1.9) (P < 0.09) and TNF-α 
levels decreased from 0.53 pg/mL (0.11, 1.1) to 0.45 pg/mL (0.12, 0.97) (P < 0.036). Contrary to data 
obtained in vitro, circulating proinflammatory cytokines tend to or decrease in human plasma after 
osmotic stimulus. In this study, osmotic stimulus does not increase circulating markers of systemic 
inflammation. 
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method  
 
Julie Refardt*, Clara Odilia Sailer*, Irina Chifu, Bettina Winzeler, Ingeborg Schnyder, Martin Fassnacht, 
Wiebke Fenske and Mirjam Christ-Crain on behalf of the CODDI-Investigators 
 
Published in “European Journal of Endocrinology”; August 01, 2019 
--------------------------------- 
* J.R. and C.O.S. contributed equally contributing to this manuscript 
 
Background: Diagnosis and treatment of dysnatremia is challenging and further complicated by the 
pitfalls of different sodium measurement methods. Routinely used sodium measurements are the 
indirect (plasma/serum) and direct (whole blood) ion-selective electrode (ISE) method, showing 
discrepant results especially in the setting of acute illness. Few clinicians are aware of the differences 
between the methods in clinically stable patients or healthy volunteers.  
Methods: Data of 140 patients and 91 healthy volunteers undergoing osmotic stimulation with 
hypertonic saline infusion were analyzed. Sodium levels were measured simultaneously by indirect 
and direct ISE method before and at different time points during osmotic stimulation up to a sodium 
threshold of ≥150 mmol/L. The primary outcome was the difference in sodium levels between the 
indirect and direct ISE method. 
Results: 878 sodium measurements were analyzed. Mean (s.d.) sodium levels ranged from 141 mmol/L 
(2.9) to 151 mmol/L (2.1) by the indirect ISE compared to 140 mmol/L (3) to 149 mmol/L (2.8) by the 
direct ISE method. The interclass correlation coefficient between the two methods was 0.844 (95% CI: 
0.823–0.863). On average, measurements by the indirect ISE were 1.9 mmol/L (95% CI limits: −3.2 to 
6.9) higher than those by the direct ISE method (P < 0.001). The tendency of the indirect ISE method 
resulting in higher levels increased with increasing sodium levels. 
Conclusion: Intra-individual sodium levels differ significantly between the indirect and direct ISE 
method also in the absence of acute illness. It is therefore crucial to adhere to the same method in 
critical situations to avoid false decisions due to measurement differences. 
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A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in 
Patients with the Syndrome of Inappropriate Antidiuresis 
 
Julie Refardt, Cornelia Imber, Clara O. Sailer, Nica Jeanloz, Laura Potasso, Alexander Kutz, Andrea 
Widmer, Sandrine Urwyler, Fahim Ebrahimi, Deborah R. Vogt, Bettina Winzeler, Mirjam Christ-Crain 
 
Published in “Journal of the American Society of Nephrology”; February 04, 2020 
 
Background: The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the 
predominant cause of hyponatremia but its treatment options are unsatisfying. The SGLT2-inhibitor 
empagliflozin promotes osmotic diuresis via urinary glucose excretion and could therefore be a novel 
treatment option for SIADH. 
Methods: From 09/2016 until 12/2018 we recruited 88 hospitalized patients with hyponatremia 
<130mmol/l due to SIADH in the University Hospital Basel. Patients were randomly assigned to either 
treatment with empagliflozin 25mg/day or placebo for four days in addition to standard fluid 
restriction of <1000ml/24h. The primary endpoint was the absolute change in plasma sodium 
concentration after four days of treatment. 
Results: 87 patients completed the trial of whom 43 (49%) received treatment with empagliflozin and 
44 (51%) placebo. Severity of the SIADH was similar, with a median plasma sodium concentration of 
125.5 mmol/l (IQR:122-127) and 126 mmol/l (IQR:123-127) in the empagliflozin and placebo group 
respectively. Treatment with empagliflozin resulted in a significantly higher increase of median plasma 
sodium concentration of 10mmol/l (IQR:5–12) compared to placebo with 7mmol/l (IQR:3–11), 
p=0.038. Severity of hyponatremia (<125 mmol/l) and baseline osmolality levels were predisposing 
factors for treatment response with empagliflozin. Treatment was tolerated well, no events of 
hypoglycemia or hypotension occurred. One severe adverse event involving transient reduction in 
kidney function was related to empagliflozin.  
Conclusion: Empagliflozin in addition to fluid restriction leads to a higher increase in plasma sodium 
levels compared to placebo in patients with SIADH and is therefore a promising new treatment option.  
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Bettina Winzeler, Nicole Cesana-Nigro, Julie Refardt, Deborah R Vogt, Cornelia Imber, Benedict Morin, 
Milica Popovic, Michelle Steinmetz, Clara O Sailer, Gabor Szinnai, Irina Chifu, Martin Fassnacht, Mirjam 
Christ-Crain 
 
Published in “The Lancet”; July 11, 2019 
 
Background Differential diagnosis of diabetes insipidus is challenging. The most reliable approach is 
hypertonic saline-stimulated copeptin measurements. However, this test is based on the induction of 
hypernatraemia and requires close monitoring of plasma sodium concentrations. Arginine-stimulated 
copeptin measurements might provide an alternative, simple, and safe test. 
Methods In this prospective diagnostic study, we recruited a development cohort from University 
Hospital Basel, Basel, Switzerland, and a validation cohort from five centres in Basel, Aarau, Luzern, 
Bern, and St Gallen, Switzerland, and the University Hospital Würzburg, Würzburg, Germany. For both 
cohorts, patients were eligible for inclusion if they were aged 18 years or older, were newly referred 
with polyuria (>50 mL/kg bodyweight per day) or had a known diagnosis of central diabetes insipidus 
or primary polydipsia. We also recruited a comparator cohort of healthy controls in parallel to each 
cohort, comprising adults (aged 18 years and older, with normal drinking habits, and no history of 
polyuria) and children who underwent arginine stimulation to diagnose growth hormone deficiency 
(children were only included in the comparator cohort to the development cohort as proof of concept). 
Patients and healthy controls underwent arginine stimulation with measurement of plasma copeptin 
at baseline and 30, 45, 60, 90, and 120 min. The primary objective in the development cohort was to 
determine the diagnostic accuracy of plasma copeptin concentrations to discriminate between 
diabetes insipidus and primary polydipsia, and in the validation cohort was to confirm those results. 
Adverse effects of the test were monitored in all participants, with tolerability of the test rated using 
a visual analogue scale (VAS) that ranged from no (0) to maximum (10) discomfort. This trial is 
registered with ClinicalTrials.gov, number NCT00757276. 
Findings Between May 24, 2013, and Jan 11, 2017, 52 patients were enrolled in the development 
cohort (12 [23%] with complete diabetes insipidus, nine [17%] with partial diabetes insipidus, and 31 
[60%] with primary polydipsia) alongside 20 healthy adults and 42 child controls. Between Oct 24, 
2017, and June 27, 2018, 46 patients were enrolled in the validation cohort (12 [26%] with complete 
diabetes insipidus, seven [15%] with partial diabetes insipidus, and 27 [59%] with primary polydipsia) 
alongside 30 healthy adult controls (two patients in this cohort were excluded from the main analysis 
Inaugural dissertation – Dr med. Clara Odilia Sailer 91 
because of early vomiting during the test). In the pooled patient and control datasets, median arginine-
stimulated copeptin concentrations increased in healthy adult controls (from 5·2 pM [IQR 3·3–10·9] to 
a maximum of 9·8 pM [6·4–19·6]) and in participants with primary polydipsia (from 3·6 pM [IQR 2·4–
5·7] to a maximum of 7·9 pM [5·1–11·8]), but only minimally in those with diabetes insipidus (2·1 pM 
[IQR 1·9–2·7] to a maximum of 2·5 pM [1·9–3·1]). In the development cohort, a cutoff of 3·5 pM at 60 
min provided the highest diagnostic accuracy of 94% (95% CI 84–98). The accuracy of this cutoff in the 
validation cohort was 86% (95% CI 73–94). By pooling the data from both cohorts, an optimal accuracy 
of 93% (95% CI 86–97) was reached at a cutoff of 3·8 pM copeptin at 60 min (sensitivity 93%, 95% CI 
86–98; specificity 92%, 95% CI 84–100). The test was safe and well tolerated, with median VAS scores 
of 3·5 (IQR 2–4) in patients with diabetes insipidus, 3 (2–4) in those with primary polydipsia, 1 (1–3) in 
healthy adults, and 1 (0–5) in healthy children in the pooled participant dataset. 
Interpretation Arginine-stimulated copeptin measurements are an innovative test for diabetes 
insipidus with high diagnostic accuracy, and could be a simplified, novel, and safe diagnostic approach 
to diabetes insipidus in clinical practice. 
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Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-
Pituitary-Adrenal Axis in Healthy Volunteers 
 
Bettina Winzeler, Ismael da Conceiçao, Julie Refardt, Clara O. Sailer, Gilles Dutilh, and Mirjam Christ-
Crain 
 
Published in “The Journal of Clinical Endocrinology & Metabolism”; January 01, 2019 
 
Context: Recent findings from animal and human studies indicate that glucagon-like peptide-1 (GLP-
1) receptor agonists (RAs) modulate stress response by activating the hypothalamic-pituitary- adrenal 
(HPA) axis, which may have relevant clinical implications. 
Objective: To investigate the influence of GLP-1 RA treatment on HPA axis activity compared with 
placebo in healthy volunteers. 
Design: Double-blind, randomized, crossover study. 
Setting: University Hospital Basel, Switzerland. 
Participants: Twenty healthy volunteers. 
Intervention: Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given 
subcutaneously once weekly for 3 weeks. 
Main Outcome Measures: Twenty-four-hour urinary free cortisol, circadian rhythm of serum and 
salivary cortisol, cortisol after 1 mg dexamethasone suppression test, and cortisol levels before and 
after stimulation with ACTH. 
Results: Urinary free cortisol levels were similar under dulaglutide [median (interquartile range) 240 
nmol/L (164, 324)] vs placebo [188 nmol/L (133, 338), P = 0.131]. The circadian rhythm of serum and 
salivary cortisol were comparable in both groups as were cortisol levels after dexamethasone 
[dulaglutide 28 nmol/L (22, 47.5) vs placebo 26.5 nmol/L (15.8, 45.5), P = 0.4]. Serum cortisol levels in 
dulaglutide and placebo treated participants were 522 nmol (388, 710) and 530 nmol/L (394, 747), 
before (P = 0.6), and 658 nmol/L (604, 810) and 636 nmol/L (512, 910) after ACTH stimulation (P = 
0.87). 
Conclusion: Our results suggest that there is no activation of the HPA axis by long-term GLP-1 RA 
exposure, particularly dulaglutide, at the medically approved dosage of 1.5 mg once weekly.  
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FGF-21 levels in polyuria-polydipsia syndrome  
 
Julie Refardt, Clara Odilia Sailer, Bettina Winzeler, Matthias Johannes Betz, Irina Chifu, Ingeborg 
Schnyder, Martin Fassnacht, Wiebke Fenske and Mirjam Christ-Crain for the CODDI-Investigators  
 
Published in “Endocrine Connections”; December 01, 2018 
 
The pathomechanism of primary polydipsia is poorly understood. Recent animal data reported a 
connection between fibroblast growth factor 21 (FGF-21) and elevated fluid intake independently of 
hormonal control by the hormone arginine-vasopressin (AVP) and osmotic stimulation. We therefore 
compared circulating FGF-21 levels in patients with primary polydipsia to patients with AVP deficiency 
(central diabetes insipidus) and healthy volunteers. In this prospective cohort study, we analyzed FGF-
21 levels of 20 patients with primary polydipsia, 20 patients with central diabetes insipidus and 20 
healthy volunteers before and after stimulation with hypertonic saline infusion targeting a plasma 
sodium level ≥150 mmol/L. The primary outcome was the difference in FGF-21 levels between the 
three groups. Baseline characteristics were similar between the groups except for patients with central 
diabetes insipidus being heavier. There was no difference in baseline FGF-21 levels between patients 
with primary polydipsia and healthy volunteers (122 pg/mL (52,277) vs 193 pg/mL (48,301), but higher 
levels in patients with central diabetes insipidus were observed (306 pg/mL (114,484); P=0.037). 
However, this was not confirmed in a multivariate linear regression analysis after adjusting for age, 
sex, BMI and smoking status. Osmotic stimulation did not affect FGF-21 levels in either group 
(difference to baseline: primary polydipsia −23 pg/mL (−43, 22); central diabetes insipidus 17pg/mL 
(−76, 88); healthy volunteers −6pg/mL (−68, 22); P=0.45). To conclude, FGF-21 levels are not increased 
in patients with primary polydipsia as compared to central diabetes insipidus or healthy volunteers. 
FGF-21 therefore does not seem to be causal of elevated fluid intake in these patients. 
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Discussion and outlook 
The main findings of my MD-PhD thesis are the following: First, one third of patients with primary 
polydipsia hospitalized with profound hyponatremia has no psychiatric comorbidity. Second, every 
patient with primary polydipsia has a contributing factor, i.e. medication, acute infection, or nausea, 
leading to an impaired renal water excretion, resulting in hyponatremia. Third, especially profound 
hyponatremia is more common during summer months regardless of the underlying cause and 
patients with primary polydipsia tend to experience hyponatremia more commonly with increased 
outdoor temperature. Fourth, arginine infusion is a non-osmotic stimulus of the posterior pituitary and 
arginine stimulated copeptin levels can differentiate between patients with primary polydipsia and 
diabetes insipidus with a high diagnostic accuracy. Lastly, GLP-1 receptor agonists reduce fluid intake 
in patients with primary polydipsia. Additionally,  
The one-year follow-up of the study regarding prevalence, characteristics, and outcome of patient with 
primary polydipsia and acute psychosis as well as the data analysis of the neuroimaging study are still 
ongoing.  
 
According to the analysis of a large prospective study in patients with profound hyponatremia 
presenting at the emergency department, 8% of patients were identified to suffer from primary 
polydipsia [127]. Our results confirm that a high percentage of patients with primary polydipsia have 
a psychiatric comorbidity, mainly addictive disorder, depression, and personality disorders [48]. The 
prevalence of a schizophrenia spectrum disorder was surprisingly low, and no patient suffered from 
an acute psychotic episode, possibly due to the fact that these patients are usually treated in the 
psychiatric department despite profound hyponatremia. Importantly, however, one third of patients 
had no psychiatric comorbidity. This underlines that primary polydipsia is a phenomenon which is 
increasingly present outside the psychiatric setting and may result in hyponatremia. We identified a 
factor contributing to the development of hyponatremia in every patient. While acute fluid intake of 
large amounts was identified as primary cause of hyponatremia in some patients, a factor impairing 
renal water excretion was present in every patient. Impaired renal water excretion be caused by 
reduced solute intake leading to a reduced capacity of the kidneys to excrete water, as it has been 
shown that the kidneys require a minimum amount of solutes to excrete fluids [27,62]. We hypothesize 
that in our cohort, especially in patients with beer potomania and anorexia nervosa, hyponatremia 
was at least partly caused by reduced solute intake due to food deprivation. Another factor limiting 
renal excretion capacity is a concomitant stimulus of the water and sodium balance regulating 
hormone vasopressin. Several trigger factors, such as antidepressant or antidiuretic drugs, pain, 
nausea, acute infections, especially pneumonia, and urogenital tract infections, and stress in general, 
can lead to an unspecific increase of vasopressin and alter the sodium-water balance. It is therefore 
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important to control sodium levels regularly in patients with known polydipsia, especially in the 
presence of any of the described contributing factors. Lastly, we found in our cohort that patients with 
primary polydipsia had an overall poor outcome with an increased rehyponatremia, rehospitalization, 
and even mortality rate. These data are important to bear in mind in treating hospitalized patients 
with primary polydipsia and measure should be implemented to prevent hyponatremia. 
 
The general advice is to increase fluid intake when outdoor temperature rises to compensate for the 
fluid loss from sweating [194]. Based on observations from clinical routine we speculated that 
hyponatremia prevalence increases during summer months. Our main finding was that especially 
profound hyponatremia prevalence increases during summer months and correlates with outdoor 
temperature [49,50]. There was furthermore a trend towards a higher hyponatremia rate due to 
primary polydipsia during increased outdoor temperatures. In the general population, we showed that 
the prevalence of hyponatremia, and especially during summer months, is elevated for female and 
elderly patients. We speculate that the combination of low fluid and solute intake, or consumption of 
primarily hypotonic fluids, together with the contributing factors discussed above increases the risk of 
hyponatremia. Our data raises the question whether the general recommendation of increased fluid 
intake, especially in summer months, may increase the risk for hyponatremia and associated poor 
outcome. The general recommendation from health authorities is to drink 1,500-2,000 ml of fluid per 
day. In the ley press, increased water intake is often called detoxifying, leading to a cleaner skin, better 
concentration, and improved digestion and the advice is “to drink plenty of water”. According to our 
results however, unspecific recommendation of increased fluid intake could lead to the intake of 
excessive amounts of fluid and with this an increased risk of hyponatremia, especially in patients with 
predisposing factors for an altered renal water excretion. It is therefore important to inform people 
that the daily fluid requirement is individual and that too much water intake is possible and associated 
with complications. Maybe we should consider also for water intake the quote of Paracelsus: All things 
are poison and nothing (is) without poison; only the dose makes that a thing is no poison. 
 
Current treatment options for patients with primary polydipsia are scarce. As primary polydipsia has 
mainly been described in the psychiatric setting, it is not surprising that most investigated treatment 
options are antipsychotics. Our results and the rising number of case reports indicate that primary 
polydipsia is also common in patients with depression and otherwise healthy people. Treating these 
patients with antipsychotics, medications that have nonetheless unfavorable side effects, such as 
weight gain, type 2 diabetes, and cardiovascular complications, is irresponsible. Behavioral therapy, 
even though the currently most efficient treatment option for patients with primary polydipsia, is time 
intensive and requires manpower, which limits its feasibility in the outpatient setting [34–37]. The gut 
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hormone glucagon-like peptide-1 (GLP-1) is has been shown to regulate appetite and energy balance 
and GLP-1 receptor agonists are successfully used to treat patients with type 2 diabetes mellitus and 
obesity [168–171]. The satiating properties of GLP-1 and its receptor agonists make these medications 
an interesting therapeutic option for regulating drinking and water-sodium homeostasis [172,173]. In 
our study, fluid intake following a three-week treatment period with the GLP-1 receptor agonist 
dulaglutide showed a significant and clinically relevant fluid reduction of 15% in patients with primary 
polydipsia as compared to placebo. In addition, patients reported reduced fluid intake, reduced 
daytime urinary frequency and lower restriction by polyuric-polydipsic behavior.  
The mechanism of action of GLP-1 and its receptor agonists regulating food and fluid intake is not 
entirely understood. Regarding food intake, it has been shown that GLP-1 slows gastric emptying and 
has a glucose dependent insulinotropic effect on the pancreatic beta cells [179,195]. It is further 
speculated, that GLP-1 acts centrally on reward centers, such as the hypothalamus, the anterior 
cingulate cortex, the orbitofrontal cortex, the insula and putamen, and reduces brain activity in 
response to highly desirable food cues [196,197]. Similar brain areas are also involved in thirst, drinking 
and overdrinking [11,12]. No study has yet investigated brain activity when exposed to drinking stimuli 
in patients with primary polydipsia. We can only speculate, but it seems plausible that primary 
polydipsia could be caused by a dysfunction in these centers, making GLP-1 receptor agonists a 
promising treatment option for those patients. Our ongoing analysis could clarify some of the 
mechanisms how GLP-1 receptor agonists act on the brain. 
 
In conclusion, the general recommendation of increased fluid intake during summer months and hot 
weather should be specified and individualized to prevent overdrinking and hyponatremia. Patients 
with primary polydipsia should be carefully monitored and factors altering the renal water excretion 
kept to a minimum to prevent the development of hyponatremia. GLP-1 receptor agonists might be a 
new treatment option for patients with primary polydipsia. 
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Direction for future research 
Even though many of the questions regarding primary polydipsia, its complications, and potential 
treatment options have been addressed by this MD-PhD, some open questions remain. 
The ongoing trial in psychiatric patients will provide evidence of the current prevalence of primary 
polydipsia in patients with acute psychosis. However, ideal amount of drinking and the prevalence of 
primary polydipsia in the general population remains unclear. Nationwide data on fluid intake, urinary 
excretion, and electrolytes could be used to assess the current daily fluid intake, providing evidence 
towards the ideal amount of daily fluid intake and the prevalence of primary polydipsia in the general 
population.  
The ongoing analysis of neuroimaging studies in patients with primary polydipsia in comparison to 
healthy controls will clarify involved brain areas in the polydiptic patients and contribute to the 
pathophysiological understanding of the disorder. Furthermore, our data will provide evidence 
towards the role of GLP-1 receptor agonists in thirst and drinking regulation. However, whether other 
central hormones or neurotransmitters are involved in the development of hyponatremia has to be 
discussed and further researched. 
The study investigating the GLP-1 receptor agonist dulaglutide to reduce fluid intake is the first study 
of this medication class as treatment option for patients with primary polydipsia. Large-scale studies 
also with other GLP-1 receptor agonists are necessary to confirm these data to ultimately accept these 
medications as treatment option for patients with primary polydipsia in clinical routine. 
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Conclusion and closing remark 
This MD-PhD thesis focuses on patients with primary polydipsia in the medical and psychiatric setting, 
a common but neglected disorder. The results of the published and further planned papers and studies 
contribute significantly to the pathophysiological understanding of the disorder, its main complication 
hyponatremia, and potential treatment options. The studies performed as part of my MD-PhD have 
clarified some of the unanswered questions in the field of primary polydipsia. However, uncertainty 
about this disorder remains: a.) the prevalence of primary polydipsia in the general population, b.) the 
role of GLP-1 and other hormones in the development of primary polydipsia, and c.) the most beneficial 
treatment option. Based on my publications, future studies can be planned to answer these research 
questions.  
 
In conclusion, I am confident that not only have I learned how to perform clinical research from the 
planning of a trial, to the conduction, data analysis, and manuscript writing, but also have I contributed 
significantly to the knowledge about patients with primary polydipsia. I am very excited and motivated 
to continue clinical research in this field and improve my personal skills as well as the general 
knowledge about patients with primary polydipsia. 
 
 
“And those who were seen dancing were thought to be insane  
by those who could not hear the music.” 
 
“Die Tanzenden wurden für verrückt gehalten  
von denjenigen, die die Musik nicht hören konnten. ” 
 
― Friedrich Nietzsche 
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